Neurotrophins    B-Cytokine114828193
and    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor    I-Cytokine114828193
α    I-Cytokine114828193
(    O
TNFα    O
)    O
are    O
other    O
cellular    O
factors    O
that    O
work    O
to    O
sensitize    O
neurons    O
to    O
pain    O
.    O

The    O
production    O
of    O
E    O
-    O
selectin    O
is    O
stimulated    O
by    O
the    O
expression    O
of    O
P    O
-    O
selectin    O
which    O
in    O
turn    O
,    O
is    O
stimulated    O
by    O
tumor    O
necrosis    O
factor    O
α    O
(    O
TNFα    B-Cytokine114828193
)    O
,    O
interleukin-1    O
(    O
IL-1    O
)    O
and    O
lipopolysaccharide    O
(    O
LPS    O
)    O
.    O

The    O
culture    O
supernatants    O
of    O
cancer    O
cells    O
can    O
trigger    O
the    O
expression    O
of    O
E    O
-    O
selectin    O
by    O
endothelial    O
cells    O
suggesting    O
that    O
cancer    O
cells    O
may    O
release    O
by    O
themselves    O
cytokines    O
such    O
as    O
TNF-α    B-Cytokine114828193
,    O
IL-1β    O
or    O
INF-γ    O
that    O
will    O
directly    O
activate    O
endothelial    O
cells    O
to    O
express    O
E    O
-    O
selectin    O
,    O
P    O
-    O
selectin    O
,    O
ICAM-2    O
or    O
VCAM    O
.    O

Study    O
shows    O
the    O
adherence    O
of    O
"    O
porphyromonas    O
gingivalis    O
"    O
to    O
human    O
umbilical    O
vein    O
endothelial    O
cells    O
increases    O
with    O
the    O
induction    O
of    O
E    O
-    O
selectin    O
expression    O
by    O
TNF-α    B-Cytokine114828193
An    O
antibody    O
to    O
E    O
-    O
selectin    O
and    O
sialyl    O
LewisX    O
suppressed    O
"    O
P.    O
gingivalis    O
"    O
adherence    O
to    O
stimulated    O
HUVECs    O
.    O
"    O

Chronic    O
consumption    O
of    O
alcohol    O
results    O
in    O
the    O
secretion    O
of    O
pro    O
-    O
inflammatory    O
cytokines    O
(    O
TNF-alpha    B-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
6    I-Cytokine114828193
[    O
IL6    O
]    O
and    O
Interleukin    B-Cytokine114828193
8    I-Cytokine114828193
[    O
IL8    O
]    O
)    O
,    O
oxidative    O
stress    O
,    O
lipid    O
peroxidation    O
,    O
and    O
acetaldehyde    O
toxicity    O
.    O

It    O
was    O
found    O
that    O
the    O
latent    O
herpesvirus    O
caused    O
an    O
increase    O
in    O
interferon    O
-    O
gamma    O
(    O
IFN-γ    O
)    O
and    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
(    O
TNF-α    O
)    O
,    O
both    O
of    O
which    O
lead    O
to    O
activation    O
of    O
macrophages    O
and    O
resistance    O
to    O
bacterial    O
infection    O
.    O

All    O
affected    O
were    O
found    O
to    O
have    O
a    O
functional    O
defect    O
in    O
the    O
upregulation    O
of    O
TNFα    B-Cytokine114828193
production    O
by    O
their    O
blood    O
macrophages    O
in    O
response    O
to    O
stimulation    O
with    O
IFNγ.    O

Inflammatory    O
responses    O
to    O
triggers    O
such    O
as    O
TNF-α    B-Cytokine114828193
involve    O
macrophages    O
with    O
components    O
that    O
include    O
miR-155    O
.    O

TOM1    O
a    O
negative    O
regulator    O
of    O
the    O
IL-1beta    O
and    O
TNF-alpha    B-Cytokine114828193
signalling    O
pathways    O
.    O

Activated    O
mast    O
cells    O
also    O
synthesize    O
and    O
secrete    O
lipid    O
-    O
derived    O
mediators    O
(    O
such    O
as    O
prostaglandins    O
,    O
leukotrienes    O
,    O
and    O
platelet    O
-    O
activating    O
factor    O
)    O
and    O
cytokines    O
(    O
such    O
as    O
interleukin    O
1    O
,    O
interleukin    B-Cytokine114828193
3    I-Cytokine114828193
,    O
interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
interleukin    O
5    O
,    O
interleukin    B-Cytokine114828193
6    I-Cytokine114828193
,    O
interleukin    B-Cytokine114828193
13    I-Cytokine114828193
,    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
,    O
GM    O
-    O
CSF    O
,    O
and    O
several    O
chemokine    B-Cytokine114828193
.    O

TNF-α    B-Cytokine114828193

The    O
exact    O
mechanism    O
in    O
which    O
these    O
diseases    O
cause    O
cachexia    O
is    O
poorly    O
understood    O
,    O
but    O
there    O
is    O
probably    O
a    O
role    O
for    O
inflammatory    O
cytokines    O
,    O
such    O
as    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
(    O
which    O
is    O
also    O
nicknamed    O
'    O
cachexin    O
'    O
or    O
'    O
cachectin    O
'    O
)    O
,    O
interferon    O
gamma    O
and    O
interleukin    B-Cytokine114828193
6    I-Cytokine114828193
,    O
as    O
well    O
as    O
the    O
tumor    O
-    O
secreted    O
proteolysis    O
-    O
inducing    O
factor    O
.    O

Although    O
the    O
pathogenesis    O
of    O
cancer    O
cachexia    O
is    O
poorly    O
understood    O
,    O
multiple    O
biologic    O
pathways    O
are    O
known    O
to    O
be    O
involved    O
,    O
including    O
proinflammatory    O
cytokines    O
such    O
as    O
TNF-alpha    B-Cytokine114828193
,    O
neuroendocrine    O
hormones    O
,    O
IGF-1    O
,    O
and    O
tumor    O
-    O
specific    O
factors    O
such    O
as    O
proteolysis    O
-    O
inducing    O
factor    O
.    O

Keratinocytes    O
also    O
modulate    O
the    O
immune    O
system    O
:    O
apart    O
from    O
the    O
above    O
-    O
mentioned    O
antimicrobial    O
peptides    O
and    O
chemokines    B-Cytokine114828193
they    O
are    O
also    O
potent    O
producers    O
of    O
anti    O
-    O
inflammatory    O
mediators    O
such    O
as    O
IL-10    B-Cytokine114828193
and    O
TGF-β    B-Cytokine114828193
When    O
activated    O
,    O
they    O
can    O
stimulate    O
cutaneous    O
inflammation    O
and    O
Langerhans    O
cell    O
activation    O
via    O
TNFα    B-Cytokine114828193
and    O
IL-1β    O
secretion    O
.    O

The    O
parasites    O
manipulate    O
the    O
cell    O
signalling    O
pathway    O
of    O
the    O
macrophages    O
,    O
such    O
as    O
down    O
-    O
regulating    O
of    O
Jak    O
/    O
stat    O
signalling    O
,    O
NO    O
and    O
TNF-α    B-Cytokine114828193
production    O
,    O
and    O
also    O
by    O
blocking    O
the    O
NF-κB    O
-    O
dependent    O
pathway    O
.    O

The    O
presence    O
of    O
viral    O
particles    O
and    O
the    O
cell    O
damage    O
resulting    O
from    O
viruses    O
budding    O
out    O
of    O
the    O
cell    O
causes    O
the    O
release    O
of    O
chemical    O
signals    O
(    O
such    O
as    O
TNF-α    B-Cytokine114828193
,    O
IL-6    B-Cytokine114828193
and    O
IL-8    B-Cytokine114828193
)    O
,    O
which    O
are    O
molecular    O
signals    O
for    O
fever    O
and    O
inflammation    O
.    O

Complex    O
feedback    O
loops    O
involving    O
cytokines    O
,    O
such    O
as    O
interleukin-1    O
and    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-α    I-Cytokine114828193
produced    O
in    O
response    O
to    O
infection    O
,    O
appear    O
to    O
also    O
play    O
a    O
role    O
in    O
the    O
regulation    O
of    O
non    O
-    O
rapid    O
eye    O
movement    O
(    O
REM    O
)    O
sleep    O
.    O

These    O
signals    O
induce    O
a    O
pro    O
-    O
inflammatory    O
state    O
through    O
the    O
production    O
of    O
the    O
pro    O
-    O
inflammatory    O
cytokines    O
interleukin-1    O
,    O
interleukin-12    B-Cytokine114828193
,    O
TNF-alpha    B-Cytokine114828193
and    O
IFN    O
-    O
gamma    O
.    O

Other    O
cytokines    O
,    O
such    O
as    O
interleukin    O
1    O
,    O
interleukin    B-Cytokine114828193
2    I-Cytokine114828193
,    O
interleukin-12    B-Cytokine114828193
,    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor    I-Cytokine114828193
and    O
colony-stimulating    B-Cytokine114828193
factor    I-Cytokine114828193
,    O
can    O
also    O
enhance    O
interferon    O
production    O
.    O

Molecules    O
called    O
pro    O
-    O
inflammatory    O
cytokines    O
,    O
which    O
include    O
interleukin-1    O
(    O
IL-1    O
)    O
,    O
Interleukin-2    B-Cytokine114828193
(    O
IL-2    O
)    O
,    O
interleukin-6    B-Cytokine114828193
(    O
IL-6    O
)    O
,    O
Interleukin-12    B-Cytokine114828193
(    O
IL-12    O
)    O
,    O
Interferon    O
-    O
gamma    O
(    O
IFN    O
-    O
Gamma    O
)    O
and    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor    I-Cytokine114828193
alpha    I-Cytokine114828193
(    O
TNF    O
-    O
alpha    O
)    O
can    O
affect    O
brain    O
growth    O
as    O
well    O
as    O
neuronal    O
function    O
.    O
Circulating    O
immune    O
cells    O
such    O
as    O
macrophages    O
,    O
as    O
well    O
as    O
glial    O
cells    O
(    O
microglia    O
and    O
astrocytes    O
)    O
secrete    O
these    O
molecules    O
.    O

Tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor    I-Cytokine114828193
(    O
TNF    O
)    O
,    O
formerly    O
known    O
as    O
TNFα    O
or    O
TNF    O
alpha    O
,    O
is    O
the    O
best    O
-    O
known    O
member    O
of    O
this    O
class    O
.    O

Tumor    O
necrosis    O
factor    O
(    O
TNF    O
)    O
(    O
also    O
known    O
as    O
cachectin    O
or    O
TNF    B-Cytokine114828193
alpha    I-Cytokine114828193
)    O
is    O
a    O
cytokine    O
that    O
has    O
a    O
wide    O
variety    O
of    O
functions    O
.    O

TNF    B-Cytokine114828193

Expression    O
of    O
CXCL16    O
is    O
induced    O
by    O
the    O
inflammatory    O
cytokines    O
IFN    O
-    O
gamma    O
and    O
TNF-alpha    B-Cytokine114828193
.    O

These    O
immune    O
cells    O
move    O
from    O
the    O
dermis    O
to    O
the    O
epidermis    O
and    O
secrete    O
inflammatory    O
chemical    O
signals    O
(    O
cytokines    O
)    O
such    O
as    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-α    I-Cytokine114828193
,    O
interleukin-1β    O
,    O
interleukin-6    B-Cytokine114828193
,    O
interleukin-36    B-Cytokine114828193
and    O
interleukin-22    O
.    O

Several    O
monoclonal    O
antibodies    O
target    O
cytokines    O
,    O
the    O
molecules    O
that    O
cells    O
use    O
to    O
send    O
inflammatory    O
signals    O
to    O
each    O
other    O
.    O
TNF-α    B-Cytokine114828193
is    O
one    O
of    O
the    O
main    O
executor    O
inflammatory    O
cytokines    O
.    O

Specifically    O
,    O
neutralization    O
occurs    O
when    O
the    O
antidrug    O
antibody    O
binds    O
to    O
infliximab    O
's    O
antigen    O
binding    O
site    O
instead    O
of    O
TNF-α.    O
When    O
infliximab    O
no    O
longer    O
binds    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor    I-Cytokine114828193
alpha    I-Cytokine114828193
,    O
it    O
no    O
longer    O
decreases    O
inflammation    O
,    O
and    O
psoriasis    O
may    O
worsen    O
.    O
Neutralizing    O
antibodies    O

Statin    O
use    O
in    O
those    O
with    O
psoriasis    O
and    O
hyperlipidemia    O
was    O
associated    O
with    O
decreased    O
levels    O
of    O
high    O
-    O
sensitivity    O
C    O
-    O
reactive    O
protein    O
and    O
TNFα    B-Cytokine114828193
as    O
well    O
as    O
decreased    O
activity    O
of    O
the    O
immune    O
protein    O
LFA-1    O
.    O

Cleaves    O
Pro    O
-    O
Leu    O
-    O
Ala    O
-    O
Gln    O
-    O
Ala    O
-    O
Val    O
-    O
Arg    O
-    O
Ser    O
-    O
Ser    O
-    O
Ser    O
in    O
the    O
membrane    O
-    O
bound    O
,    O
26-kDa    O
form    O
of    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor    I-Cytokine114828193
alpha    I-Cytokine114828193
(    O
TNFalpha    O
)    O
.    O

Both    O
pro    O
-    O
inflammatory    O
cytokines    O
(    O
such    O
as    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
,    O
Interleukin-1    O
,    O
and    O
Interleukin-6    B-Cytokine114828193
)    O
and    O
anti    O
-    O
inflammatory    O
cytokines    O
(    O
such    O
as    O
interleukin    B-Cytokine114828193
10    I-Cytokine114828193
and    O
interleukin    B-Cytokine114828193
1    I-Cytokine114828193
receptor    I-Cytokine114828193
antagonist    I-Cytokine114828193
)    O
are    O
elevated    O
in    O
the    O
serum    O
of    O
patients    O
experiencing    O
a    O
cytokine    O
storm    O
.    O

Some    O
types    O
of    O
arthritis    O
medications    O
are    O
designed    O
to    O
reduce    O
inflammation    O
by    O
inhibiting    O
the    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
pathway    O
to    O
immune    O
cell    O
activation    O
;    O
these    O
drugs    O
are    O
known    O
as    O
TNF    O
-    O
alpha    O
blockers    O
.    O

It    O
is    O
known    O
that    O
monocytes    O
and    O
macrophages    O
also    O
produce    O
higher    O
levels    O
of    O
tumor    O
necrosis    O
factor    O
alpha    O
(    O
TNF-α    B-Cytokine114828193
)    O
,    O
interleukin    O
6(IL-6    O
)    O
other    O
than    O
IL    O
-    O
Iβ    O
During    O
the    O
febrile    O
(    O
fever    O
)    O
attacks    O
and    O
during    O
the    O
attacks    O
the    O
C    O
-    O
reactive    O
protein    O
(    O
CRP    O
)    O
also    O
increases    O
.    O
[    O
9    O
]    O
.    O

Signaling    O
pathway    O
of    O
TNF    B-Cytokine114828193
-    O
R1    O
.    O
Dashed    O
grey    O
lines    O
represent    O
multiple    O
steps    O
.    O

This    O
protein    O
induces    O
the    O
production    O
of    O
TNF-alpha    B-Cytokine114828193
from    O
macrophage    O
cells    O
.    O

Interleukin    O
32    O
(    O
IL-32    O
)    O
is    O
a    O
pro    O
-    O
inflammatory    O
cytokine    O
that    O
can    O
induce    O
cells    O
of    O
the    O
immune    O
system    O
(    O
such    O
as    O
monocytes    O
and    O
macrophages    O
)    O
to    O
secrete    O
inflammatory    O
cytokines    O
,    O
such    O
as    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
(    O
TNF-α    O
)    O
and    O
IL-6    O
.    O

The    O
axis    O
inhibits    O
bone    O
marrow    O
-    O
derived    O
dendritic    O
cells    O
(    O
i.e.    O
antigen    O
-    O
presenting    O
cells    O
that    O
process    O
antigen    O
material    O
,    O
present    O
it    O
on    O
their    O
surfaces    O
for    O
delivery    O
to    O
T    O
cells    O
,    O
and    O
otherwise    O
regulate    O
innate    O
and    O
adaptive    O
immune    O
system    O
responses    O
)    O
from    O
producing    O
pro    O
-    O
inflammatory    O
cytokines    O
(    O
e.g.    O
IL-12    B-Cytokine114828193
,    O
TNF-alpha    B-Cytokine114828193
,    O
IL-1-alpha    B-Cytokine114828193
,    O
and    O
IL-6    B-Cytokine114828193
)    O
while    O
stimulating    O
them    O
to    O
increase    O
production    O
of    O
the    O
anti    O
-    O
inflammatory    O
cytokine    O
,    O
IL-10    O
.    O

suPAR    O
levels    O
are    O
positively    O
correlated    O
with    O
pro    O
-    O
inflammatory    O
biomarkers    O
,    O
such    O
as    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-α    I-Cytokine114828193
,    O
leukocyte    O
counts    O
,    O
and    O
C    O
-    O
reactive    O
protein    O
.    O

An    O
increase    O
in    O
shear    O
stress    O
causes    O
an    O
increase    O
in    O
the    O
number    O
of    O
monocyte    O
chemoattractant    O
protein-1    O
(    O
MCP-1    O
)    O
molecules    O
expressed    O
on    O
the    O
surface    O
of    O
vessel    O
walls    O
as    O
well    O
as    O
increased    O
levels    O
of    O
TNF-α    B-Cytokine114828193
,    O
bFGF    O
,    O
and    O
MMP    O
.    O

Monocytes    O
can    O
enter    O
the    O
vessel    O
wall    O
to    O
become    O
macrophages    O
and    O
produce    O
inflammatory    O
cytokines    O
such    O
as    O
TNF-α    B-Cytokine114828193
in    O
addition    O
to    O
aiding    O
the    O
production    O
of    O
bFGF    O
and    O
MMP    O
(    O
Van    O
Royen    O
"    O
et    O
al    O
.    O
"    O
,    O
2000    O
)    O
.    O

Relative    O
to    O
other    O
NSAIDs    O
,    O
salsalate    O
has    O
a    O
weak    O
inhibitory    O
effect    O
on    O
the    O
cyclooxygenase    O
enzyme    O
and    O
decreases    O
the    O
production    O
of    O
several    O
proinflammatory    O
chemical    O
signals    O
such    O
as    O
interleukin-6    B-Cytokine114828193
,    O
TNF-alpha    B-Cytokine114828193
,    O
and    O
C    O
-    O
reactive    O
protein    O
.    O

Lipopolysaccharide    O
-    O
induced    O
production    O
of    O
TNFα    B-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
6    I-Cytokine114828193
,    O
and    O
IL1B    O
)    O
while    O
concurrently    O
activating    O
anti    O
-    O
oxidant    O
responses    O
upregulated    O
through    O
the    O
anti    O
-    O
oxidant    O
response    O
element    O
(    O
ARE    O
)    O
by    O
forcing    O
cytosolic    O
KEAP1    O
to    O
release    O
NFE2L2    O
which    O
then    O
moves    O
to    O
the    O
nucleus    O
,    O
binds    O
ARE    O
,    O
and    O
induces    O
production    O
of    O
,    O
e.g.    O
hemoxygenase-1    O
,    O
NADPH    O
-    O
quinone    O
oxidoreductase    O
,    O
and    O
possibly    O
glutamate    O
-    O
cysteine    O
ligase    O
modifier    O
.    O

SSRIs    O
,    O
SNRIs    O
and    O
tricyclic    O
antidepressants    O
acting    O
on    O
serotonin    O
,    O
norepinephrine    O
and    O
dopamine    O
receptors    O
have    O
been    O
shown    O
to    O
be    O
immunomodulatory    O
and    O
anti    O
-    O
inflammatory    O
against    O
pro    O
-    O
inflammatory    O
cytokine    O
processes    O
,    O
specifically    O
on    O
the    O
regulation    O
of    O
Interferon    O
-    O
gamma    O
(    O
IFN    O
-    O
gamma    O
)    O
and    O
Interleukin-10    B-Cytokine114828193
(    O
IL-10    O
)    O
,    O
as    O
well    O
as    O
TNF-alpha    B-Cytokine114828193
and    O
Interleukin-6    B-Cytokine114828193
(    O
IL-6    O
)    O
.    O

After    O
an    O
injury    O
to    O
the    O
cornea    O
,    O
some    O
keratocytes    O
undergo    O
apoptosis    O
,    O
prompted    O
by    O
the    O
signaling    O
molecules    O
secreted    O
by    O
the    O
upper    O
layers    O
,    O
such    O
as    O
IL1    B-Cytokine114828193
alpha    I-Cytokine114828193
and    O
TNF-alpha    B-Cytokine114828193
.    O

The    O
differentiation    O
,    O
induced    O
by    O
γδ    O
T    O
-    O
APC    O
,    O
most    O
often    O
led    O
to    O
T    O
helper    O
cell    O
response    O
,    O
in    O
the    O
most    O
of    O
cases    O
to    O
pro    O
-    O
inflammatory    O
Th1    O
response    O
with    O
subsequent    O
production    O
of    O
IFN-γ    O
and    O
TNF-α    B-Cytokine114828193

Delivery    O
of    O
miRNA-210    O
to    O
an    O
ischemic    O
heart    O
improves    O
heart    O
function    O
,    O
possibly    O
by    O
promoting    O
the    O
release    O
of    O
angiogenic    O
factors    O
like    O
interleukin-1α    O
(    O
IL-1α    O
)    O
,    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-α    I-Cytokine114828193
(    O
TNF-α    O
)    O
and    O
leptin    O
,    O
as    O
seen    O
in    O
HL-1    O
cardiomyocytes    O
injected    O
with    O
miRNA-210    O
.    O

The    O
cyclosporin    O
-    O
cyclophilin    O
A    O
complex    O
inhibits    O
a    O
calcium    O
/    O
calmodulin    O
-    O
dependent    O
phosphatase    O
,    O
calcineurin    O
,    O
the    O
inhibition    O
of    O
which    O
is    O
thought    O
to    O
suppress    O
organ    O
rejection    O
by    O
halting    O
the    O
production    O
of    O
the    O
pro    O
-    O
inflammatory    O
molecules    O
TNF    B-Cytokine114828193
alpha    I-Cytokine114828193
and    O
interleukin    B-Cytokine114828193
2    I-Cytokine114828193
.    O

Serum    O
TNF-α    B-Cytokine114828193
is    O
significantly    O
elevated    O
in    O
cases    O
while    O
IL-6    B-Cytokine114828193
and    O
IL-8    B-Cytokine114828193
are    O
present    O
in    O
significantly    O
higher    O
quantities    O
in    O
the    O
aqueous    O
humour    O
in    O
patients    O
with    O
both    O
quiescent    O
and    O
active    O
uveitis    O
.    O

The    O
levels    O
of    O
inflammatory    O
cytokines    O
(    O
e.g.    O
,    O
IL-1β    O
,    O
IL-2    B-Cytokine114828193
,    O
IL-6    B-Cytokine114828193
,    O
and    O
TNF-α    B-Cytokine114828193
)    O
in    O
blood    O
plasma    O
are    O
affected    O
by    O
zinc    O
deficiency    O
and    O
zinc    O
supplementation    O
produces    O
a    O
dose    O
-    O
dependent    O
response    O
in    O
the    O
level    O
of    O
these    O
cytokines    O
.    O

It    O
has    O
been    O
found    O
that    O
endotoxin    O
LPS    O
and    O
inflammatory    O
mediators    O
as    O
IFN-γ    O
,    O
TNF-α    B-Cytokine114828193
and    O
IL-1β    O
can    O
induce    O
iNOS    O
(    O
NO    O
synthesis    O
enzyme    O
)    O
gene    O
expression    O
by    O
activating    O
transcription    O
factors    O
including    O
NF-κB    O
and    O
STAT1a    O
.    O

Upregulation    O
of    O
VCAM-1    O
in    O
endothelial    O
cells    O
by    O
cytokines    O
occurs    O
as    O
a    O
result    O
of    O
increased    O
gene    O
transcription    O
(    O
e.g.    O
,    O
in    O
response    O
to    O
Tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
(    O
TNF-α    O
)    O
and    O
Interleukin-1    O
(    O
IL-1    O
)    O
)    O
and    O
through    O
stabilization    O
of    O
Messenger    O
RNA    O
(    O
mRNA    O
)    O
(    O
e.g.    O
,    O
Interleukin-4    B-Cytokine114828193
(    O
IL-4    O
)    O
)    O
.    O

DOI    O
has    O
been    O
shown    O
to    O
be    O
an    O
extremely    O
potent    O
inhibitor    O
of    O
tumour    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
inflammation    O
at    O
picomolar    O
concentrations    O
in    O
cell    O
studies    O
.    O

Using    O
this    O
model    O
Powrie    O
further    O
identified    O
the    O
pathogenic    O
role    O
played    O
by    O
IFN-γ    O
and    O
TNF-α    B-Cytokine114828193
in    O
intestinal    O
inflammation    O
and    O
the    O
therapeutic    O
potential    O
of    O
IL-10    B-Cytokine114828193
and    O
highlighted    O
the    O
requirement    O
for    O
TGF-β    B-Cytokine114828193
in    O
the    O
prevention    O
of    O
colitis    O
by    O
the    O
CD4+CD45RBlo    O
regulatory    O
T    O
cell    O
subset    O

In    O
a    O
rat    O
model    O
of    O
rheumatoid    O
arthritis    O
HWTX    O
-    O
I    O
is    O
able    O
to    O
decrease    O
the    O
concentration    O
of    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor    I-Cytokine114828193
α    I-Cytokine114828193
(    O
TNF-α    O
)    O
in    O
serum    O
and    O
decrease    O
the    O
mRNA    O
expression    O
level    O
interleukin    O
1β    O
(    O
IL-1β    O
)    O
and    O
interleukin    B-Cytokine114828193
6    I-Cytokine114828193
(    O
IL-6    O
)    O
.    O

Bisphosphonates    O
,    O
RANKL    B-Cytokine114828193
inhibitor    I-Cytokine114828193
,    O
SERMs—    O

TNFSF4    O
(    O
OX40L    O
)    O
;    O
TNFSF8    O
(    O
CD153    O
)    O
;    O
TNFSF9    O
;    O
TNFSF10    O
(    O
TRAIL    O
)    O
;    O
TNFSF11    B-Cytokine114828193
(RANKL)    I-Cytokine114828193
;    O
TNFSF12    O
(    O
TWEAK    O
)    O
;    O
TNFSF13    O
;    O
TNFSF13B    B-Cytokine114828193
;    O
TNFSF14    O
;    O
TNFSF15    O
;    O
TNFSF18    O
;    O

This    O
effect    O
may    O
result    O
from    O
regulating    O
the    O
expression    O
of    O
arthritis    O
-    O
related    O
,    O
pro    O
-    O
inflammatory    O
genes    O
(    O
i.e.    O
those    O
for    O
IL-6    B-Cytokine114828193
,    O
VEGF    O
-    O
A    O
,    O
and    O
RANKL    B-Cytokine114828193
)    O
.    O

C4    O
-    O
2B    O
cells    O
also    O
express    O
higher    O
levels    O
of    O
osteoprotegerin    O
(    O
OPG    O
)    O
,    O
alkaline    O
phosphatase    O
,    O
bone    O
sialoprotein    O
(    O
BSP    O
)    O
,    O
Osteocalcin    O
(    O
OCN    O
)    O
,    O
RANKL    B-Cytokine114828193
,    O
and    O
Osteonectin    O
(    O
OSN    O
)    O
mRNA    O
,    O
all    O
of    O
which    O
are    O
highly    O
expressed    O
by    O
osteoblasts    O
.    O

Strontium    O
ranelate    O
also    O
stimulates    O
osteoblasts    O
to    O
secrete    O
osteoprotegerin    O
in    O
inhibiting    O
osteoclasts    O
formed    O
from    O
pre    O
-    O
osteoclasts    O
in    O
relation    O
to    O
the    O
RANKL    B-Cytokine114828193
system    O
,    O
which    O
leads    O
to    O
the    O
decrease    O
of    O
bone    O
resorption    O
.    O

Group    O
2    O
ILCs    O
can    O
produce    O
type    O
2    O
cytokines    O
(    O
e.g.    O
IL-4    B-Cytokine114828193
,    O
IL-5    O
,    O
IL-9    B-Cytokine114828193
,    O
IL-13    B-Cytokine114828193
)    O
.    O

Together    O
with    O
Interleukin-2    B-Cytokine114828193
(    O
IL-2    B-Cytokine114828193
)    O
,    O
Interleukin-4    B-Cytokine114828193
(    O
IL-4    B-Cytokine114828193
)    O
,    O
Interleukin-7    B-Cytokine114828193
(    O
IL-7    B-Cytokine114828193
)    O
,    O
Interleukin-9    B-Cytokine114828193
(    O
IL-9    B-Cytokine114828193
)    O
,    O
granulocyte    B-Cytokine114828193
colony-stimulating    I-Cytokine114828193
factor    I-Cytokine114828193
(    O
G-CSF    B-Cytokine114828193
)    O
,    O
and    O
granulocyte    O
-    O
macrophage    O
colony    O
-    O
stimulating    O
factor    O
(    O
GM    O
-    O
CSF    O
)    O
,    O
IL-15    O
belongs    O
to    O
the    O
four    O
α-helix    O
bundle    O
family    O
of    O
cytokine    O
.    O

The    O
gene    O
IL2RG    O
codes    O
for    O
the    O
common    O
gamma    O
chain    O
protein    O
,    O
which    O
is    O
a    O
common    O
subunit    O
of    O
the    O
individual    O
receptors    O
for    O
Interleukin    B-Cytokine114828193
2    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
7    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
9    I-Cytokine114828193
,    O
Interleukin    O
15    O
and    O
Interleukin    B-Cytokine114828193
21    I-Cytokine114828193
.    O

Additionally    O
,    O
neutrophil    O
apoptosis    O
,    O
immunoglobulin    O
release    O
from    O
B    O
-    O
lymphocytes    O
and    O
interleukin    O
release    O
e.g.    O
IL-8    B-Cytokine114828193
and    O
CCL5    B-Cytokine114828193
are    O
all    O
impaired    O
by    O
pyocyanin    O
causing    O
the    O
immune    O
system    O
of    O
the    O
lung    O
to    O
be    O
weakened    O
.    O

Other    O
signals    O
such    O
as    O
PF4    B-Cytokine114828193
,    O
CXCL5    B-Cytokine114828193
,    O
CXCL7    B-Cytokine114828193
,    O
and    O
CCL5    B-Cytokine114828193
inhibit    O
platelet    O
formation    O
.    O

regulated    O
upon    O
activation    O
normal    O
T    O
expressed    O
and    O
secreted    O
(    O
RANTES    O
)    O
-    O
CCL5    B-Cytokine114828193

Genetic    O
association    O
studies    O
that    O
have    O
uncovered    O
the    O
same    O
polymorphisms    O
in    O
people    O
with    O
asthma    O
and    O
COPD    O
provide    O
support    O
for    O
the    O
notion    O
that    O
the    O
two    O
conditions    O
share    O
some    O
biological    O
characteristics    O
;    O
implicated    O
genes    O
include    O
"    O
ADAM33    O
"    O
,    O
"    O
CCL5    B-Cytokine114828193
"    O
and    O
"    O
IL17F    O
"    O
.    O

Several    O
CC    O
chemokines    O
:    O
CCL1    B-Cytokine114828193
,    O
CCL2    B-Cytokine114828193
,    O
CCL3    B-Cytokine114828193
,    O
CCL4    O
,    O
CCL5    B-Cytokine114828193
,    O
CCL7    B-Cytokine114828193
,    O
CCL8    B-Cytokine114828193
,    O
CCL11    B-Cytokine114828193
,    O
CCL13    B-Cytokine114828193
,    O
CCL14    B-Cytokine114828193
,    O
CCL15    B-Cytokine114828193
,    O
CCL16    B-Cytokine114828193
,    O
CCL18    B-Cytokine114828193
,    O
and    O
CCL23    B-Cytokine114828193

Elevated    O
expression    O
levels    O
of    O
CCL2    B-Cytokine114828193
,    O
CCL5    B-Cytokine114828193
and    O
CCL17    B-Cytokine114828193
which    O
result    O
in    O
chemoattracted    O
CD4    O
+    O
and    O
CD8    O
+    O
T    O
cell    O
populations    O
to    O
the    O
surrounding    O
area    O
may    O
be    O
responsible    O
for    O
exerting    O
a    O
downmodulatory    O
effect    O
on    O
the    O
AchE    O
and    O
CHRM3    O
expressions    O
.    O

Other    O
molecular    O
signals    O
for    O
megakaryocyte    O
differentiation    O
include    O
GM    O
-    O
CSF    O
,    O
IL-3    B-Cytokine114828193
,    O
IL-6    B-Cytokine114828193
,    O
IL-11    B-Cytokine114828193
,    O
chemokines    B-Cytokine114828193
(    O
SDF-1    B-Cytokine114828193
,    O
FGF-4    O
)    O
.    O
and    O
erythropoietin    O
.    O

Certain    O
cytokines    O
such    O
as    O
IL-3    B-Cytokine114828193
,    O
IL-6    B-Cytokine114828193
,    O
IL-11    B-Cytokine114828193
,    O
LIF    B-Cytokine114828193
,    O
erythropoietin    O
,    O
and    O
thrombopoietin    B-Cytokine114828193
all    O
stimulate    O
the    O
maturation    O
of    O
megakaryocytic    O
progenitor    O
cells    O
.    O

There    O
are    O
many    O
other    O
proteins    O
which    O
associate    O
with    O
gp130    O
,    O
such    O
as    O
cardiotrophin    O
1    O
(    O
CT-1    O
)    O
,    O
leukemia    B-Cytokine114828193
inhibitory    I-Cytokine114828193
factor    I-Cytokine114828193
(    O
LIF    O
)    O
,    O
ciliary    O
neurotrophic    O
factor    O
(    O
CNTF    O
)    O
,    O
oncostatin    B-Cytokine114828193
M    I-Cytokine114828193
(    O
OSM    O
)    O
,    O
and    O
IL-11    B-Cytokine114828193
.    O

:*    O
IL21    B-Cytokine114828193

Interleukin    B-Cytokine114828193
21    I-Cytokine114828193
(    O
IL-21    B-Cytokine114828193
)    O
is    O
a    O
protein    O
that    O
in    O
humans    O
is    O
encoded    O
by    O
the    O
"    O
IL21    O
"    O
gene    O
.    O

The    O
gene    O
IL2RG    O
codes    O
for    O
the    O
common    O
gamma    O
chain    O
protein    O
,    O
which    O
is    O
a    O
common    O
subunit    O
of    O
the    O
individual    O
receptors    O
for    O
Interleukin    B-Cytokine114828193
2    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
7    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
9    I-Cytokine114828193
,    O
Interleukin    O
15    O
and    O
Interleukin    B-Cytokine114828193
21    I-Cytokine114828193
.    O

XCL2    B-Cytokine114828193

The    O
gene    O
for    O
CCL17    O
is    O
located    O
on    O
chromosome    O
16    O
,    O
in    O
humans    O
,    O
along    O
with    O
other    O
chemokines    O
called    O
CCL22    B-Cytokine114828193
and    O
CX3CL1    B-Cytokine114828193
.    O

Fractalkine    B-Cytokine114828193
also    O
known    O
as    O
chemokine    B-Cytokine114828193
(C-X3-C    I-Cytokine114828193
motif)    I-Cytokine114828193
ligand    I-Cytokine114828193
1    I-Cytokine114828193
is    O
a    O
protein    O
that    O
in    O
humans    O
is    O
encoded    O
by    O
the    O
CX3CL1    O
gene    O
.    O

Bone    B-Cytokine114828193
morphogenetic    I-Cytokine114828193
protein    I-Cytokine114828193
1    I-Cytokine114828193
(    O
BMP1    O
)    O

Secretion    B-Cytokine114828193
assay    I-Cytokine114828193

Several    O
CC    O
chemokines    O
:    O
CCL1    B-Cytokine114828193
,    O
CCL2    B-Cytokine114828193
,    O
CCL3    B-Cytokine114828193
,    O
CCL4    O
,    O
CCL5    B-Cytokine114828193
,    O
CCL7    B-Cytokine114828193
,    O
CCL8    B-Cytokine114828193
,    O
CCL11    B-Cytokine114828193
,    O
CCL13    B-Cytokine114828193
,    O
CCL14    B-Cytokine114828193
,    O
CCL15    B-Cytokine114828193
,    O
CCL16    B-Cytokine114828193
,    O
CCL18    B-Cytokine114828193
,    O
and    O
CCL23    B-Cytokine114828193

CXCR3-A    O
binds    O
to    O
the    O
CXC    O
chemokines    O
CXCL9    B-Cytokine114828193
(    O
MIG    O
)    O
,    O
CXCL10    B-Cytokine114828193
(    O
IP-10    O
)    O
,    O
and    O
CXCL11    B-Cytokine114828193
(    O
I    O
-    O
TAC    O
)    O
whereas    O
CXCR3-B    O
can    O
also    O
bind    O
to    O
CXCL4    B-Cytokine114828193
in    O
addition    O
to    O
CXCL9    O
,    O
CXCL10    O
,    O
and    O
CXCL11    O
.    O

Nemosis    O
of    O
fibroblasts    O
,    O
or    O
mesenchymal    O
cells    O
in    O
general    O
,    O
generates    O
large    O
amounts    O
of    O
mediators    O
of    O
inflammation    O
,    O
such    O
as    O
prostaglandins    O
,    O
as    O
well    O
as    O
growth    O
factors    O
such    O
as    O
hepatocyte    B-Cytokine114828193
growth    I-Cytokine114828193
factor    I-Cytokine114828193
.    O

Hepatocyte    B-Cytokine114828193
growth    I-Cytokine114828193
factor    I-Cytokine114828193
,    O
a    O
paracrine    O
cellular    O
growth    O
,    O
motility    O
and    O
morphogenic    O
factor    O

Human    B-Cytokine114828193
hepatocyte    I-Cytokine114828193
growth    I-Cytokine114828193
factor    I-Cytokine114828193
(HGF)    I-Cytokine114828193
is    O
an    O
80kD    O
pleiotropic    O
protein    O
that    O
is    O
endogenously    O
produced    O
by    O
a    O
variety    O
of    O
cell    O
types    O
from    O
the    O
mesenchymal    O
cell    O
lineage    O
(    O
such    O
as    O
cardiomyocytes    O
and    O
neurons    O
)    O
.    O

Epinephrine    O
induces    O
platelet    O
aggregation    O
,    O
and    O
so    O
does    O
hepatocyte    B-Cytokine114828193
growth    I-Cytokine114828193
factor    I-Cytokine114828193
(    O
HGF    O
)    O
.    O

Myocyte    O
nuclear    O
factor    O
(    O
MNF    O
)    O
,    O
and    O
c    O
-    O
met    O
proto    O
-    O
oncogene    O
(    O
receptor    O
for    O
hepatocyte    O
growth    O
factor    O
(    O
HGF    B-Cytokine114828193
)    O
)    O
are    O
less    O
commonly    O
used    O
markers    O
.    O

Notably    O
,    O
HGF    B-Cytokine114828193
,    O
a    O
cytokine    O
,    O
is    O
transferred    O
from    O
the    O
extracellular    O
matrix    O
into    O
muscles    O
through    O
the    O
nitric    O
-    O
oxide    O
dependent    O
pathway    O
.    O

This    O
phenotype    O
mimics    O
an    O
effect    O
produced    O
by    O
hepatocyte    B-Cytokine114828193
growth    I-Cytokine114828193
factor    I-Cytokine114828193
which    O
may    O
participate    O
in    O
various    O
aspects    O
of    O
cancer    O
,    O
including    O
metastasis    O
.    O

Several    O
CC    O
chemokines    O
:    O
CCL1    B-Cytokine114828193
,    O
CCL2    B-Cytokine114828193
,    O
CCL3    B-Cytokine114828193
,    O
CCL4    O
,    O
CCL5    B-Cytokine114828193
,    O
CCL7    B-Cytokine114828193
,    O
CCL8    B-Cytokine114828193
,    O
CCL11    B-Cytokine114828193
,    O
CCL13    B-Cytokine114828193
,    O
CCL14    B-Cytokine114828193
,    O
CCL15    B-Cytokine114828193
,    O
CCL16    B-Cytokine114828193
,    O
CCL18    B-Cytokine114828193
,    O
and    O
CCL23    B-Cytokine114828193

A    O
macrophage-activating    B-Cytokine114828193
factor    I-Cytokine114828193
(    O
MAF    O
)    O
is    O
a    O
lymphokine    O
or    O
other    O
receptor    O
based    O
signal    O
that    O
primes    O
macrophages    O
towards    O
cytotoxicity    O
to    O
tumors    O
,    O
cytokine    O
secretion    O
,    O
or    O
clearance    O
of    O
pathogens    O
.    O

:*    O
IL35    B-Cytokine114828193

In    O
early    O
July    O
,    O
the    O
company    O
announced    O
it    O
would    O
acquire    O
Cormorant    O
Pharmaceuticals    O
for    O
$    O
520    O
million    O
,    O
boosting    O
BMS    O
'    O
onclogy    O
offering    O
through    O
Cormorants    O
monoclonal    O
antibody    O
targeted    O
against    O
interleukin-8    B-Cytokine114828193
.    O

Several    O
cytokines    O
are    O
involved    O
in    O
lichen    O
planus    O
,    O
including    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor    I-Cytokine114828193
alpha    I-Cytokine114828193
,    O
interferon    O
gamma    O
,    O
interleukin-1    B-Cytokine114828193
alpha    I-Cytokine114828193
,    O
interleukin    B-Cytokine114828193
6    I-Cytokine114828193
,    O
and    O
interleukin    B-Cytokine114828193
8    I-Cytokine114828193
.    O

Additionally    O
,    O
neutrophil    O
apoptosis    O
,    O
immunoglobulin    O
release    O
from    O
B    O
-    O
lymphocytes    O
and    O
interleukin    O
release    O
e.g.    O
IL-8    B-Cytokine114828193
and    O
CCL5    B-Cytokine114828193
are    O
all    O
impaired    O
by    O
pyocyanin    O
causing    O
the    O
immune    O
system    O
of    O
the    O
lung    O
to    O
be    O
weakened    O
.    O

Interleukin-8    O
(    O
IL-8    O
)    O
-    O
CXCL8    B-Cytokine114828193

IL-17    O
induces    O
the    O
production    O
of    O
many    O
other    O
cytokines    O
(    O
such    O
as    O
IL-6    B-Cytokine114828193
,    O
G-CSF    B-Cytokine114828193
,    O
GM    O
-    O
CSF    O
,    O
IL-1β    O
,    O
TGF-β    B-Cytokine114828193
,    O
TNF-α    B-Cytokine114828193
)    O
,    O
chemokines    B-Cytokine114828193
(    O
including    O
IL-8    B-Cytokine114828193
,    O
GRO-α    O
,    O
and    O
MCP-1    O
)    O
,    O
and    O
prostaglandins    O
(    O
e.g.    O
,    O
PGE2    O
)    O
from    O
many    O
cell    O
types    O
(    O
fibroblasts    O
,    O
endothelial    O
cells    O
,    O
epithelial    O
cells    O
,    O
keratinocytes    O
,    O
and    O
macrophages    O
)    O
.    O

IL-17    O
interaction    O
with    O
IL-17RA    O
receptors    O
,    O
abundant    O
on    O
the    O
keratinocyte    O
cell    O
surface    O
,    O
incite    O
epidermal    O
cells    O
to    O
increase    O
expression    O
of    O
IL-6    O
,    O
antimicrobial    O
peptides    O
,    O
IL-8    B-Cytokine114828193
and    O
CCL20    B-Cytokine114828193
.    O

Chronic    O
consumption    O
of    O
alcohol    O
results    O
in    O
the    O
secretion    O
of    O
pro    O
-    O
inflammatory    O
cytokines    O
(    O
TNF-alpha    B-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
6    I-Cytokine114828193
[    O
IL6    O
]    O
and    O
Interleukin    B-Cytokine114828193
8    I-Cytokine114828193
[    O
IL8    O
]    O
)    O
,    O
oxidative    O
stress    O
,    O
lipid    O
peroxidation    O
,    O
and    O
acetaldehyde    O
toxicity    O
.    O

The    O
p65    O
subunit    O
of    O
NF-κB    O
is    O
a    O
SirT1    O
substrate    O
;    O
in    O
the    O
absence    O
of    O
SirT1    O
activity    O
,    O
NFκB    O
is    O
active    O
,    O
promoting    O
inflammation    O
and    O
the    O
production    O
of    O
the    O
chemokines    O
IL-8    B-Cytokine114828193
and    O
MCP-1    B-Cytokine114828193
.    O

It    O
has    O
nootropic    O
effects    O
and    O
was    O
originally    O
developed    O
as    O
a    O
potential    O
treatment    O
for    O
Alzheimer    O
's    O
disease    O
,    O
but    O
a    O
second    O
action    O
that    O
was    O
subsequently    O
found    O
was    O
that    O
it    O
inhibits    O
the    O
production    O
of    O
Interleukin-8    B-Cytokine114828193
and    O
thus    O
produces    O
an    O
antiinflammatory    O
effect    O
,    O
and    O
so    O
it    O
has    O
also    O
been    O
developed    O
as    O
a    O
potential    O
treatment    O
for    O
ulcerative    O
colitis    O
.    O

The    O
presence    O
of    O
viral    O
particles    O
and    O
the    O
cell    O
damage    O
resulting    O
from    O
viruses    O
budding    O
out    O
of    O
the    O
cell    O
causes    O
the    O
release    O
of    O
chemical    O
signals    O
(    O
such    O
as    O
TNF-α    B-Cytokine114828193
,    O
IL-6    B-Cytokine114828193
and    O
IL-8    B-Cytokine114828193
)    O
,    O
which    O
are    O
molecular    O
signals    O
for    O
fever    O
and    O
inflammation    O
.    O

For    O
instance    O
,    O
their    O
effector    O
EspG    O
can    O
reduce    O
the    O
secretion    O
of    O
interleukin-8    B-Cytokine114828193
(    O
IL-8    O
)    O
,    O
and    O
thus    O
affect    O
the    O
immune    O
system    O
(    O
immunomodulation    O
)    O
.    O

In    O
addition    O
,    O
it    O
can    O
also    O
induce    O
the    O
production    O
of    O
chemokines    B-Cytokine114828193
such    O
as    O
IL-8    B-Cytokine114828193
and    O
MIP-2    O
/    O
CXCL2    B-Cytokine114828193
.    O

EP3-deficient    O
mice    O
as    O
well    O
as    O
mice    O
selectively    O
deleted    O
of    O
EP3    O
expression    O
in    O
the    O
brain    O
's    O
median    O
preoptic    O
nucleus    O
fail    O
to    O
develop    O
fever    O
in    O
response    O
to    O
endotoxin    O
(    O
i.e.    O
bacteria    O
-    O
derived    O
lipopolysaccharide    O
)    O
or    O
the    O
host    O
-    O
derived    O
regulator    O
of    O
body    O
temperature    O
,    O
IL-1β.    O
The    O
ability    O
of    O
endotoxind    O
and    O
IL-1β    O
but    O
not    O
that    O
of    O
PGE2    O
to    O
trigger    O
fever    O
is    O
blocked    O
by    O
inhibitors    O
of    O
nitric    O
oxide    O
and    O
PG2    O
EP33-deficient    O
mice    O
exhibit    O
normal    O
febrile    O
responses    O
to    O
stress    O
,    O
interleukin-8    B-Cytokine114828193
,    O
and    O
macrophage    O
inflammatory    O
protein-1beta    O
(    O
MIP-1β    O
)    O
.    O

Glucocorticoids    O
suppress    O
cell    O
-    O
mediated    O
immunity    O
by    O
inhibiting    O
genes    O
that    O
code    O
for    O
the    O
cytokines    O
IL-1    O
,    O
IL-2    B-Cytokine114828193
,    O
IL-3    B-Cytokine114828193
,    O
IL-4    B-Cytokine114828193
,    O
IL-5    O
,    O
IL-6    B-Cytokine114828193
,    O
IL-8    B-Cytokine114828193
and    O
IFN-γ    O
,    O
the    O
most    O
important    O
of    O
which    O
is    O
IL-2    O
.    O

Serum    O
TNF-α    B-Cytokine114828193
is    O
significantly    O
elevated    O
in    O
cases    O
while    O
IL-6    B-Cytokine114828193
and    O
IL-8    B-Cytokine114828193
are    O
present    O
in    O
significantly    O
higher    O
quantities    O
in    O
the    O
aqueous    O
humour    O
in    O
patients    O
with    O
both    O
quiescent    O
and    O
active    O
uveitis    O
.    O

Further    O
Johannessen    O
found    O
that    O
levels    O
of    O
IL-6    B-Cytokine114828193
were    O
reduced    O
to    O
90%    O
when    O
exposed    O
to    O
25    O
μg    O
/    O
mL    O
citrinin    O
(    O
CTN    O
)    O
and    O
to    O
40%    O
when    O
exposed    O
to    O
50    O
μg    O
/    O
mL.    O
Levels    O
of    O
IL-8    B-Cytokine114828193
and    O
cell    O
viability    O
were    O
also    O
reduced    O
to    O
80%    O
and    O
20%    O
when    O
exposed    O
to    O
respectively    O
25    O
and    O
50    O
μg    O
/    O
mL    O
CTN    O
for    O
72    O
hours    O
.    O

The    O
end    O
-    O
result    O
includes    O
activation    O
of    O
arachidonic    O
acid    O
pathway    O
and    O
production    O
of    O
thromboxane    O
A2    O
,    O
production    O
of    O
IL-8    B-Cytokine114828193
,    O
platelet    O
-    O
activating    O
factor    O
,    O
and    O
several    O
intercellular    O
adhesion    O
molecules    O
.    O

Kaushansky    O
K    O
,    O
Lok    O
S    O
,    O
Holly    O
RD    O
,    O
Broudy    O
VC    O
,    O
Lin    O
N    O
,    O
Bailey    O
MC    O
,    O
Forstrom    O
JW    O
,    O
Buddle    O
M    O
,    O
Oort    O
PJ    O
,    O
Hagen    O
FS    O
,    O
Roth    O
GJ    O
,    O
Papayannopoulou    O
Th    O
,    O
Foster    O
DC    O
:    O
Promotion    O
of    O
megakaryocyte    O
progenitor    O
expansion    O
and    O
differentiation    O
by    O
the    O
c    O
-    O
Mpl    O
ligand    O
thrombopoietin    B-Cytokine114828193
.    O

Lok    O
S    O
,    O
Kaushansky    O
K    O
,    O
Holly    O
RD    O
,    O
Kuijper    O
JL    O
,    O
Lofton    O
-    O
Day    O
CE    O
,    O
Oort    O
PJ    O
,    O
Grant    O
FJ    O
,    O
Heipel    O
MD    O
,    O
Burkhead    O
SK    O
,    O
Kramer    O
JM    O
,    O
Bell    O
LA    O
,    O
Sprecher    O
CA    O
,    O
Blumberg    O
H    O
,    O
Johnson    O
R    O
,    O
Prunkard    O
D    O
,    O
Ching    O
AFT    O
,    O
Mathewes    O
S    O
,    O
Bailey    O
MC    O
,    O
Forstrom    O
JW    O
,    O
Buddle    O
MM    O
,    O
Osborn    O
SG    O
,    O
Evans    O
SJ    O
,    O
Sheppard    O
PO    O
,    O
Presnell    O
SR    O
,    O
O'Hara    O
PJ    O
,    O
Hagen    O
FS    O
,    O
Roth    O
GJ    O
.    O
,    O
Foster    O
DC    O
:    O
Cloning    O
and    O
expression    O
of    O
murine    O
thrombopoietin    B-Cytokine114828193
cDNA    O
and    O
stimulation    O
of    O
platelet    O
production    O
in    O
vivo    O
.    O

Kaushansky    O
K    O
,    O
Broudy    O
VC    O
,    O
Lin    O
N    O
,    O
Jorgensen    O
MJ    O
,    O
McCarty    O
J    O
,    O
Fox    O
N    O
,    O
Zucker    O
-    O
Franklin    O
D    O
,    O
Lofton    O
-    O
Day    O
C    O
:    O
Thrombopoietin    B-Cytokine114828193
,    O
the    O
Mpl    O
-    O
ligand    O
,    O
is    O
essential    O
for    O
full    O
megakaryocyte    O
development    O
.    O
"    O
Proc    O
.    O
Natl    O
.    O
Acad    O
.    O
Sci    O
.    O
USA    O
"    O
92:3234    O
-    O
3238    O
,    O
1995    O
.    O

Kaushansky    O
K    O
,    O
Broudy    O
,    O
VC    O
,    O
Grossmann    O
A    O
,    O
Humes    O
J    O
,    O
Lin    O
N    O
,    O
Ren    O
H    O
-    O
P    O
,    O
Bailey    O
MC    O
,    O
Papayannopoulou    O
Th    O
,    O
Forstrom    O
JW    O
,    O
Sprugel    O
KH    O
:    O
Thrombopoietin    B-Cytokine114828193
expands    O
erythroid    O
progenitors    O
,    O
increases    O
red    O
cell    O
production    O
,    O
and    O
enhances    O
erythroid    O
recovery    O
after    O
myelosuppressive    O
therapy    O
.    O
"    O
J.    O
Clin    O
.    O
Invest    O
.    O
"    O

Hitchcock    O
I    O
,    O
Chen    O
M    O
,    O
Fox    O
NE    O
,    O
Kaushansky    O
K.    O
YRRL    O
motifs    O
in    O
the    O
cytoplasmic    O
domain    O
of    O
the    O
thrombopoietin    B-Cytokine114828193
receptor    O
regulate    O
receptor    O
internalization    O
and    O
degradation    O
.    O

Kaushansky    O
K    O
:    O
Thrombopoietin:    B-Cytokine114828193
Biological    I-Cytokine114828193
and    I-Cytokine114828193
preclinical    I-Cytokine114828193
properties    I-Cytokine114828193
.    O
"    O
Leukemia    O
"    O
10:Suppl    O
.    O
S46    O
-    O
48    O
,    O
1996    O

It    O
is    O
a    O
small    O
molecule    O
agonist    O
of    O
the    O
c    O
-    O
mpl    O
(    O
TpoR    O
)    O
receptor    O
,    O
which    O
is    O
the    O
physiological    O
target    O
of    O
the    O
hormone    O
thrombopoietin    B-Cytokine114828193
.    O

IL-17    O
interaction    O
with    O
IL-17RA    O
receptors    O
,    O
abundant    O
on    O
the    O
keratinocyte    O
cell    O
surface    O
,    O
incite    O
epidermal    O
cells    O
to    O
increase    O
expression    O
of    O
IL-6    O
,    O
antimicrobial    O
peptides    O
,    O
IL-8    B-Cytokine114828193
and    O
CCL20    B-Cytokine114828193
.    O

Chemokine    B-Cytokine114828193
(C-C    I-Cytokine114828193
motif)    I-Cytokine114828193
ligand    I-Cytokine114828193
19    I-Cytokine114828193
(    O
CCL19    O
)    O
is    O
a    O
protein    O
that    O
in    O
humans    O
is    O
encoded    O
by    O
the    O
"    O
CCL19    O
"    O
gene    O
.    O

EBI-1    O
ligand    O
chemokine    O
,    O
also    O
known    O
as    O
CCL19    B-Cytokine114828193

CCL4    O
has    O
been    O
shown    O
to    O
interact    O
with    O
CCL3    B-Cytokine114828193
.    O

Several    O
CC    O
chemokines    O
:    O
CCL1    B-Cytokine114828193
,    O
CCL2    B-Cytokine114828193
,    O
CCL3    B-Cytokine114828193
,    O
CCL4    O
,    O
CCL5    B-Cytokine114828193
,    O
CCL7    B-Cytokine114828193
,    O
CCL8    B-Cytokine114828193
,    O
CCL11    B-Cytokine114828193
,    O
CCL13    B-Cytokine114828193
,    O
CCL14    B-Cytokine114828193
,    O
CCL15    B-Cytokine114828193
,    O
CCL16    B-Cytokine114828193
,    O
CCL18    B-Cytokine114828193
,    O
and    O
CCL23    B-Cytokine114828193

The    O
protein    O
encoded    O
by    O
this    O
gene    O
is    O
a    O
glycosylated    O
membrane    O
protein    O
and    O
a    O
non    O
-    O
specific    O
receptor    O
for    O
several    O
chemokine    B-Cytokine114828193
.    O

Evidence    O
that    O
oncogenic    O
-    O
stress    O
can    O
cause    O
Focal    O
Adhesion    O
Kinase    O
(    O
FAK    O
)    O
to    O
move    O
to    O
the    O
nucleus    O
to    O
regulate    O
expression    O
of    O
genes    O
(    O
chemokine    B-Cytokine114828193
&    O
cytokines    O
)    O
that    O
promote    O
tumor    O
evasion    O
by    O
inducing    O
an    O
immuno    O
-    O
suppressive    O
microenvironment    O
,    O
and    O
demonstration    O
that    O
FAK    O
inhibitor    O
in    O
clinical    O
development    O
can    O
help    O
the    O
body    O
's    O
immune    O
system    O
to    O
fight    O
cancer    O
.    O

IL-17    O
induces    O
the    O
production    O
of    O
many    O
other    O
cytokines    O
(    O
such    O
as    O
IL-6    B-Cytokine114828193
,    O
G-CSF    B-Cytokine114828193
,    O
GM    O
-    O
CSF    O
,    O
IL-1β    O
,    O
TGF-β    B-Cytokine114828193
,    O
TNF-α    B-Cytokine114828193
)    O
,    O
chemokines    B-Cytokine114828193
(    O
including    O
IL-8    B-Cytokine114828193
,    O
GRO-α    O
,    O
and    O
MCP-1    O
)    O
,    O
and    O
prostaglandins    O
(    O
e.g.    O
,    O
PGE2    O
)    O
from    O
many    O
cell    O
types    O
(    O
fibroblasts    O
,    O
endothelial    O
cells    O
,    O
epithelial    O
cells    O
,    O
keratinocytes    O
,    O
and    O
macrophages    O
)    O
.    O

In    O
the    O
second    O
phase    O
of    O
elimination    O
,    O
newly    O
synthesized    O
IFN    O
-    O
gamma    O
induces    O
tumor    O
death    O
(    O
to    O
a    O
limited    O
amount    O
)    O
as    O
well    O
as    O
promoting    O
the    O
production    O
of    O
chemokines    B-Cytokine114828193
CXCL10    B-Cytokine114828193
,    O
CXCL9    B-Cytokine114828193
and    O
CXCL11    B-Cytokine114828193
.    O

C    O
/    O
EBPβ    O
function    O
is    O
regulated    O
by    O
multiple    O
mechanisms    O
,    O
including    O
phosphorylation    O
,    O
acetylation    O
,    O
activation    O
,    O
autoregulation    O
,    O
and    O
repression    O
via    O
other    O
transcription    O
factors    O
,    O
oncogenic    O
elements    O
,    O
or    O
chemokines    B-Cytokine114828193
.    O

As    O
the    O
inflammatory    O
response    O
progresses    O
,    O
chemokine    B-Cytokine114828193
released    O
by    O
injured    O
tissue    O
enter    O
the    O
blood    O
vessels    O
and    O
activate    O
the    O
rolling    O
leukocytes    O
,    O
which    O
are    O
now    O
able    O
to    O
tightly    O
bind    O
to    O
the    O
endothelial    O
surface    O
and    O
begin    O
making    O
their    O
way    O
into    O
the    O
tissue    O
.    O

The    O
rolling    O
cancer    O
cells    O
then    O
become    O
activated    O
by    O
locally    O
released    O
chemokine    B-Cytokine114828193
present    O
at    O
the    O
surface    O
of    O
endothelial    O
cells    O
.    O

Induction    O
of    O
FPR    O
triggers    O
multiple    O
changes    O
in    O
eukaryotic    O
cells    O
including    O
rearrangement    O
of    O
the    O
cytoskeleton    O
which    O
in    O
turn    O
facilitates    O
cell    O
migration    O
and    O
the    O
synthesis    O
of    O
chemokine    B-Cytokine114828193
.    O

Production    O
of    O
CXCL12    B-Cytokine114828193
,    O
a    O
chemokine    B-Cytokine114828193
,    O
is    O
regulated    O
by    O
mir-126    O
.    O

Activated    O
mast    O
cells    O
also    O
synthesize    O
and    O
secrete    O
lipid    O
-    O
derived    O
mediators    O
(    O
such    O
as    O
prostaglandins    O
,    O
leukotrienes    O
,    O
and    O
platelet    O
-    O
activating    O
factor    O
)    O
and    O
cytokines    O
(    O
such    O
as    O
interleukin    O
1    O
,    O
interleukin    B-Cytokine114828193
3    I-Cytokine114828193
,    O
interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
interleukin    O
5    O
,    O
interleukin    B-Cytokine114828193
6    I-Cytokine114828193
,    O
interleukin    B-Cytokine114828193
13    I-Cytokine114828193
,    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
,    O
GM    O
-    O
CSF    O
,    O
and    O
several    O
chemokine    B-Cytokine114828193
.    O

The    O
encoded    O
protein    O
may    O
be    O
involved    O
in    O
the    O
regulation    O
of    O
granulocyte    O
function    O
through    O
the    O
chemokine    B-Cytokine114828193
signal    O
transduction    O
pathway    O
.    O

Once    O
pathogens    O
start    O
to    O
invade    O
the    O
upper    O
layers    O
of    O
the    O
epidermis    O
,    O
keratinocytes    O
can    O
react    O
by    O
producing    O
proinflammatory    O
mediators    O
,    O
particularly    O
chemokines    B-Cytokine114828193
such    O
as    O
CXCL10    B-Cytokine114828193
and    O
CCL2    B-Cytokine114828193
which    O
attract    O
leukocytes    O
to    O
the    O
site    O
of    O
pathogen    O
invasion    O
.    O

Keratinocytes    O
also    O
modulate    O
the    O
immune    O
system    O
:    O
apart    O
from    O
the    O
above    O
-    O
mentioned    O
antimicrobial    O
peptides    O
and    O
chemokines    B-Cytokine114828193
they    O
are    O
also    O
potent    O
producers    O
of    O
anti    O
-    O
inflammatory    O
mediators    O
such    O
as    O
IL-10    B-Cytokine114828193
and    O
TGF-β    B-Cytokine114828193
When    O
activated    O
,    O
they    O
can    O
stimulate    O
cutaneous    O
inflammation    O
and    O
Langerhans    O
cell    O
activation    O
via    O
TNFα    B-Cytokine114828193
and    O
IL-1β    O
secretion    O
.    O

Common    O
cytokines    O
include    O
interleukins    O
that    O
are    O
responsible    O
for    O
communication    O
between    O
white    O
blood    O
cells    O
;    O
chemokine    B-Cytokine114828193
that    O
promote    O
chemotaxis    O
;    O
and    O
interferons    O
that    O
have    O
anti    O
-    O
viral    O
effects    O
,    O
such    O
as    O
shutting    O
down    O
protein    O
synthesis    O
in    O
the    O
host    O
cell    O
.    O

These    O
factors    O
include    O
most    O
particularly    O
chemokines    B-Cytokine114828193
such    O
as    O
monocyte    B-Cytokine114828193
chemotactic    I-Cytokine114828193
protein-1    I-Cytokine114828193
(    O
CCL2    O
)    O
and    O
monocyte    B-Cytokine114828193
chemotactic    I-Cytokine114828193
protein-3    I-Cytokine114828193
(CCL7)    I-Cytokine114828193
;    O
certain    O
arachidonic    O
acid    O
metabolites    O
such    O
as    O
Leukotriene    O
B4    O
and    O
members    O
of    O
the    O
5-Hydroxyicosatetraenoic    O
acid    O
and    O
5-oxo    O
-    O
eicosatetraenoic    O
acid    O
family    O
of    O
OXE1    O
receptor    O
agonists    O
(    O
e.g.    O
,    O
5-HETE    O
and    O
5-oxo    O
-    O
ETE    O
)    O
;    O
and    O
N    O
-    O
Formylmethionine    O
leucyl    O
-    O
phenylalanine    O
and    O
other    O
N    O
-    O
formylated    O
oligopeptides    O
which    O
are    O
made    O
by    O
bacteria    O
and    O
activate    O
the    O
formyl    O
peptide    O
receptor    O
1    O
.    O

At    O
a    O
concentration    O
of    O
1    O
μM    O
,    O
cationic    O
cliotides    O
are    O
capable    O
of    O
augmenting    O
the    O
secretion    O
of    O
various    O
cytokines    O
and    O
chemokine    B-Cytokine114828193
in    O
human    O
monocytes    O
at    O
both    O
resting    O
and    O
LPS    O
-    O
stimulated    O
states    O
.    O

However    O
,    O
cytokines    O
and    O
chemokine    B-Cytokine114828193
also    O
modulate    O
central    O
nervous    O
system    O
(    O
CNS    O
)    O
function    O
in    O
the    O
absence    O
of    O
overt    O
immunological    O
,    O
physiological    O
,    O
or    O
psychological    O
challenges    O
.    O

Chemokine    B-Cytokine114828193
(C-X-C    I-Cytokine114828193
motif)    I-Cytokine114828193
ligand    I-Cytokine114828193
6    I-Cytokine114828193
(    O
CXCL6    O
)    O
is    O
a    O
small    O
cytokine    O
belonging    O
to    O
the    O
CXC    O
chemokine    B-Cytokine114828193
family    O
that    O
is    O
also    O
known    O
as    O
granulocyte    O
chemotactic    O
protein    O
2    O
(    O
GCP-2    O
)    O
.    O

Chemokine    B-Cytokine114828193
(C-X-C    I-Cytokine114828193
motif)    I-Cytokine114828193
ligand    I-Cytokine114828193
16    I-Cytokine114828193
(    O
CXCL16    O
)    O
is    O
a    O
small    O
cytokine    O
belonging    O
to    O
the    O
CXC    O
chemokine    B-Cytokine114828193
family    O
.    O

In    O
addition    O
,    O
it    O
can    O
also    O
induce    O
the    O
production    O
of    O
chemokines    B-Cytokine114828193
such    O
as    O
IL-8    B-Cytokine114828193
and    O
MIP-2    O
/    O
CXCL2    B-Cytokine114828193
.    O

There    O
are    O
several    O
ways    O
in    O
which    O
PTECs    O
may    O
respond    O
:    O
producing    O
cytokines    O
,    O
chemokines    B-Cytokine114828193
,    O
and    O
collagen    O
;    O
undergoing    O
epithelial    O
mesenchymal    O
trans    O
-    O
differentiation    O
;    O
necrosis    O
or    O
apoptosis    O
.    O

It    O
seems    O
that    O
human    O
Vγ9Vδ2    O
T    O
cells    O
are    O
characterized    O
by    O
a    O
specific    O
inflammatory    O
migration    O
program    O
,    O
including    O
multiple    O
receptors    O
for    O
inflammatory    O
chemokines    B-Cytokine114828193
(    O
CXCR3    O
,    O
CCR1    O
,    O
CCR2    O
and    O
CCR5    O
)    O
.    O

Nonetheless    O
,    O
there    O
still    O
exists    O
the    O
potential    O
for    O
side    O
effects    O
,    O
such    O
as    O
elevated    O
levels    O
of    O
cytokines    O
and    O
chemokine    B-Cytokine114828193
in    O
normal    O
tissues    O
,    O
depending    O
on    O
the    O
cellular    O
environment    O
.    O

In    O
addition    O
to    O
being    O
the    O
cellular    O
effector    O
of    O
hemostasis    O
,    O
platelets    O
are    O
rapidly    O
deployed    O
to    O
sites    O
of    O
injury    O
or    O
infection    O
,    O
and    O
potentially    O
modulate    O
inflammatory    O
processes    O
by    O
interacting    O
with    O
leukocytes    O
and    O
by    O
secreting    O
cytokines    O
,    O
chemokines    B-Cytokine114828193
,    O
and    O
other    O
inflammatory    O
mediators    O
.    O

This    O
signaling    O
pathway    O
also    O
induces    O
transcription    O
of    O
many    O
cytokine    O
and    O
chemokine    B-Cytokine114828193
genes    O
.    O

Chemokine    B-Cytokine114828193
(C-C    I-Cytokine114828193
motif)    I-Cytokine114828193
ligand    I-Cytokine114828193
28    I-Cytokine114828193
(    O
CCL28    O
)    O
,    O
also    O
known    O
as    O
mucosae    O
-    O
associated    O
epithelial    O
chemokine    O
(    O
MEC    O
)    O
,    O
CCK1    O
and    O
SCYA28    O
,    O
is    O
a    O
chemokine    B-Cytokine114828193
.    O

In    O
2010    O
,    O
the    O
structures    O
of    O
the    O
human    O
chemokine    B-Cytokine114828193
CXCR4    O
receptor    O
(    O
HIV    O
co    O
-    O
receptor    O
)    O
,    O
the    O
human    O
dopamine    O
D3    O
receptor    O
and    O
the    O
human    O
Histamine    O
H1    O
receptor    O
were    O
published    O
.    O

This    O
area    O
is    O
filled    O
with    O
pro    O
-    O
inflammatory    O
factors    O
such    O
as    O
antibodies    O
,    O
complement    O
proteins    O
,    O
cytokines    O
,    O
and    O
chemokines    B-Cytokine114828193
.    O

Chemokine    B-Cytokine114828193

The    O
function    O
of    O
TAMs    O
is    O
controversial    O
as    O
there    O
is    O
growing    O
evidence    O
for    O
their    O
involvement    O
in    O
both    O
pro    O
-    O
tumor    O
(    O
e.g.    O
promotion    O
of    O
growth    O
and    O
metastasis    O
through    O
tumor    O
angiogenesis    O
)    O
as    O
well    O
as    O
anti    O
-    O
tumor    O
(    O
tumoricidal    O
and    O
tumorostatic    O
)    O
processes    O
.    O
TAMs    O
interact    O
with    O
a    O
wide    O
range    O
of    O
growth    O
factors    O
,    O
cytokines    O
and    O
chemokines    B-Cytokine114828193
in    O
the    O
tumor    O
microenvironment    O
which    O
is    O
thought    O
to    O
educate    O
the    O
TAMs    O
and    O
determine    O
their    O
specific    O
phenotype    O
and    O
hence    O
functional    O
role    O
as    O
the    O
microenvironment    O
varies    O
between    O
different    O
types    O
of    O
tumors    O
.    O

Elevated    O
expression    O
levels    O
of    O
CCL2    B-Cytokine114828193
,    O
CCL5    B-Cytokine114828193
and    O
CCL17    B-Cytokine114828193
which    O
result    O
in    O
chemoattracted    O
CD4    O
+    O
and    O
CD8    O
+    O
T    O
cell    O
populations    O
to    O
the    O
surrounding    O
area    O
may    O
be    O
responsible    O
for    O
exerting    O
a    O
downmodulatory    O
effect    O
on    O
the    O
AchE    O
and    O
CHRM3    O
expressions    O
.    O

Synthetic    O
–    O
Promegapoietin    B-Cytokine114828193

Together    O
with    O
Interleukin-2    B-Cytokine114828193
(    O
IL-2    B-Cytokine114828193
)    O
,    O
Interleukin-4    B-Cytokine114828193
(    O
IL-4    B-Cytokine114828193
)    O
,    O
Interleukin-7    B-Cytokine114828193
(    O
IL-7    B-Cytokine114828193
)    O
,    O
Interleukin-9    B-Cytokine114828193
(    O
IL-9    B-Cytokine114828193
)    O
,    O
granulocyte    B-Cytokine114828193
colony-stimulating    I-Cytokine114828193
factor    I-Cytokine114828193
(    O
G-CSF    B-Cytokine114828193
)    O
,    O
and    O
granulocyte    O
-    O
macrophage    O
colony    O
-    O
stimulating    O
factor    O
(    O
GM    O
-    O
CSF    O
)    O
,    O
IL-15    O
belongs    O
to    O
the    O
four    O
α-helix    O
bundle    O
family    O
of    O
cytokine    O
.    O

The    O
combination    O
of    O
this    O
cytokine    O
and    O
IL12    O
has    O
been    O
shown    O
to    O
inhibit    O
IL-4    B-Cytokine114828193
dependent    O
IgE    O
and    O
IgG1    O
production    O
,    O
and    O
enhance    O
IgG2a    O
production    O
in    O
B    O
cells    O
.    O

Interleukin    O
33    O
is    O
a    O
member    O
of    O
the    O
IL-1    O
family    O
that    O
potently    O
drives    O
production    O
of    O
T    O
helper-2    O
(    O
Th2)-associated    O
cytokines    O
(    O
e.g.    O
,    O
IL-4    B-Cytokine114828193
)    O
.    O

,    O
LTC4    O
,    O
LTD4    O
,    O
and    O
LTE4    O
)    O
,    O
all    O
of    O
which    O
have    O
bronchoconstricting    O
and    O
otherwise    O
pro    O
-    O
allergic    O
actions    O
;    O
inhibits    O
pro    O
-    O
allergic    O
eosinophil    O
apoptosis    O
,    O
chemotaxis    O
,    O
and    O
release    O
of    O
pro    O
-    O
allergic    O
granule    O
contents    O
;    O
and    O
reduces    O
release    O
of    O
the    O
pro    O
-    O
allergic    O
cytokines    O
Interleukin    O
5    O
,    O
Interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
and    O
interleukin    B-Cytokine114828193
13    I-Cytokine114828193
from    O
human    O
blood    O
mononuclear    O
cells    O
.    O

In    O
this    O
model    O
,    O
EP33-deficient    O
mice    O
,    O
upon    O
ovalbumin    O
challenge    O
,    O
exhibited    O
worsened    O
allergic    O
inflammation    O
as    O
measured    O
by    O
increased    O
airway    O
eosinophils    O
,    O
neutrophils    O
,    O
lymphocytes    O
,    O
and    O
pro    O
-    O
allergic    O
cytokines    O
(    O
i.e.    O
interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
interleukin    O
5    O
,    O
and    O
interleukin    B-Cytokine114828193
13    I-Cytokine114828193
)    O
as    O
compared    O
to    O
wild    O
type    O
mice    O
.    O
EP3    O
receptor    O
-    O
deficient    O
mice    O
and/or    O
wild    O
type    O
mice    O
treated    O
with    O
an    O
EP3    O
receptor    O
agonist    O
are    O
similarly    O
protected    O
from    O
allergic    O
responses    O
in    O
models    O
of    O
allergic    O
conjunctivitis    O
and    O
contact    O
hypersensitivity    O
.    O

Glucocorticoids    O
suppress    O
cell    O
-    O
mediated    O
immunity    O
by    O
inhibiting    O
genes    O
that    O
code    O
for    O
the    O
cytokines    O
IL-1    O
,    O
IL-2    B-Cytokine114828193
,    O
IL-3    B-Cytokine114828193
,    O
IL-4    B-Cytokine114828193
,    O
IL-5    O
,    O
IL-6    B-Cytokine114828193
,    O
IL-8    B-Cytokine114828193
and    O
IFN-γ    O
,    O
the    O
most    O
important    O
of    O
which    O
is    O
IL-2    O
.    O

But    O
in    O
the    O
case    O
of    O
a    O
low    O
γδ    O
T    O
-    O
APC    O
:    O
CD4    O
+    O
ratio    O
it    O
leads    O
to    O
differentiation    O
of    O
some    O
naïve    O
αβ    O
T    O
cells    O
into    O
Th2    O
(    O
IL-4    B-Cytokine114828193
)    O
or    O
Th0    O
(    O
IL-4    O
plus    O
IFN-γ    O
)    O
cells    O
.    O

CD23a    O
is    O
present    O
on    O
follicular    O
B    O
cells    O
,    O
whereas    O
CD23b    O
requires    O
IL-4    B-Cytokine114828193
to    O
be    O
expressed    O
on    O
T    O
-    O
cells    O
,    O
monocytes    O
,    O
Langerhans    O
cells    O
,    O
eosinophils    O
,    O
and    O
macrophages    O
.    O

He    O
is    O
also    O
known    O
for    O
his    O
molecular    O
identification    O
of    O
cytokines    O
:    O
IL-4    B-Cytokine114828193
and    O
IL-5    O
,    O
as    O
well    O
as    O
the    O
discovery    O
of    O
Activation    O
-    O
induced    O
Cytidine    O
Deaminase    O
(    O
ACD    O
)    O
that    O
is    O
essential    O
for    O
class    O
switch    O
recombination    O
and    O
somatic    O
hypermutation    O
.    O

He    O
succeeded    O
in    O
cDNA    O
clonings    O
of    O
IL-4    B-Cytokine114828193
and    O
IL-5    O
cytokines    O
involved    O
in    O
class    O
switching    O
and    O
IL-2    B-Cytokine114828193
receptor    O
alpha    O
chain    O
in    O
1986    O
,    O
and    O
went    O
on    O
further    O
to    O
discover    O
AID    O
in    O
2000    O
,    O
demonstrating    O
its    O
importance    O
in    O
class    O
switch    O
recombination    O
and    O
somatic    O
hypermutation    O
.    O

The    O
gene    O
IL2RG    O
codes    O
for    O
the    O
common    O
gamma    O
chain    O
protein    O
,    O
which    O
is    O
a    O
common    O
subunit    O
of    O
the    O
individual    O
receptors    O
for    O
Interleukin    B-Cytokine114828193
2    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
7    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
9    I-Cytokine114828193
,    O
Interleukin    O
15    O
and    O
Interleukin    B-Cytokine114828193
21    I-Cytokine114828193
.    O

The    O
most    O
important    O
receptors    O
for    O
X    O
-    O
SCID    O
are    O
those    O
for    O
Interleukin    B-Cytokine114828193
2    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
7    I-Cytokine114828193
,    O
and    O
Interleukin    O
15    O
.    O

Likewise    O
,    O
the    O
action    O
of    O
Interleukin    B-Cytokine114828193
4    I-Cytokine114828193
and    O
Interleukin    O
15    O
will    O
lead    O
to    O
proliferation    O
and    O
differentiation    O
of    O
B    O
-    O
cells    O
into    O
antibody    O
secreting    O
plasma    O
cells    O
.    O

Upregulation    O
of    O
VCAM-1    O
in    O
endothelial    O
cells    O
by    O
cytokines    O
occurs    O
as    O
a    O
result    O
of    O
increased    O
gene    O
transcription    O
(    O
e.g.    O
,    O
in    O
response    O
to    O
Tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
(    O
TNF-α    O
)    O
and    O
Interleukin-1    O
(    O
IL-1    O
)    O
)    O
and    O
through    O
stabilization    O
of    O
Messenger    O
RNA    O
(    O
mRNA    O
)    O
(    O
e.g.    O
,    O
Interleukin-4    B-Cytokine114828193
(    O
IL-4    O
)    O
)    O
.    O

Interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
a    O
cytokine    O
that    O
stimulates    O
the    O
proliferation    O
of    O
activated    O
B    O
-    O
cells    O

The    O
procedure    O
for    O
the    O
transfection    O
of    O
an    O
interleukin-4    B-Cytokine114828193
gene    O
into    O
a    O
mousepox    O
virus    O
is    O
described    O
.    O

:    O
:    O
:    O
XCR1    B-Cytokine114828193

Chemokine    B-Cytokine114828193
(C-C    I-Cytokine114828193
motif)    I-Cytokine114828193
ligand    I-Cytokine114828193
6    I-Cytokine114828193
(    O
CCL6    O
)    O
is    O
a    O
small    O
cytokine    O
belonging    O
to    O
the    O
CC    O
chemokine    B-Cytokine114828193
family    O
that    O
has    O
only    O
been    O
identified    O
in    O
rodents    O
.    O

CCL12    B-Cytokine114828193

GcMAF    B-Cytokine114828193
(    O
or    O
Gc    B-Cytokine114828193
protein-derived    I-Cytokine114828193
macrophage    I-Cytokine114828193
activating    I-Cytokine114828193
factor    I-Cytokine114828193
)    O
is    O
a    O
protein    O
produced    O
by    O
modification    O
of    O
vitamin    O
D    O
-    O
binding    O
protein    O
.    O

CCL28    B-Cytokine114828193
,    O
chemokine    O

Closely    O
related    O
to    O
interferon    O
beta-1a    O
is    O
interferon    B-Cytokine114828193
beta-1b    I-Cytokine114828193
,    O
which    O
is    O
also    O
indicated    O
for    O
MS    O
,    O
but    O
is    O
formulated    O
with    O
a    O
different    O
dose    O
and    O
administered    O
with    O
a    O
different    O
frequency    O
.    O

To    O
protect    O
the    O
secret    O
of    O
her    O
husband    O
's    O
multiple    O
sclerosis    O
,    O
Abbey    O
gives    O
the    O
President    O
doses    O
of    O
betaseron    B-Cytokine114828193
,    O
which    O
help    O
keep    O
his    O
MS    O
in    O
check    O
.    O

Interferon    O
beta-1a    O
and    O
interferon    B-Cytokine114828193
beta-1b    I-Cytokine114828193
are    O
used    O
to    O
treat    O
and    O
control    O
multiple    O
sclerosis    O
,    O
an    O
autoimmune    O
disorder    O
.    O

Chemokine    B-Cytokine114828193
(C-X-C    I-Cytokine114828193
motif)    I-Cytokine114828193
ligand    I-Cytokine114828193
16    I-Cytokine114828193
(    O
CXCL16    O
)    O
is    O
a    O
small    O
cytokine    O
belonging    O
to    O
the    O
CXC    O
chemokine    B-Cytokine114828193
family    O
.    O

By    O
decreasing    O
the    O
levels    O
of    O
p300    O
,    O
the    O
expression    O
of    O
IFN-β    B-Cytokine114828193
,    O
ISG15    O
,    O
IL-1β    O
and    O
IL6    B-Cytokine114828193
is    O
impaired    O
,    O
resulting    O
in    O
the    O
net    O
suppression    O
of    O
antiviral    O
immunity    O
.    O

Its    O
re    O
-    O
expression    O
induced    O
apoptosis    O
and    O
cell    O
cycle    O
arrest    O
and    O
resulted    O
in    O
a    O
mesenchymal    O
-    O
to    O
-    O
epithelial    O
transition    O
,    O
such    O
as    O
up    O
-    O
regulation    O
of    O
E    O
-    O
cadherin    O
and    O
reduction    O
of    O
cell    O
locomotion    O
and    O
invasion    O
,    O
and    O
in    O
the    O
down    O
-    O
regulation    O
of    O
several    O
oncogenes    O
known    O
to    O
be    O
involved    O
in    O
disease    O
progression    O
(    O
i.e.    O
,    O
interleukin    B-Cytokine114828193
6    I-Cytokine114828193
,    O
caveolin-1    O
,    O
EZH2    O
)    O
.    O

Activated    O
mast    O
cells    O
also    O
synthesize    O
and    O
secrete    O
lipid    O
-    O
derived    O
mediators    O
(    O
such    O
as    O
prostaglandins    O
,    O
leukotrienes    O
,    O
and    O
platelet    O
-    O
activating    O
factor    O
)    O
and    O
cytokines    O
(    O
such    O
as    O
interleukin    O
1    O
,    O
interleukin    B-Cytokine114828193
3    I-Cytokine114828193
,    O
interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
interleukin    O
5    O
,    O
interleukin    B-Cytokine114828193
6    I-Cytokine114828193
,    O
interleukin    B-Cytokine114828193
13    I-Cytokine114828193
,    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
,    O
GM    O
-    O
CSF    O
,    O
and    O
several    O
chemokine    B-Cytokine114828193
.    O

IL-6    B-Cytokine114828193

The    O
exact    O
mechanism    O
in    O
which    O
these    O
diseases    O
cause    O
cachexia    O
is    O
poorly    O
understood    O
,    O
but    O
there    O
is    O
probably    O
a    O
role    O
for    O
inflammatory    O
cytokines    O
,    O
such    O
as    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
(    O
which    O
is    O
also    O
nicknamed    O
'    O
cachexin    O
'    O
or    O
'    O
cachectin    O
'    O
)    O
,    O
interferon    O
gamma    O
and    O
interleukin    B-Cytokine114828193
6    I-Cytokine114828193
,    O
as    O
well    O
as    O
the    O
tumor    O
-    O
secreted    O
proteolysis    O
-    O
inducing    O
factor    O
.    O

The    O
inﬂammatory    O
cytokines    O
involved    O
in    O
wasting    O
diseases    O
are    O
interleukin    B-Cytokine114828193
6    I-Cytokine114828193
,    O
TNF    O
-    O
alpha    O
,    O
IL1B    O
,    O
and    O
interferon    O
-    O
gamma    O
.    O

Meta    O
analysis    O
on    O
cytokine    O
levels    O
in    O
depressed    O
patients    O
have    O
demonstrated    O
increased    O
levels    O
of    O
IL-1    O
,    O
IL-6    B-Cytokine114828193
,    O
C    O
-    O
reactive    O
protein    O
,    O
but    O
not    O
IL-10    B-Cytokine114828193
in    O
depressed    O
patients    O
.    O

The    O
presence    O
of    O
viral    O
particles    O
and    O
the    O
cell    O
damage    O
resulting    O
from    O
viruses    O
budding    O
out    O
of    O
the    O
cell    O
causes    O
the    O
release    O
of    O
chemical    O
signals    O
(    O
such    O
as    O
TNF-α    B-Cytokine114828193
,    O
IL-6    B-Cytokine114828193
and    O
IL-8    B-Cytokine114828193
)    O
,    O
which    O
are    O
molecular    O
signals    O
for    O
fever    O
and    O
inflammation    O
.    O

Molecules    O
called    O
pro    O
-    O
inflammatory    O
cytokines    O
,    O
which    O
include    O
interleukin-1    O
(    O
IL-1    O
)    O
,    O
Interleukin-2    B-Cytokine114828193
(    O
IL-2    O
)    O
,    O
interleukin-6    B-Cytokine114828193
(    O
IL-6    O
)    O
,    O
Interleukin-12    B-Cytokine114828193
(    O
IL-12    O
)    O
,    O
Interferon    O
-    O
gamma    O
(    O
IFN    O
-    O
Gamma    O
)    O
and    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor    I-Cytokine114828193
alpha    I-Cytokine114828193
(    O
TNF    O
-    O
alpha    O
)    O
can    O
affect    O
brain    O
growth    O
as    O
well    O
as    O
neuronal    O
function    O
.    O
Circulating    O
immune    O
cells    O
such    O
as    O
macrophages    O
,    O
as    O
well    O
as    O
glial    O
cells    O
(    O
microglia    O
and    O
astrocytes    O
)    O
secrete    O
these    O
molecules    O
.    O

These    O
immune    O
cells    O
move    O
from    O
the    O
dermis    O
to    O
the    O
epidermis    O
and    O
secrete    O
inflammatory    O
chemical    O
signals    O
(    O
cytokines    O
)    O
such    O
as    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-α    I-Cytokine114828193
,    O
interleukin-1β    O
,    O
interleukin-6    B-Cytokine114828193
,    O
interleukin-36    B-Cytokine114828193
and    O
interleukin-22    O
.    O

Both    O
pro    O
-    O
inflammatory    O
cytokines    O
(    O
such    O
as    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
,    O
Interleukin-1    O
,    O
and    O
Interleukin-6    B-Cytokine114828193
)    O
and    O
anti    O
-    O
inflammatory    O
cytokines    O
(    O
such    O
as    O
interleukin    B-Cytokine114828193
10    I-Cytokine114828193
and    O
interleukin    B-Cytokine114828193
1    I-Cytokine114828193
receptor    I-Cytokine114828193
antagonist    I-Cytokine114828193
)    O
are    O
elevated    O
in    O
the    O
serum    O
of    O
patients    O
experiencing    O
a    O
cytokine    O
storm    O
.    O

Erythropoietin    O
is    O
the    O
primary    O
erythropoietic    O
factor    O
that    O
cooperates    O
with    O
various    O
other    O
growth    O
factors    O
(    O
e.g.    O
,    O
IL-3    B-Cytokine114828193
,    O
IL-6    B-Cytokine114828193
,    O
glucocorticoids    O
,    O
and    O
SCF    O
)    O
involved    O
in    O
the    O
development    O
of    O
erythroid    O
lineage    O
from    O
multipotent    O
progenitors    O
.    O

Mutations    O
in    O
interleukin    B-Cytokine114828193
6    I-Cytokine114828193
may    O
be    O
protective    O
.    O
.    O

The    O
axis    O
inhibits    O
bone    O
marrow    O
-    O
derived    O
dendritic    O
cells    O
(    O
i.e.    O
antigen    O
-    O
presenting    O
cells    O
that    O
process    O
antigen    O
material    O
,    O
present    O
it    O
on    O
their    O
surfaces    O
for    O
delivery    O
to    O
T    O
cells    O
,    O
and    O
otherwise    O
regulate    O
innate    O
and    O
adaptive    O
immune    O
system    O
responses    O
)    O
from    O
producing    O
pro    O
-    O
inflammatory    O
cytokines    O
(    O
e.g.    O
IL-12    B-Cytokine114828193
,    O
TNF-alpha    B-Cytokine114828193
,    O
IL-1-alpha    B-Cytokine114828193
,    O
and    O
IL-6    B-Cytokine114828193
)    O
while    O
stimulating    O
them    O
to    O
increase    O
production    O
of    O
the    O
anti    O
-    O
inflammatory    O
cytokine    O
,    O
IL-10    O
.    O

This    O
effect    O
may    O
result    O
from    O
regulating    O
the    O
expression    O
of    O
arthritis    O
-    O
related    O
,    O
pro    O
-    O
inflammatory    O
genes    O
(    O
i.e.    O
those    O
for    O
IL-6    B-Cytokine114828193
,    O
VEGF    O
-    O
A    O
,    O
and    O
RANKL    B-Cytokine114828193
)    O
.    O

In    O
addition    O
,    O
IL-3    O
stimulates    O
proliferation    O
of    O
all    O
cells    O
in    O
the    O
myeloid    O
lineage    O
(    O
granulocytes    O
,    O
monocytes    O
,    O
and    O
dendritic    O
cells    O
)    O
,    O
in    O
conjunction    O
with    O
other    O
cytokines    O
,    O
e.g.    O
,    O
Erythropoietin    O
(    O
EPO    O
)    O
,    O
Granulocyte    O
macrophage    O
colony    O
-    O
stimulating    O
factor    O
(    O
GM    O
-    O
CSF    O
)    O
,    O
and    O
IL-6    B-Cytokine114828193
.    O

Interleukin    B-Cytokine114828193
6    I-Cytokine114828193
is    O
a    O
cytokine    O
relevant    O
to    O
many    O
inflammatory    O
diseases    O
and    O
many    O
cancers    O
.    O

Siltuximab    O
was    O
also    O
tested    O
in    O
the    O
phase    O
I    O
/    O
II    O
study    O
for    O
therapy    O
of    O
patients    O
with    O
metastatic    O
castration    O
-    O
associated    O
prostate    O
cancer    O
in    O
combination    O
with    O
docetaxel    O
and    O
in    O
renal    O
cell    O
carcinoma    O
;    O
phase    O
II    O
trials    O
in    O
ovarian    O
cancer    O
resulted    O
in    O
39%    O
of    O
patients    O
showed    O
disease    O
stabilization    O
via    O
IL-6    B-Cytokine114828193
downregulation    O
of    O
CCL2    B-Cytokine114828193
,    O
CXCL12    B-Cytokine114828193
and    O
VEGF    O
.    O

Anti    O
-    O
IL-6    O
therapies    O
should    O
therefore    O
take    O
into    O
consideration    O
the    O
(    O
beneficial    O
)    O
anti    O
-    O
inflammatory    O
effects    O
of    O
myokine    B-Cytokine114828193
generally    O
,    O
including    O
the    O
now    O
-    O
established    O
multiple    O
benefits    O
of    O
muscle    O
-    O
derived    O
Interleukin    B-Cytokine114828193
6    I-Cytokine114828193
.    O

It    O
has    O
been    O
reported    O
that    O
lunasin    O
,    O
a    O
soy    O
peptide    O
,    O
reduces    O
inflammation    O
by    O
reducing    O
interleukin    B-Cytokine114828193
6    I-Cytokine114828193
and    O
may    O
help    O
in    O
leukemia    O
.    O

Relative    O
to    O
other    O
NSAIDs    O
,    O
salsalate    O
has    O
a    O
weak    O
inhibitory    O
effect    O
on    O
the    O
cyclooxygenase    O
enzyme    O
and    O
decreases    O
the    O
production    O
of    O
several    O
proinflammatory    O
chemical    O
signals    O
such    O
as    O
interleukin-6    B-Cytokine114828193
,    O
TNF-alpha    B-Cytokine114828193
,    O
and    O
C    O
-    O
reactive    O
protein    O
.    O

Lipopolysaccharide    O
-    O
induced    O
production    O
of    O
TNFα    B-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
6    I-Cytokine114828193
,    O
and    O
IL1B    O
)    O
while    O
concurrently    O
activating    O
anti    O
-    O
oxidant    O
responses    O
upregulated    O
through    O
the    O
anti    O
-    O
oxidant    O
response    O
element    O
(    O
ARE    O
)    O
by    O
forcing    O
cytosolic    O
KEAP1    O
to    O
release    O
NFE2L2    O
which    O
then    O
moves    O
to    O
the    O
nucleus    O
,    O
binds    O
ARE    O
,    O
and    O
induces    O
production    O
of    O
,    O
e.g.    O
hemoxygenase-1    O
,    O
NADPH    O
-    O
quinone    O
oxidoreductase    O
,    O
and    O
possibly    O
glutamate    O
-    O
cysteine    O
ligase    O
modifier    O
.    O

SSRIs    O
,    O
SNRIs    O
and    O
tricyclic    O
antidepressants    O
acting    O
on    O
serotonin    O
,    O
norepinephrine    O
and    O
dopamine    O
receptors    O
have    O
been    O
shown    O
to    O
be    O
immunomodulatory    O
and    O
anti    O
-    O
inflammatory    O
against    O
pro    O
-    O
inflammatory    O
cytokine    O
processes    O
,    O
specifically    O
on    O
the    O
regulation    O
of    O
Interferon    O
-    O
gamma    O
(    O
IFN    O
-    O
gamma    O
)    O
and    O
Interleukin-10    B-Cytokine114828193
(    O
IL-10    O
)    O
,    O
as    O
well    O
as    O
TNF-alpha    B-Cytokine114828193
and    O
Interleukin-6    B-Cytokine114828193
(    O
IL-6    O
)    O
.    O

Glucocorticoids    O
suppress    O
cell    O
-    O
mediated    O
immunity    O
by    O
inhibiting    O
genes    O
that    O
code    O
for    O
the    O
cytokines    O
IL-1    O
,    O
IL-2    B-Cytokine114828193
,    O
IL-3    B-Cytokine114828193
,    O
IL-4    B-Cytokine114828193
,    O
IL-5    O
,    O
IL-6    B-Cytokine114828193
,    O
IL-8    B-Cytokine114828193
and    O
IFN-γ    O
,    O
the    O
most    O
important    O
of    O
which    O
is    O
IL-2    O
.    O

In    O
terms    O
of    O
both    O
structure    O
and    O
function    O
,    O
leptin    O
resembles    O
IL-6    B-Cytokine114828193
and    O
is    O
a    O
member    O
of    O
the    O
cytokine    O
superfamily    O
.    O

Serum    O
TNF-α    B-Cytokine114828193
is    O
significantly    O
elevated    O
in    O
cases    O
while    O
IL-6    B-Cytokine114828193
and    O
IL-8    B-Cytokine114828193
are    O
present    O
in    O
significantly    O
higher    O
quantities    O
in    O
the    O
aqueous    O
humour    O
in    O
patients    O
with    O
both    O
quiescent    O
and    O
active    O
uveitis    O
.    O

The    O
levels    O
of    O
inflammatory    O
cytokines    O
(    O
e.g.    O
,    O
IL-1β    O
,    O
IL-2    B-Cytokine114828193
,    O
IL-6    B-Cytokine114828193
,    O
and    O
TNF-α    B-Cytokine114828193
)    O
in    O
blood    O
plasma    O
are    O
affected    O
by    O
zinc    O
deficiency    O
and    O
zinc    O
supplementation    O
produces    O
a    O
dose    O
-    O
dependent    O
response    O
in    O
the    O
level    O
of    O
these    O
cytokines    O
.    O

Further    O
Johannessen    O
found    O
that    O
levels    O
of    O
IL-6    B-Cytokine114828193
were    O
reduced    O
to    O
90%    O
when    O
exposed    O
to    O
25    O
μg    O
/    O
mL    O
citrinin    O
(    O
CTN    O
)    O
and    O
to    O
40%    O
when    O
exposed    O
to    O
50    O
μg    O
/    O
mL.    O
Levels    O
of    O
IL-8    B-Cytokine114828193
and    O
cell    O
viability    O
were    O
also    O
reduced    O
to    O
80%    O
and    O
20%    O
when    O
exposed    O
to    O
respectively    O
25    O
and    O
50    O
μg    O
/    O
mL    O
CTN    O
for    O
72    O
hours    O
.    O

The    O
members    O
of    O
the    O
IL-6    B-Cytokine114828193
receptor    O
family    O
all    O
complex    O
with    O
gp130    O
for    O
signal    O
transduction    O
.    O

Interleukin    B-Cytokine114828193
6    I-Cytokine114828193
,    O
a    O
pro    O
-    O
inflammatory    O
cytokine    O

In    O
a    O
rat    O
model    O
of    O
rheumatoid    O
arthritis    O
HWTX    O
-    O
I    O
is    O
able    O
to    O
decrease    O
the    O
concentration    O
of    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor    I-Cytokine114828193
α    I-Cytokine114828193
(    O
TNF-α    O
)    O
in    O
serum    O
and    O
decrease    O
the    O
mRNA    O
expression    O
level    O
interleukin    O
1β    O
(    O
IL-1β    O
)    O
and    O
interleukin    B-Cytokine114828193
6    I-Cytokine114828193
(    O
IL-6    O
)    O
.    O

Chemokine    B-Cytokine114828193
(C-C    I-Cytokine114828193
motif)    I-Cytokine114828193
ligand    I-Cytokine114828193
27    I-Cytokine114828193
(    O
CCL27    O
)    O
is    O
a    O
small    O
cytokine    O
belonging    O
to    O
the    O
CC    O
chemokine    B-Cytokine114828193
family    O
also    O
known    O
under    O
the    O
names    O
IL-11    O
R    O
-    O
alpha    O
-    O
locus    O
chemokine    O
(    O
ILC    O
)    O
,    O
Skinkine    O
,    O
ESkine    O
and    O
Cutaneous    O
T    O
-    O
cell    O
-    O
attracting    O
chemokine    O
(    O
CTACK    O
)    O
.    O

:*    O
IL34    B-Cytokine114828193

Interferon    B-Cytokine114828193
type    I-Cytokine114828193
III    I-Cytokine114828193
:    O
Signal    O
through    O
a    O
receptor    O
complex    O
consisting    O
of    O
IL10R2    O
(    O
also    O
called    O
CRF2    O
-    O
4    O
)    O
and    O
IFNLR1    O
(    O
also    O
called    O
CRF2    O
-    O
12    O
)    O
.    O

:*    O
OSM    B-Cytokine114828193
(    O
Oncostatin    O
M    O
)    O

There    O
are    O
many    O
other    O
proteins    O
which    O
associate    O
with    O
gp130    O
,    O
such    O
as    O
cardiotrophin    O
1    O
(    O
CT-1    O
)    O
,    O
leukemia    B-Cytokine114828193
inhibitory    I-Cytokine114828193
factor    I-Cytokine114828193
(    O
LIF    O
)    O
,    O
ciliary    O
neurotrophic    O
factor    O
(    O
CNTF    O
)    O
,    O
oncostatin    B-Cytokine114828193
M    I-Cytokine114828193
(    O
OSM    O
)    O
,    O
and    O
IL-11    B-Cytokine114828193
.    O

Chemokine    B-Cytokine114828193
(C-X-C    I-Cytokine114828193
motif)    I-Cytokine114828193
ligand    I-Cytokine114828193
6    I-Cytokine114828193
(    O
CXCL6    O
)    O
is    O
a    O
small    O
cytokine    O
belonging    O
to    O
the    O
CXC    O
chemokine    B-Cytokine114828193
family    O
that    O
is    O
also    O
known    O
as    O
granulocyte    O
chemotactic    O
protein    O
2    O
(    O
GCP-2    O
)    O
.    O

Neutrophil    O
activating    O
peptide-2    O
(    O
NAP-2    O
)    O
-    O
CXCL7    B-Cytokine114828193

Several    O
CC    O
chemokines    O
:    O
CCL1    B-Cytokine114828193
,    O
CCL2    B-Cytokine114828193
,    O
CCL3    B-Cytokine114828193
,    O
CCL4    O
,    O
CCL5    B-Cytokine114828193
,    O
CCL7    B-Cytokine114828193
,    O
CCL8    B-Cytokine114828193
,    O
CCL11    B-Cytokine114828193
,    O
CCL13    B-Cytokine114828193
,    O
CCL14    B-Cytokine114828193
,    O
CCL15    B-Cytokine114828193
,    O
CCL16    B-Cytokine114828193
,    O
CCL18    B-Cytokine114828193
,    O
and    O
CCL23    B-Cytokine114828193

Lymphotoxin-alpha    B-Cytokine114828193
,    O
formerly    O
known    O
as    O
Tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-beta    I-Cytokine114828193
(    O
TNF-β    O
)    O
,    O
is    O
a    O
cytokine    O
that    O
is    O
inhibited    O
by    O
interleukin    B-Cytokine114828193
10    I-Cytokine114828193
.    O

Lymphotoxin-alpha    B-Cytokine114828193
(    O
LT    O
-    O
alpha    O
)    O
and    O
lymphotoxin-beta    B-Cytokine114828193
(    O
LT    O
-    O
beta    O
)    O
,    O
two    O
related    O
cytokines    O
produced    O
by    O
lymphocytes    O
that    O
are    O
cytotoxic    O
for    O
a    O
wide    O
range    O
of    O
tumor    O
cells    O
in    O
vitro    O
and    O
in    O
vivo    O
.    O

CD40LG    O
(    O
TNFSF5    O
)    O
;    O
CD70    O
(    O
TNFSF7    O
)    O
;    O
EDA    O
;    O
FASLG    O
(    O
TNFSF6    O
)    O
;    O
LTA    B-Cytokine114828193
(TNFSF1)    I-Cytokine114828193
;    O
LTB    B-Cytokine114828193
(TNFSF3)    I-Cytokine114828193
;    O

CX3CL1    O
elicits    O
its    O
adhesive    O
and    O
migratory    O
functions    O
by    O
interacting    O
with    O
the    O
chemokine    O
receptor    O
CX3CR1    B-Cytokine114828193
.    O

CSF1    B-Cytokine114828193

:*    O
CSF1    B-Cytokine114828193
(    O
M    O
-    O
CSF    O
)    O

Undifferentiated    O
bone    O
marrow    O
cells    O
are    O
cultured    O
in    O
macrophage    B-Cytokine114828193
colony-stimulating    I-Cytokine114828193
factor    I-Cytokine114828193
(    O
M    O
-    O
CSF    O
;    O
CSF1    O
)    O
for    O
at    O
least    O
five    O
to    O
seven    O
days    O
.    O

M-CSF    B-Cytokine114828193

ILC3s    O
are    O
a    O
lymphoid    O
cell    O
population    O
that    O
can    O
produce    O
IL-22    O
and    O
expresses    O
NKp46    B-Cytokine114828193
(    O
an    O
NK    O
cell    O
activating    O
receptor    O
)    O
.    O

Activated    O
mast    O
cells    O
also    O
synthesize    O
and    O
secrete    O
lipid    O
-    O
derived    O
mediators    O
(    O
such    O
as    O
prostaglandins    O
,    O
leukotrienes    O
,    O
and    O
platelet    O
-    O
activating    O
factor    O
)    O
and    O
cytokines    O
(    O
such    O
as    O
interleukin    O
1    O
,    O
interleukin    B-Cytokine114828193
3    I-Cytokine114828193
,    O
interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
interleukin    O
5    O
,    O
interleukin    B-Cytokine114828193
6    I-Cytokine114828193
,    O
interleukin    B-Cytokine114828193
13    I-Cytokine114828193
,    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
,    O
GM    O
-    O
CSF    O
,    O
and    O
several    O
chemokine    B-Cytokine114828193
.    O

IL-13    B-Cytokine114828193

Group    O
2    O
ILCs    O
can    O
produce    O
type    O
2    O
cytokines    O
(    O
e.g.    O
IL-4    B-Cytokine114828193
,    O
IL-5    O
,    O
IL-9    B-Cytokine114828193
,    O
IL-13    B-Cytokine114828193
)    O
.    O

They    O
are    O
a    O
major    O
early    O
source    O
of    O
IL-13    B-Cytokine114828193
,    O
which    O
can    O
activate    O
T    O
cells    O
and    O
induce    O
physiological    O
responses    O
that    O
will    O
help    O
expel    O
a    O
parasite    O
.    O

As    O
a    O
cytokine    O
,    O
IL-33    O
interacts    O
with    O
the    O
receptors    O
ST2    O
(    O
also    O
known    O
as    O
IL1RL1    O
)    O
and    O
IL-1    O
Receptor    O
Accessory    O
Protein    O
(    O
IL1RAP    O
)    O
,    O
activating    O
intracellular    O
molecules    O
in    O
the    O
NF-κB    O
and    O
MAP    O
kinase    O
signaling    O
pathways    O
that    O
drive    O
production    O
of    O
type    O
2    O
cytokines    O
(    O
e.g.    O
IL-5    O
and    O
IL-13    B-Cytokine114828193
)    O
from    O
polarized    O
Th2    O
cells    O
.    O

,    O
LTC4    O
,    O
LTD4    O
,    O
and    O
LTE4    O
)    O
,    O
all    O
of    O
which    O
have    O
bronchoconstricting    O
and    O
otherwise    O
pro    O
-    O
allergic    O
actions    O
;    O
inhibits    O
pro    O
-    O
allergic    O
eosinophil    O
apoptosis    O
,    O
chemotaxis    O
,    O
and    O
release    O
of    O
pro    O
-    O
allergic    O
granule    O
contents    O
;    O
and    O
reduces    O
release    O
of    O
the    O
pro    O
-    O
allergic    O
cytokines    O
Interleukin    O
5    O
,    O
Interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
and    O
interleukin    B-Cytokine114828193
13    I-Cytokine114828193
from    O
human    O
blood    O
mononuclear    O
cells    O
.    O

In    O
this    O
model    O
,    O
EP33-deficient    O
mice    O
,    O
upon    O
ovalbumin    O
challenge    O
,    O
exhibited    O
worsened    O
allergic    O
inflammation    O
as    O
measured    O
by    O
increased    O
airway    O
eosinophils    O
,    O
neutrophils    O
,    O
lymphocytes    O
,    O
and    O
pro    O
-    O
allergic    O
cytokines    O
(    O
i.e.    O
interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
interleukin    O
5    O
,    O
and    O
interleukin    B-Cytokine114828193
13    I-Cytokine114828193
)    O
as    O
compared    O
to    O
wild    O
type    O
mice    O
.    O
EP3    O
receptor    O
-    O
deficient    O
mice    O
and/or    O
wild    O
type    O
mice    O
treated    O
with    O
an    O
EP3    O
receptor    O
agonist    O
are    O
similarly    O
protected    O
from    O
allergic    O
responses    O
in    O
models    O
of    O
allergic    O
conjunctivitis    O
and    O
contact    O
hypersensitivity    O
.    O

showed    O
a    O
greatly    O
reduced    O
ability    O
to    O
stimulate    O
the    O
proliferation    O
of    O
T    O
helper    O
cell    O
as    O
well    O
as    O
the    O
ability    O
of    O
these    O
cells    O
to    O
produce    O
pro    O
-    O
allergic    O
cytokines    O
(    O
i.e.    O
IL-5    O
and    O
IL-13    B-Cytokine114828193
.    O

Macrophage-derived    B-Cytokine114828193
chemokine    I-Cytokine114828193
(    O
CCL22    O
)    O
,    O
a    O
human    O
cytokine    O

This    O
rejuvenation    O
and    O
increased    O
proliferation    O
was    O
accompanied    O
by    O
upregulation    O
of    O
genes    O
that    O
promote    O
cell    O
cycle    O
progression    O
(    O
cyclin    O
D1    O
,    O
ΔNp63    O
,    O
FgfR2IIIb    O
)    O
and    O
that    O
are    O
required    O
in    O
the    O
thymic    O
epithelial    O
cells    O
to    O
promote    O
specific    O
aspects    O
of    O
T    O
cell    O
development    O
(    O
Dll4    O
,    O
Kitl    O
,    O
Ccl25    B-Cytokine114828193
,    O
Cxcl12    B-Cytokine114828193
,    O
Cd40    O
,    O
Cd80    O
,    O
Ctsl    O
,    O
Pax1    O
)    O
.    O

In    O
addition    O
,    O
it    O
can    O
also    O
induce    O
the    O
production    O
of    O
chemokines    B-Cytokine114828193
such    O
as    O
IL-8    B-Cytokine114828193
and    O
MIP-2    O
/    O
CXCL2    B-Cytokine114828193
.    O

Pro-interleukin-16    B-Cytokine114828193
is    O
a    O
protein    O
that    O
in    O
humans    O
is    O
encoded    O
by    O
the    O
"    O
IL16    O
"    O
gene    O
.    O

Interleukin    B-Cytokine114828193
16    I-Cytokine114828193

Activation    O
of    O
FcγRIII    O
by    O
IgG    O
causes    O
the    O
release    O
of    O
cytokines    O
such    O
as    O
IFN-γ    B-Cytokine114828193
that    O
signal    O
to    O
other    O
immune    O
cells    O
,    O
and    O
cytotoxic    O
mediators    O
like    O
perforin    O
and    O
granzyme    O
that    O
enter    O
the    O
target    O
cell    O
and    O
promote    O
cell    O
death    O
by    O
triggering    O
apoptosis    O
.    O

Interferon    B-Cytokine114828193
type    I-Cytokine114828193
II    I-Cytokine114828193
(    O
IFN-γ    O
in    O
humans    O
)    O
:    O
This    O
is    O
also    O
known    O
as    O
immune    O
interferon    O
and    O
is    O
activated    O
by    O
Interleukin-12    O
.    O

These    O
immune    O
cells    O
move    O
from    O
the    O
dermis    O
to    O
the    O
epidermis    O
and    O
secrete    O
inflammatory    O
chemical    O
signals    O
(    O
cytokines    O
)    O
such    O
as    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-α    I-Cytokine114828193
,    O
interleukin-1β    O
,    O
interleukin-6    B-Cytokine114828193
,    O
interleukin-36    B-Cytokine114828193
and    O
interleukin-22    O
.    O

Monocyte    B-Cytokine114828193
chemotactic    I-Cytokine114828193
protein    I-Cytokine114828193
1    I-Cytokine114828193
(CCL2)    I-Cytokine114828193

These    O
factors    O
include    O
most    O
particularly    O
chemokines    B-Cytokine114828193
such    O
as    O
monocyte    B-Cytokine114828193
chemotactic    I-Cytokine114828193
protein-1    I-Cytokine114828193
(    O
CCL2    O
)    O
and    O
monocyte    B-Cytokine114828193
chemotactic    I-Cytokine114828193
protein-3    I-Cytokine114828193
(CCL7)    I-Cytokine114828193
;    O
certain    O
arachidonic    O
acid    O
metabolites    O
such    O
as    O
Leukotriene    O
B4    O
and    O
members    O
of    O
the    O
5-Hydroxyicosatetraenoic    O
acid    O
and    O
5-oxo    O
-    O
eicosatetraenoic    O
acid    O
family    O
of    O
OXE1    O
receptor    O
agonists    O
(    O
e.g.    O
,    O
5-HETE    O
and    O
5-oxo    O
-    O
ETE    O
)    O
;    O
and    O
N    O
-    O
Formylmethionine    O
leucyl    O
-    O
phenylalanine    O
and    O
other    O
N    O
-    O
formylated    O
oligopeptides    O
which    O
are    O
made    O
by    O
bacteria    O
and    O
activate    O
the    O
formyl    O
peptide    O
receptor    O
1    O
.    O

Several    O
CC    O
chemokines    O
:    O
CCL1    B-Cytokine114828193
,    O
CCL2    B-Cytokine114828193
,    O
CCL3    B-Cytokine114828193
,    O
CCL4    O
,    O
CCL5    B-Cytokine114828193
,    O
CCL7    B-Cytokine114828193
,    O
CCL8    B-Cytokine114828193
,    O
CCL11    B-Cytokine114828193
,    O
CCL13    B-Cytokine114828193
,    O
CCL14    B-Cytokine114828193
,    O
CCL15    B-Cytokine114828193
,    O
CCL16    B-Cytokine114828193
,    O
CCL18    B-Cytokine114828193
,    O
and    O
CCL23    B-Cytokine114828193

MCP1    O
(    O
now    O
called    O
CCL2    B-Cytokine114828193
)    O
is    O
especially    O
important    O
in    O
arteriogenesis    O
.    O

Siltuximab    O
was    O
also    O
tested    O
in    O
the    O
phase    O
I    O
/    O
II    O
study    O
for    O
therapy    O
of    O
patients    O
with    O
metastatic    O
castration    O
-    O
associated    O
prostate    O
cancer    O
in    O
combination    O
with    O
docetaxel    O
and    O
in    O
renal    O
cell    O
carcinoma    O
;    O
phase    O
II    O
trials    O
in    O
ovarian    O
cancer    O
resulted    O
in    O
39%    O
of    O
patients    O
showed    O
disease    O
stabilization    O
via    O
IL-6    B-Cytokine114828193
downregulation    O
of    O
CCL2    B-Cytokine114828193
,    O
CXCL12    B-Cytokine114828193
and    O
VEGF    O
.    O

It    O
inhibits    O
formation    O
of    O
pro    O
-    O
inflammatory    O
cytokines    O
(    O
MCP-1    B-Cytokine114828193
,    O
MMP-9    O
)    O
in    O
vitro    O
and    O
results    O
in    O
reduction    O
of    O
hsCRP    O
in    O
patients    O
.    O

Elevated    O
expression    O
levels    O
of    O
CCL2    B-Cytokine114828193
,    O
CCL5    B-Cytokine114828193
and    O
CCL17    B-Cytokine114828193
which    O
result    O
in    O
chemoattracted    O
CD4    O
+    O
and    O
CD8    O
+    O
T    O
cell    O
populations    O
to    O
the    O
surrounding    O
area    O
may    O
be    O
responsible    O
for    O
exerting    O
a    O
downmodulatory    O
effect    O
on    O
the    O
AchE    O
and    O
CHRM3    O
expressions    O
.    O

B-cell    B-Cytokine114828193
activating    I-Cytokine114828193
factor    I-Cytokine114828193
(    O
BAFF    B-Cytokine114828193
)    O
also    O
known    O
as    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor    I-Cytokine114828193
ligand    I-Cytokine114828193
superfamily    I-Cytokine114828193
member    I-Cytokine114828193
13B    I-Cytokine114828193
is    O
a    O
protein    O
that    O
in    O
humans    O
is    O
encoded    O
by    O
the    O
"    O
TNFSF13B    O
"    O
gene    O
.    O

TNFSF4    O
(    O
OX40L    O
)    O
;    O
TNFSF8    O
(    O
CD153    O
)    O
;    O
TNFSF9    O
;    O
TNFSF10    O
(    O
TRAIL    O
)    O
;    O
TNFSF11    B-Cytokine114828193
(RANKL)    I-Cytokine114828193
;    O
TNFSF12    O
(    O
TWEAK    O
)    O
;    O
TNFSF13    O
;    O
TNFSF13B    B-Cytokine114828193
;    O
TNFSF14    O
;    O
TNFSF15    O
;    O
TNFSF18    O
;    O

The    O
designer    O
protein    O
combines    O
the    O
binding    O
site    O
for    O
two    O
cytokines    O
that    O
regulate    O
maturation    O
,    O
function    O
,    O
and    O
survival    O
of    O
B    O
cells    O
-    O
B-lymphocyte    B-Cytokine114828193
stimulator    I-Cytokine114828193
(    O
BLyS    O
)    O
and    O
A    O
proliferation    O
-    O
inducing    O
ligand    O
(    O
APRIL    O
)    O
,    O
with    O
the    O
constant    O
region    O
of    O
immunoglobin    O
.    O

CCL11    B-Cytokine114828193

Several    O
CC    O
chemokines    O
:    O
CCL1    B-Cytokine114828193
,    O
CCL2    B-Cytokine114828193
,    O
CCL3    B-Cytokine114828193
,    O
CCL4    O
,    O
CCL5    B-Cytokine114828193
,    O
CCL7    B-Cytokine114828193
,    O
CCL8    B-Cytokine114828193
,    O
CCL11    B-Cytokine114828193
,    O
CCL13    B-Cytokine114828193
,    O
CCL14    B-Cytokine114828193
,    O
CCL15    B-Cytokine114828193
,    O
CCL16    B-Cytokine114828193
,    O
CCL18    B-Cytokine114828193
,    O
and    O
CCL23    B-Cytokine114828193

In    O
the    O
third    O
phase    O
,    O
natural    O
killer    O
cells    O
and    O
macrophages    O
transactivate    O
one    O
another    O
via    O
the    O
reciprocal    O
production    O
of    O
IFN    O
-    O
gamma    O
and    O
IL-12    B-Cytokine114828193
.    O

These    O
signals    O
induce    O
a    O
pro    O
-    O
inflammatory    O
state    O
through    O
the    O
production    O
of    O
the    O
pro    O
-    O
inflammatory    O
cytokines    O
interleukin-1    O
,    O
interleukin-12    B-Cytokine114828193
,    O
TNF-alpha    B-Cytokine114828193
and    O
IFN    O
-    O
gamma    O
.    O

Other    O
cytokines    O
,    O
such    O
as    O
interleukin    O
1    O
,    O
interleukin    B-Cytokine114828193
2    I-Cytokine114828193
,    O
interleukin-12    B-Cytokine114828193
,    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor    I-Cytokine114828193
and    O
colony-stimulating    B-Cytokine114828193
factor    I-Cytokine114828193
,    O
can    O
also    O
enhance    O
interferon    O
production    O
.    O

Typical    O
cytokines    O
produced    O
by    O
monocytes    O
are    O
TNF    O
,    O
IL-1    O
,    O
and    O
IL-12    B-Cytokine114828193
.    O

After    O
stimulation    O
with    O
microbial    O
products    O
the    O
CD14+CD16++    O
monocytes    O
produce    O
high    O
amounts    O
of    O
pro    O
-    O
inflammatory    O
cytokines    O
like    O
tumor    O
necrosis    O
factor    O
and    O
interleukin-12    B-Cytokine114828193
.    O

Molecules    O
called    O
pro    O
-    O
inflammatory    O
cytokines    O
,    O
which    O
include    O
interleukin-1    O
(    O
IL-1    O
)    O
,    O
Interleukin-2    B-Cytokine114828193
(    O
IL-2    O
)    O
,    O
interleukin-6    B-Cytokine114828193
(    O
IL-6    O
)    O
,    O
Interleukin-12    B-Cytokine114828193
(    O
IL-12    O
)    O
,    O
Interferon    O
-    O
gamma    O
(    O
IFN    O
-    O
Gamma    O
)    O
and    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor    I-Cytokine114828193
alpha    I-Cytokine114828193
(    O
TNF    O
-    O
alpha    O
)    O
can    O
affect    O
brain    O
growth    O
as    O
well    O
as    O
neuronal    O
function    O
.    O
Circulating    O
immune    O
cells    O
such    O
as    O
macrophages    O
,    O
as    O
well    O
as    O
glial    O
cells    O
(    O
microglia    O
and    O
astrocytes    O
)    O
secrete    O
these    O
molecules    O
.    O

IL-18    O
works    O
by    O
binding    O
to    O
the    O
interleukin-18    O
receptor    O
,    O
and    O
together    O
with    O
IL-12    B-Cytokine114828193
it    O
induces    O
cell    O
-    O
mediated    O
immunity    O
following    O
infection    O
with    O
microbial    O
products    O
like    O
lipopolysaccharide    O
(    O
LPS    O
)    O
.    O

The    O
axis    O
inhibits    O
bone    O
marrow    O
-    O
derived    O
dendritic    O
cells    O
(    O
i.e.    O
antigen    O
-    O
presenting    O
cells    O
that    O
process    O
antigen    O
material    O
,    O
present    O
it    O
on    O
their    O
surfaces    O
for    O
delivery    O
to    O
T    O
cells    O
,    O
and    O
otherwise    O
regulate    O
innate    O
and    O
adaptive    O
immune    O
system    O
responses    O
)    O
from    O
producing    O
pro    O
-    O
inflammatory    O
cytokines    O
(    O
e.g.    O
IL-12    B-Cytokine114828193
,    O
TNF-alpha    B-Cytokine114828193
,    O
IL-1-alpha    B-Cytokine114828193
,    O
and    O
IL-6    B-Cytokine114828193
)    O
while    O
stimulating    O
them    O
to    O
increase    O
production    O
of    O
the    O
anti    O
-    O
inflammatory    O
cytokine    O
,    O
IL-10    O
.    O

Activated    O
T    O
cells    O
are    O
promoted    O
by    O
IL-12    B-Cytokine114828193
to    O
differentiate    O
towards    O
the    O
Th1    O
type    O
,    O
producing    O
cytokines    O
including    O
IL-12    O
and    O
IFNγ.    O
OPN    O
inhibits    O
production    O
of    O
the    O
Th2    O
cytokine    O
IL-10    O
,    O
which    O
leads    O
to    O
enhanced    O
Th1    O
response    O
.    O

Like    O
ustekinumab    O
,    O
the    O
antibody    O
targets    O
the    O
interleukins    O
12    B-Cytokine114828193
and    O
23    O
.    O

These    O
include    O
interleukin    B-Cytokine114828193
12    I-Cytokine114828193
(    O
IL-12    O
)    O
,    O
interferon    O
gamma    O
(    O
IFNγ    O
)    O
and    O
interleukin    B-Cytokine114828193
10    I-Cytokine114828193
(    O
IL-10    O
)    O
.    O

Growth    O
related    O
gene    O
alpha    O
(    O
GRO-α    O
)    O
-    O
CXCL1    B-Cytokine114828193

CXCR3    O
has    O
been    O
shown    O
to    O
interact    O
with    O
CXCL9    B-Cytokine114828193
.    O

:    O
:*    O
CCL9    B-Cytokine114828193

Neurotrophins    B-Cytokine114828193
and    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor    I-Cytokine114828193
α    I-Cytokine114828193
(    O
TNFα    O
)    O
are    O
other    O
cellular    O
factors    O
that    O
work    O
to    O
sensitize    O
neurons    O
to    O
pain    O
.    O

Bromantane    O
has    O
been    O
found    O
to    O
increase    O
the    O
expression    O
of    O
neurotrophin    B-Cytokine114828193
including    O
brain    O
-    O
derived    O
neurotrophic    O
factor    O
and    O
nerve    O
growth    O
factor    O
in    O
certain    O
rat    O
brain    O
areas    O
.    O

The    O
precursor    O
protein    O
exists    O
both    O
as    O
a    O
secretory    O
protein    O
and    O
as    O
an    O
integral    O
membrane    O
protein    O
and    O
has    O
neurotrophic    B-Cytokine114828193
activities    O
.    O

They    O
produce    O
a    O
variety    O
of    O
factors    O
,    O
including    O
neurotrophin    B-Cytokine114828193
,    O
and    O
also    O
transfer    O
essential    O
molecules    O
across    O
to    O
axons    O
.    O

It    O
has    O
been    O
proposed    O
that    O
the    O
MAGE    O
conserved    O
domain    O
of    O
MAGE    O
-    O
D    O
proteins    O
might    O
interact    O
with    O
p75    O
neurotrophin    B-Cytokine114828193
or    O
related    O
receptors    O
.    O

He    O
earned    O
acclaim    O
for    O
his    O
teaching    O
and    O
initiated    O
a    O
program    O
of    O
research    O
that    O
centered    O
on    O
the    O
role    O
of    O
neurotrophins    B-Cytokine114828193
in    O
the    O
growth    O
and    O
survival    O
of    O
nerve    O
cells    O
,    O
and    O
in    O
the    O
synaptic    O
activity    O
related    O
to    O
the    O
formation    O
of    O
memories    O
.    O

The    O
hippocampus    O
plays    O
a    O
significant    O
role    O
in    O
neurotrophy    B-Cytokine114828193
:    O
the    O
cognitive    O
adaptation    O
to    O
changing    O
environments    O
and    O
the    O
process    O
of    O
learning    O
and    O
it    O
is    O
a    O
potent    O
stimulator    O
of    O
growth    O
hormone    O
.    O

List    O
of    O
neurosteroids    O
–    O
excitatory    O
,    O
inhibitory    O
,    O
mixed    O
,    O
neurotrophic    B-Cytokine114828193
,    O
antineurotrophic    B-Cytokine114828193
,    O
and    O
other    O
neurosteroids    O
,    O
as    O
well    O
as    O
pheromones    O
and    O
pherines    O

Neurotrophins    B-Cytokine114828193
are    O
a    O
family    O
of    O
proteins    O
that    O
induce    O
the    O
survival    O
,    O
development    O
,    O
and    O
function    O
of    O
neurons    O
.    O

These    O
signals    O
include    O
IFN-γ    O
,    O
CCL21    B-Cytokine114828193
,    O
CCL2    B-Cytokine114828193
.    O

CCL21    B-Cytokine114828193

Many    O
medical    O
symptoms    O
such    O
as    O
inflammation    O
,    O
fever    O
,    O
pain    O
,    O
sickness    B-Cytokine114828193
behavior    I-Cytokine114828193
,    O
or    O
morning    O
sickness    O
have    O
an    O
evolutionary    O
medicine    O
function    O
of    O
enabling    O
the    O
body    O
to    O
protect    O
,    O
heal    O
or    O
restore    O
itself    O
from    O
injury    O
,    O
infection    O
or    O
other    O
physiological    O
disruption    O
.    O

Sickness    B-Cytokine114828193
behavior    I-Cytokine114828193

A    O
shaman    O
from    O
the    O
Amazon    O
Rainforest    O
:    O
the    O
health    O
management    O
system    O
uses    O
information    O
about    O
being    O
treated    O
from    O
healers    O
to    O
limit    O
the    O
deployment    O
of    O
the    O
body    O
's    O
own    O
evolved    O
self    O
-    O
treatments    O
such    O
as    O
fever    O
,    O
sickness    B-Cytokine114828193
behavior    I-Cytokine114828193
,    O
and    O
pain    O
.    O

sickness    B-Cytokine114828193
behavior    I-Cytokine114828193

Approval    O
for    O
PEGylated    B-Cytokine114828193
interferon-alpha-2a    I-Cytokine114828193
(    O
"    O
Pegasys    O
"    O
)    O
followed    O
in    O
October    O
2002    O
.    O

Peginterferon    B-Cytokine114828193
alfa-2a    I-Cytokine114828193
,    O
an    O
antiviral    O
drug    O
used    O
in    O
treatment    O
for    O
hepatitis    O
C    O
and    O
hepatitis    O
B    O

NS5A    O
inhibitors    O
have    O
been    O
found    O
particularly    O
effective    O
in    O
the    O
treatment    O
of    O
HCV    O
where    O
they    O
have    O
been    O
used    O
in    O
combination    O
with    O
other    O
protease    O
inhibitors    O
such    O
as    O
NS5B    O
inhibitors    O
(    O
e.g.    O
sofosbuvir    O
)    O
,    O
pegylated    O
interferons    O
(    O
e.g.    O
peginterferon    B-Cytokine114828193
alfa-2a    I-Cytokine114828193
)    O
,    O
and    O
ribonucleic    O
analogs    O
(    O
e.g.    O
ribavirin    O
)    O
.    O

Peginterferon    B-Cytokine114828193
alfa-2a    I-Cytokine114828193
(    O
Pegasys    O
)    O
–    O

Acylation    B-Cytokine114828193
stimulating    I-Cytokine114828193
protein    I-Cytokine114828193

Several    O
CC    O
chemokines    O
:    O
CCL1    B-Cytokine114828193
,    O
CCL2    B-Cytokine114828193
,    O
CCL3    B-Cytokine114828193
,    O
CCL4    O
,    O
CCL5    B-Cytokine114828193
,    O
CCL7    B-Cytokine114828193
,    O
CCL8    B-Cytokine114828193
,    O
CCL11    B-Cytokine114828193
,    O
CCL13    B-Cytokine114828193
,    O
CCL14    B-Cytokine114828193
,    O
CCL15    B-Cytokine114828193
,    O
CCL16    B-Cytokine114828193
,    O
CCL18    B-Cytokine114828193
,    O
and    O
CCL23    B-Cytokine114828193

As    O
a    O
myokine    B-Cytokine114828193
,    O
IL-15    O
appears    O
to    O
play    O
a    O
significant    O
role    O
in    O
the    O
reduction    O
of    O
visceral    O
(    O
intra    O
-    O
abdominal    O
or    O
interstitial    O
)    O
fat    O
.    O

New    O
research    O
has    O
found    O
IL-6    O
to    O
be    O
an    O
anti    O
-    O
inflammatory    O
cytokine    O
with    O
multiple    O
beneficial    O
effects    O
when    O
released    O
by    O
contracting    O
muscle    O
as    O
a    O
myokine    B-Cytokine114828193
.    O

Anti    O
-    O
IL-6    O
therapies    O
should    O
therefore    O
take    O
into    O
consideration    O
the    O
(    O
beneficial    O
)    O
anti    O
-    O
inflammatory    O
effects    O
of    O
myokine    B-Cytokine114828193
generally    O
,    O
including    O
the    O
now    O
-    O
established    O
multiple    O
benefits    O
of    O
muscle    O
-    O
derived    O
Interleukin    B-Cytokine114828193
6    I-Cytokine114828193
.    O

Several    O
CC    O
chemokines    O
:    O
CCL1    B-Cytokine114828193
,    O
CCL2    B-Cytokine114828193
,    O
CCL3    B-Cytokine114828193
,    O
CCL4    O
,    O
CCL5    B-Cytokine114828193
,    O
CCL7    B-Cytokine114828193
,    O
CCL8    B-Cytokine114828193
,    O
CCL11    B-Cytokine114828193
,    O
CCL13    B-Cytokine114828193
,    O
CCL14    B-Cytokine114828193
,    O
CCL15    B-Cytokine114828193
,    O
CCL16    B-Cytokine114828193
,    O
CCL18    B-Cytokine114828193
,    O
and    O
CCL23    B-Cytokine114828193

Viral    O
replication    O
triggers    O
the    O
release    B-Cytokine114828193
of    I-Cytokine114828193
high    I-Cytokine114828193
levels    I-Cytokine114828193
of    I-Cytokine114828193
inflammatory    I-Cytokine114828193
chemical    I-Cytokine114828193
signals    I-Cytokine114828193
and    O
leads    O
to    O
a    O
septic    O
state    O
.    O

A    O
cytokine    B-Cytokine114828193
storm    I-Cytokine114828193
,    O
also    O
known    O
as    O
cytokine    B-Cytokine114828193
cascade    I-Cytokine114828193
and    O
hypercytokinemia    B-Cytokine114828193
,    O
is    O
a    O
potentially    O
fatal    O
immune    O
reaction    O
consisting    O
of    O
a    O
positive    O
feedback    O
loop    O
between    O
cytokines    O
and    O
white    O
blood    O
cells    O
,    O
with    O
highly    O
elevated    O
levels    O
of    O
various    O
cytokines    O
.    O

Severe    O
cases    O
have    O
been    O
called    O
"    O
cytokine    B-Cytokine114828193
storm    I-Cytokine114828193
"    O
,    O
a    O
term    O
borrowed    O
from    O
discussions    O
of    O
the    O
pathophysiology    O
of    O
immune    O
disorders    O
and    O
infectious    O
disease    O
.    O

Some    O
of    O
the    O
more    O
serious    O
damage    O
caused    O
by    O
SARS    O
may    O
be    O
due    O
to    O
the    O
body    O
's    O
own    O
immune    O
system    O
reacting    O
in    O
what    O
is    O
known    O
as    O
cytokine    B-Cytokine114828193
storm    I-Cytokine114828193
.    O

IVIG    O
has    O
long    O
been    O
used    O
for    O
the    O
treatment    O
of    O
autoimmune    O
and    O
MGUS    O
-    O
associated    O
syndromes    O
,    O
because    O
of    O
its    O
potential    O
immunomodulatory    O
and    O
anticytokine    B-Cytokine114828193
properties    O
.    O

p40    O
,    O
alias    O
for    O
interleukin-12    B-Cytokine114828193
subunit    I-Cytokine114828193
beta    I-Cytokine114828193

IL-12    O
and    O
IL-23    O
share    O
a    O
common    O
domain    O
,    O
p40    B-Cytokine114828193
,    O
which    O
is    O
the    O
target    O
of    O
the    O
recently    O
FDA    O
-    O
approved    O
ustekinumab    O
.    O

Once    O
pathogens    O
start    O
to    O
invade    O
the    O
upper    O
layers    O
of    O
the    O
epidermis    O
,    O
keratinocytes    O
can    O
react    O
by    O
producing    O
proinflammatory    O
mediators    O
,    O
particularly    O
chemokines    B-Cytokine114828193
such    O
as    O
CXCL10    B-Cytokine114828193
and    O
CCL2    B-Cytokine114828193
which    O
attract    O
leukocytes    O
to    O
the    O
site    O
of    O
pathogen    O
invasion    O
.    O

CXCR3-A    O
binds    O
to    O
the    O
CXC    O
chemokines    O
CXCL9    B-Cytokine114828193
(    O
MIG    O
)    O
,    O
CXCL10    B-Cytokine114828193
(    O
IP-10    O
)    O
,    O
and    O
CXCL11    B-Cytokine114828193
(    O
I    O
-    O
TAC    O
)    O
whereas    O
CXCR3-B    O
can    O
also    O
bind    O
to    O
CXCL4    B-Cytokine114828193
in    O
addition    O
to    O
CXCL9    O
,    O
CXCL10    O
,    O
and    O
CXCL11    O
.    O

Both    O
have    O
been    O
shown    O
to    O
down    O
regulate    O
IFN-γ    O
,    O
IL-1α    B-Cytokine114828193
,    O
GM    O
-    O
CSF    O
,    O
IL-6    B-Cytokine114828193
and    O
TNF-α    B-Cytokine114828193
,    O
which    O
are    O
all    O
pro    O
-    O
inflammatory    O
cytokines    O
.    O

Among    O
other    O
proteins    O
,    O
β    O
trefoil    O
fold    O
is    O
found    O
in    O
Kunitz    O
inhibitors    O
of    O
several    O
plants    O
such    O
as    O
soybean    O
,    O
"    O
Erythrina    O
caffra    O
"    O
and    O
wheat    O
;    O
in    O
members    O
of    O
the    O
interleukin    O
1    O
cytokine    O
family    O
(    O
interleukin-1    B-Cytokine114828193
alpha    I-Cytokine114828193
,    O
interleukin-1    O
beta    O
and    O
interleukin-1    B-Cytokine114828193
receptor    I-Cytokine114828193
antagonist    I-Cytokine114828193
)    O
;    O
and    O
in    O
fibroblast    O
growth    O
factors    O
1    O
and    O
2    O
.    O

The    O
axis    O
inhibits    O
bone    O
marrow    O
-    O
derived    O
dendritic    O
cells    O
(    O
i.e.    O
antigen    O
-    O
presenting    O
cells    O
that    O
process    O
antigen    O
material    O
,    O
present    O
it    O
on    O
their    O
surfaces    O
for    O
delivery    O
to    O
T    O
cells    O
,    O
and    O
otherwise    O
regulate    O
innate    O
and    O
adaptive    O
immune    O
system    O
responses    O
)    O
from    O
producing    O
pro    O
-    O
inflammatory    O
cytokines    O
(    O
e.g.    O
IL-12    B-Cytokine114828193
,    O
TNF-alpha    B-Cytokine114828193
,    O
IL-1-alpha    B-Cytokine114828193
,    O
and    O
IL-6    B-Cytokine114828193
)    O
while    O
stimulating    O
them    O
to    O
increase    O
production    O
of    O
the    O
anti    O
-    O
inflammatory    O
cytokine    O
,    O
IL-10    O
.    O

After    O
an    O
injury    O
to    O
the    O
cornea    O
,    O
some    O
keratocytes    O
undergo    O
apoptosis    O
,    O
prompted    O
by    O
the    O
signaling    O
molecules    O
secreted    O
by    O
the    O
upper    O
layers    O
,    O
such    O
as    O
IL1    B-Cytokine114828193
alpha    I-Cytokine114828193
and    O
TNF-alpha    B-Cytokine114828193
.    O

As    O
soon    O
as    O
the    O
basement    O
membrane    O
of    O
corneal    O
epithelium    O
is    O
restored    O
,    O
TGF    B-Cytokine114828193
beta    I-Cytokine114828193
inflow    O
into    O
the    O
stroma    O
drastically    O
decreases    O
and    O
myofibroblasts    O
disappear    O
,    O
after    O
which    O
the    O
remaining    O
activated    O
keratocytes    O
continue    O
for    O
some    O
time    O
to    O
reshape    O
the    O
extracellular    O
matrix    O
,    O
secreting    O
IL1-alpha    B-Cytokine114828193
in    O
order    O
to    O
maintain    O
their    O
"    O
repair    O
phenotype    O
"    O
.    O

XCL1    B-Cytokine114828193

:    O
:*    O
CXCL14    B-Cytokine114828193

IL-17    O
induces    O
the    O
production    O
of    O
many    O
other    O
cytokines    O
(    O
such    O
as    O
IL-6    B-Cytokine114828193
,    O
G-CSF    B-Cytokine114828193
,    O
GM    O
-    O
CSF    O
,    O
IL-1β    O
,    O
TGF-β    B-Cytokine114828193
,    O
TNF-α    B-Cytokine114828193
)    O
,    O
chemokines    B-Cytokine114828193
(    O
including    O
IL-8    B-Cytokine114828193
,    O
GRO-α    O
,    O
and    O
MCP-1    O
)    O
,    O
and    O
prostaglandins    O
(    O
e.g.    O
,    O
PGE2    O
)    O
from    O
many    O
cell    O
types    O
(    O
fibroblasts    O
,    O
endothelial    O
cells    O
,    O
epithelial    O
cells    O
,    O
keratinocytes    O
,    O
and    O
macrophages    O
)    O
.    O

Recombinant    O
proteins    O
,    O
such    O
as    O
insulin    O
,    O
hepatitis    O
B    O
vaccine    O
,    O
interferon    O
,    O
granulocyte    B-Cytokine114828193
colony-stimulating    I-Cytokine114828193
factor    I-Cytokine114828193
,    O
streptokinase    O
and    O
others    O
are    O
also    O
made    O
this    O
way    O
.    O

His    O
work    O
has    O
assisted    O
in    O
the    O
understanding    O
of    O
"    O
Chronic    O
HBV    O
Infection    O
"    O
,    O
Liver    O
cancer    O
and    O
the    O
B    O
and    O
C    O
variants    O
of    O
Hepatitis    O
and    O
his    O
recent    O
studies    O
on    O
"    O
acute    O
-    O
on    O
-    O
chronic    O
liver    O
failure    O
"    O
(    O
ACLF    O
)    O
disease    O
and    O
its    O
therapy    O
using    O
Granulocyte    B-Cytokine114828193
colony-stimulating    I-Cytokine114828193
factor    I-Cytokine114828193
(    O
G    O
-    O
CSF    O
)    O
,    O
a    O
glycoprotein    O
is    O
known    O
to    O
have    O
been    O
successful    O
in    O
clinical    O
trials    O
.    O

Other    O
treatments    O
may    O
include    O
allopurinol    O
and    O
human    B-Cytokine114828193
granulocyte    I-Cytokine114828193
colony    I-Cytokine114828193
stimulating    I-Cytokine114828193
factor    I-Cytokine114828193
.    O

Drug    O
-    O
induced    O
psoriasis    O
may    O
occur    O
with    O
beta    O
blockers    O
,    O
lithium    O
,    O
antimalarial    O
medications    O
,    O
non    O
-    O
steroidal    O
anti    O
-    O
inflammatory    O
drugs    O
,    O
terbinafine    O
,    O
calcium    O
channel    O
blockers    O
,    O
captopril    O
,    O
glyburide    O
,    O
granulocyte    B-Cytokine114828193
colony-stimulating    I-Cytokine114828193
factor    I-Cytokine114828193
,    O
interleukins    O
,    O
interferons    O
,    O
lipid    O
-    O
lowering    O
drugs    O
,    O
and    O
paradoxically    O
TNF    O
inhibitors    O
such    O
as    O
infliximab    O
or    O
adalimumab    O
.    O

Together    O
with    O
Interleukin-2    B-Cytokine114828193
(    O
IL-2    B-Cytokine114828193
)    O
,    O
Interleukin-4    B-Cytokine114828193
(    O
IL-4    B-Cytokine114828193
)    O
,    O
Interleukin-7    B-Cytokine114828193
(    O
IL-7    B-Cytokine114828193
)    O
,    O
Interleukin-9    B-Cytokine114828193
(    O
IL-9    B-Cytokine114828193
)    O
,    O
granulocyte    B-Cytokine114828193
colony-stimulating    I-Cytokine114828193
factor    I-Cytokine114828193
(    O
G-CSF    B-Cytokine114828193
)    O
,    O
and    O
granulocyte    O
-    O
macrophage    O
colony    O
-    O
stimulating    O
factor    O
(    O
GM    O
-    O
CSF    O
)    O
,    O
IL-15    O
belongs    O
to    O
the    O
four    O
α-helix    O
bundle    O
family    O
of    O
cytokine    O
.    O

G-CSF    B-Cytokine114828193
is    O
used    O
clinically    O
(    O
see    O
Neutropenia    O
)    O
but    O
tests    O
in    O
mice    O
suggest    O
it    O
may    O
lead    O
to    O
bone    O
loss    O
.    O

Atkinson    O
has    O
led    O
or    O
contributed    O
to    O
clinical    O
trials    O
utilizing    O
several    O
types    O
of    O
interventions    O
to    O
stop    O
the    O
progression    O
of    O
or    O
reverse    O
type    O
1    O
diabetes    O
,    O
including    O
prophylactic    O
insulin    O
,    O
glutamic    O
acid    O
decarboxylase    O
,    O
cord    O
blood    O
,    O
cord    O
blood    O
plus    O
Omega-3    O
FA    O
,    O
granulocyte    B-Cytokine114828193
colony-stimulating    I-Cytokine114828193
factor    I-Cytokine114828193
(    O
GCSF    O
)    O
,    O
and    O
anti    O
-    O
thymocyte    O
globulin    O
(    O
ATG    O
)    O
plus    O
GCSF    O
.    O

These    O
are    O
difficult    O
to    O
distinguish    O
from    O
the    O
red    O
marrow    O
hyperplasia    O
of    O
hematopoiesis    O
,    O
as    O
can    O
occur    O
with    O
tobacco    O
smoking    O
,    O
chronically    O
anemic    O
disease    O
states    O
like    O
sickle    O
cell    O
anemia    O
or    O
beta    O
thalassemia    O
,    O
medications    O
such    O
as    O
granulocyte    B-Cytokine114828193
colony-stimulating    I-Cytokine114828193
factor    I-Cytokine114828193
,    O
or    O
during    O
recovery    O
from    O
chronic    O
nutritional    O
anemias    O
or    O
therapeutic    O
bone    O
marrow    O
suppression    O
.    O

There    O
is    O
now    O
good    O
evidence    O
that    O
treatment    O
with    O
hematopoietic    O
growth    O
factors    O
—    O
including    O
granulocyte    B-Cytokine114828193
colony-stimulating    I-Cytokine114828193
factor    I-Cytokine114828193
(    O
G    O
-    O
CSF    O
)    O
,    O
which    O
is    O
used    O
to    O
treat    O
AML    O
,    O
and    O
granulocyte    O
-    O
macrophage    O
colony    O
-    O
stimulating    O
factor    O
—    O
can    O
cause    O
SS    O
.    O
Lesions    O
typically    O
occur    O
when    O
the    O
patient    O
has    O
leukocytosis    O
and    O
neutrophilia    O
but    O
not    O
when    O
the    O
patient    O
is    O
neutropenic    O
.    O

Pegfilgrastim    O
(    O
Neulasta    O
)    O
–    O
PEGylated    O
recombinant    O
methionyl    O
human    O
granulocyte    B-Cytokine114828193
colony-stimulating    I-Cytokine114828193
factor    I-Cytokine114828193
for    O
severe    O
cancer    O
chemotherapy    O
-    O
induced    O
neutropenia    O
(    O
Amgen    O
,    O
2002    O
)    O

At    O
the    O
current    O
time    O
,    O
G-CSF    B-Cytokine114828193
is    O
the    O
main    O
drug    O
used    O
for    O
mobilization    O
;    O
it    O
indirectly    O
activates    O
CD117    O
.    O

Others    O
oprelvekin    B-Cytokine114828193
,    O
romiplostim    O
,    O
eltrombopag    O
,    O
argatroban    O

Production    O
of    O
CXCL12    B-Cytokine114828193
,    O
a    O
chemokine    B-Cytokine114828193
,    O
is    O
regulated    O
by    O
mir-126    O
.    O

For    O
extracellular    O
signaling    O
molecules    O
,    O
they    O
looked    O
at    O
expression    O
of    O
the    O
genes    O
IGFBP6    O
and    O
SDF1    B-Cytokine114828193
.    O

Siltuximab    O
was    O
also    O
tested    O
in    O
the    O
phase    O
I    O
/    O
II    O
study    O
for    O
therapy    O
of    O
patients    O
with    O
metastatic    O
castration    O
-    O
associated    O
prostate    O
cancer    O
in    O
combination    O
with    O
docetaxel    O
and    O
in    O
renal    O
cell    O
carcinoma    O
;    O
phase    O
II    O
trials    O
in    O
ovarian    O
cancer    O
resulted    O
in    O
39%    O
of    O
patients    O
showed    O
disease    O
stabilization    O
via    O
IL-6    B-Cytokine114828193
downregulation    O
of    O
CCL2    B-Cytokine114828193
,    O
CXCL12    B-Cytokine114828193
and    O
VEGF    O
.    O

Stromal    B-Cytokine114828193
cell-derived    I-Cytokine114828193
factor-1    I-Cytokine114828193
(    O
SDF-1    O
,    O
SDF1    O
,    O
Sdf1    O
)    O

Stromal    B-Cytokine114828193
cell-derived    I-Cytokine114828193
factor-1    I-Cytokine114828193
(    O
SDF-1    O
,    O
SDF1    O
,    O
Sdf1    O
)    O

There    O
is    O
also    O
evidence    O
that    O
biglycan    O
binds    O
to    O
TGF-beta    B-Cytokine114828193
1    I-Cytokine114828193
.    O

Fimastartan    O
can    O
also    O
block    O
TGF-β1    B-Cytokine114828193
production    O
(    O
also    O
AT1    O
dependent    O
)    O
,    O
which    O
contributes    O
to    O
fibrosis    O
and    O
ventricular    O
damage    O
post    O
-    O
infarct    O
.    O

One    O
of    O
the    O
main    O
signaling    O
receptors    O
involved    O
in    O
this    O
pathway    O
is    O
the    O
TGF-β1    B-Cytokine114828193
co    O
-    O
receptor    O
(    O
complex    O
of    O
type    O
I    O
and    O
type    O
II    O
receptors    O
)    O
,    O
which    O
acts    O
as    O
a    O
trans    O
-    O
membrane    O
protein    O
serine    O
/    O
threonine    O
kinase    O
.    O

These    O
receptors    O
bind    O
members    O
of    O
the    O
TGFβ    O
superfamily    O
of    O
growth    O
factor    O
and    O
cytokine    O
signaling    O
proteins    O
such    O
as    O
TGFβ    B-Cytokine114828193
(    O
TGFβ1    B-Cytokine114828193
,    O
TGFβ2    O
,    O
TGFβ3    O
)    O
,    O
bone    B-Cytokine114828193
morphogenetic    I-Cytokine114828193
protein    I-Cytokine114828193
(    O
BMPs    O
)    O
,    O
growth    O
differentiation    O
factors    O
(    O
GDFs    O
)    O
,    O
activin    O
and    O
inhibin    O
,    O
myostatin    O
,    O
anti    O
-    O
Müllerian    O
hormone    O
(    O
AMH    O
)    O
,    O
and    O
nodal    O
.    O

α    O
granules    O
(    O
alpha    O
granules    O
)    O
–    O
containing    O
P    O
-    O
selectin    O
,    O
platelet    B-Cytokine114828193
factor    I-Cytokine114828193
4    I-Cytokine114828193
,    O
transforming    B-Cytokine114828193
growth    I-Cytokine114828193
factor-β1    I-Cytokine114828193
,    O
platelet    O
-    O
derived    O
growth    O
factor    O
,    O
fibronectin    O
,    O
B    O
-    O
thromboglobulin    O
,    O
vWF    O
,    O
fibrinogen    O
,    O
and    O
coagulation    O
factors    O
V    O
and    O
XIII    O
.    O

Levels    O
of    O
TGFβ1    B-Cytokine114828193
along    O
with    O
cell    O
viability    O
were    O
reduced    O
to    O
90%    O
of    O
control    O
levels    O
when    O
incubated    O
48    O
h    O
with    O
25    O
μg    O
/    O
mL    O
citrinin    O
.    O

In    O
addition    O
,    O
JDP2    O
overexpression    O
reverses    O
the    O
epithelial    O
-    O
to    O
-    O
mesenchymal    O
transition    O
(    O
EMT    O
)    O
induced    O
by    O
co    O
-    O
treatment    O
with    O
TGF-β1    B-Cytokine114828193
and    O
EGF    O
in    O
human    O
pancreatic    O
BxPC3    O
cells    O
,    O
suggesting    O
that    O
JDP2    O
may    O
be    O
a    O
molecular    O
target    O
for    O
pancreatic    O
carcinoma    O
intervention    O
.    O

:    O
:*    O
CXCL13    B-Cytokine114828193

Examples    O
of    O
protein    O
markers    O
evaluated    O
in    O
such    O
profiling    O
include    O
CXCL13    B-Cytokine114828193
and    O
granulocyte    O
-    O
macrophage    O
colony    O
-    O
stimulating    O
factor    O
,    O
where    O
lower    O
protein    O
amounts    O
are    O
associated    O
with    O
higher    O
implantation    O
rates    O
.    O

:    O
:*    O
CXCL15    B-Cytokine114828193

Colony-stimulating    B-Cytokine114828193
factor    I-Cytokine114828193

The    O
presentation    O
noted    O
that    O
"    O
He    O
discovered    O
and    O
identified    O
a    O
group    O
of    O
proteins    O
among    O
them    O
colony-stimulating    B-Cytokine114828193
factor    I-Cytokine114828193
and    O
some    O
interleukins    O
that    O
control    O
the    O
viability    O
and    O
growth    O
of    O
blood    O
stem    O
cells    O
and    O
their    O
development    O
into    O
different    O
types    O
of    O
mature    O
blood    O
cells    O
.    O
"    O

For    O
instance    O
,    O
they    O
generate    O
colony    B-Cytokine114828193
stimulating    I-Cytokine114828193
factors    I-Cytokine114828193
,    O
which    O
have    O
a    O
significant    O
effect    O
on    O
hematopoiesis    O
.    O

During    O
this    O
time    O
,    O
the    O
group    O
led    O
by    O
Professor    O
Donald    O
Metcalf    O
discovered    O
and    O
characterised    O
the    O
colony-stimulating    B-Cytokine114828193
factors    I-Cytokine114828193
(    O
CSFs    O
)    O
,    O
which    O
have    O
benefited    O
more    O
than    O
10    O
million    O
cancer    O
patients    O
worldwide    O
.    O

Type    O
I    O
cytokine    O
receptors    O
include    O
interleukin    O
receptors    O
,    O
colony    B-Cytokine114828193
stimulating    I-Cytokine114828193
factor    I-Cytokine114828193
receptors    O
and    O
other    O
cytokine    O
receptors    O

Other    O
regulatory    O
immune    O
cells    O
include    O
T    O
cell    O
subsets    O
similar    O
to    O
but    O
phenotypically    O
distinct    O
from    O
Treg    O
cells    O
,    O
including    O
TR1    O
cells    O
that    O
make    O
IL-10    O
but    O
do    O
not    O
express    O
Foxp3    O
,    O
TGF-β    B-Cytokine114828193
TH3    O
cells    O
,    O
as    O
well    O
as    O
other    O
less    O
well    O
-    O
characterized    O
cells    O
that    O
help    O
establish    O
a    O
local    O
tolerogenic    O
environment    O
.    O

A    O
subset    O
of    O
B    O
regulatory    O
cells    O
that    O
makes    O
IL-10    B-Cytokine114828193
and    O
TGF-β    B-Cytokine114828193
also    O
exists    O
.    O

:*    O
Secretion    O
of    O
TGF-β    B-Cytokine114828193
,    O
which    O
sensitizes    O
cells    O
to    O
suppression    O
and    O
promotes    O
Treg    O
-    O
like    O
cell    O
differentiation    O

In    O
particular    O
,    O
specialized    O
gut    O
CD103    O
+    O
DCs    O
that    O
produce    O
both    O
TGF-β    B-Cytokine114828193
and    O
retinoic    O
acid    O
efficiently    O
promotes    O
the    O
differentiation    O
of    O
iTreg    O
cells    O
in    O
the    O
gut    O
lymphoid    O
tissue    O
.    O

Upregulation    O
of    O
GFAP    O
,    O
which    O
is    O
induced    O
by    O
FGF    O
,    O
TGFB    B-Cytokine114828193
,    O
and    O
ciliary    O
neurotrophic    O
factor    O
(    O
CNTF    O
)    O
,    O
is    O
a    O
classic    O
marker    O
for    O
reactive    O
gliosis    O
.    O

TGFB    B-Cytokine114828193
is    O
a    O
regulatory    O
molecule    O
involved    O
in    O
proteoglycan    O
production    O
.    O

These    O
receptors    O
bind    O
members    O
of    O
the    O
TGFβ    O
superfamily    O
of    O
growth    O
factor    O
and    O
cytokine    O
signaling    O
proteins    O
such    O
as    O
TGFβ    B-Cytokine114828193
(    O
TGFβ1    B-Cytokine114828193
,    O
TGFβ2    O
,    O
TGFβ3    O
)    O
,    O
bone    B-Cytokine114828193
morphogenetic    I-Cytokine114828193
protein    I-Cytokine114828193
(    O
BMPs    O
)    O
,    O
growth    O
differentiation    O
factors    O
(    O
GDFs    O
)    O
,    O
activin    O
and    O
inhibin    O
,    O
myostatin    O
,    O
anti    O
-    O
Müllerian    O
hormone    O
(    O
AMH    O
)    O
,    O
and    O
nodal    O
.    O

IL-17    O
induces    O
the    O
production    O
of    O
many    O
other    O
cytokines    O
(    O
such    O
as    O
IL-6    B-Cytokine114828193
,    O
G-CSF    B-Cytokine114828193
,    O
GM    O
-    O
CSF    O
,    O
IL-1β    O
,    O
TGF-β    B-Cytokine114828193
,    O
TNF-α    B-Cytokine114828193
)    O
,    O
chemokines    B-Cytokine114828193
(    O
including    O
IL-8    B-Cytokine114828193
,    O
GRO-α    O
,    O
and    O
MCP-1    O
)    O
,    O
and    O
prostaglandins    O
(    O
e.g.    O
,    O
PGE2    O
)    O
from    O
many    O
cell    O
types    O
(    O
fibroblasts    O
,    O
endothelial    O
cells    O
,    O
epithelial    O
cells    O
,    O
keratinocytes    O
,    O
and    O
macrophages    O
)    O
.    O

Several    O
groups    O
have    O
identified    O
ways    O
to    O
induce    O
IL-17    O
production    O
both    O
"    O
in    O
vitro    O
"    O
and    O
"    O
in    O
vivo    O
"    O
by    O
distinct    O
cytokines    O
,    O
called    O
TGF-β    B-Cytokine114828193
and    O
IL-6    B-Cytokine114828193
,    O
without    O
the    O
need    O
for    O
IL-23    O
.    O

PAK1    O
knockdown    O
in    O
prostate    O
cancer    O
cells    O
is    O
associated    O
with    O
reduced    O
motility    O
,    O
reduced    O
MMP9    O
secretion    O
and    O
increased    O
TGFβ    B-Cytokine114828193
expression    O
,    O
which    O
in    O
these    O
cases    O
,    O
is    O
growth    O
inhibitory    O
.    O

The    O
excitable    O
medium    O
is    O
the    O
limb    O
bud    O
mesenchyme    O
,    O
in    O
which    O
cells    O
interact    O
by    O
positively    O
autoregulatory    O
morphogens    O
such    O
as    O
TGF-β    B-Cytokine114828193
and    O
inhibitory    O
signaling    O
pathways    O
involving    O
FGF    O
and    O
Notch    O
.    O

Under    O
pathologic    O
conditions    O
and    O
in    O
the    O
presence    O
of    O
transforming    B-Cytokine114828193
growth    I-Cytokine114828193
factor    I-Cytokine114828193
beta    I-Cytokine114828193
(    O
TGFβ    O
)    O
,    O
fibroblasts    O
accumulate    O
in    O
these    O
areas    O
of    O
damage    O
and    O
differentiate    O
into    O
myofibroblasts    O
that    O
secrete    O
collagen    O
and    O
other    O
proteins    O
.    O

TGF-β    B-Cytokine114828193

Activins    O
are    O
dimeric    O
growth    O
and    O
differentiation    O
factors    O
which    O
belong    O
to    O
the    O
transforming    B-Cytokine114828193
growth    I-Cytokine114828193
factor-beta    I-Cytokine114828193
(    O
TGF    O
-    O
beta    O
)    O
superfamily    O
of    O
structurally    O
related    O
signaling    O
proteins    O
.    O

The    O
Activin    O
type    O
2    O
receptors    O
modulate    O
signals    O
for    O
ligands    O
belonging    O
to    O
the    O
Transforming    B-Cytokine114828193
growth    I-Cytokine114828193
factor    I-Cytokine114828193
beta    I-Cytokine114828193
superfamily    O
of    O
ligands    O
.    O

Activins    O
are    O
dimeric    O
growth    O
and    O
differentiation    O
factors    O
which    O
belong    O
to    O
the    O
transforming    B-Cytokine114828193
growth    I-Cytokine114828193
factor-beta    I-Cytokine114828193
(    O
TGF    O
-    O
beta    O
)    O
superfamily    O
of    O
structurally    O
related    O
signaling    O
proteins    O
.    O

Keratinocytes    O
also    O
modulate    O
the    O
immune    O
system    O
:    O
apart    O
from    O
the    O
above    O
-    O
mentioned    O
antimicrobial    O
peptides    O
and    O
chemokines    B-Cytokine114828193
they    O
are    O
also    O
potent    O
producers    O
of    O
anti    O
-    O
inflammatory    O
mediators    O
such    O
as    O
IL-10    B-Cytokine114828193
and    O
TGF-β    B-Cytokine114828193
When    O
activated    O
,    O
they    O
can    O
stimulate    O
cutaneous    O
inflammation    O
and    O
Langerhans    O
cell    O
activation    O
via    O
TNFα    B-Cytokine114828193
and    O
IL-1β    O
secretion    O
.    O

Some    O
tumor    O
cells    O
also    O
release    O
products    O
that    O
inhibit    O
the    O
immune    O
response    O
;    O
for    O
example    O
by    O
secreting    O
the    O
cytokine    O
TGF-β    B-Cytokine114828193
,    O
which    O
suppresses    O
the    O
activity    O
of    O
macrophages    O
and    O
lymphocytes    O
.    O

LEMD3    O
also    O
has    O
several    O
implications    O
in    O
regulating    O
the    O
cytokine    O
family    O
such    O
as    O
the    O
transforming    B-Cytokine114828193
growth    I-Cytokine114828193
factor    I-Cytokine114828193
beta    I-Cytokine114828193
(    O
TGF-β    O
)    O
and    O
bone    B-Cytokine114828193
morphogenic    I-Cytokine114828193
protein    I-Cytokine114828193
(    O
BMPs    O
)    O
.    O

After    O
heavier    O
injuries    O
or    O
at    O
the    O
advanced    O
stages    O
of    O
healing    O
process    O
a    O
number    O
of    O
keratocytes    O
transforms    O
into    O
myofibroblasts    O
actively    O
secreting    O
ECM    O
components    O
;    O
this    O
transformation    O
is    O
thought    O
to    O
be    O
caused    O
by    O
TGF-beta    B-Cytokine114828193
.    O

As    O
soon    O
as    O
the    O
basement    O
membrane    O
of    O
corneal    O
epithelium    O
is    O
restored    O
,    O
TGF    B-Cytokine114828193
beta    I-Cytokine114828193
inflow    O
into    O
the    O
stroma    O
drastically    O
decreases    O
and    O
myofibroblasts    O
disappear    O
,    O
after    O
which    O
the    O
remaining    O
activated    O
keratocytes    O
continue    O
for    O
some    O
time    O
to    O
reshape    O
the    O
extracellular    O
matrix    O
,    O
secreting    O
IL1-alpha    B-Cytokine114828193
in    O
order    O
to    O
maintain    O
their    O
"    O
repair    O
phenotype    O
"    O
.    O

During    O
mouse    O
embryonic    O
development    O
,    O
Nodal    O
,    O
a    O
transforming    B-Cytokine114828193
growth    I-Cytokine114828193
factor-beta    I-Cytokine114828193
superfamily    O
ligand    O
,    O
is    O
a    O
key    O
gene    O
involved    O
in    O
patterning    O
both    O
the    O
anterior    O
-    O
posterior    O
axis    O
and    O
the    O
left    O
-    O
right    O
axis    O
of    O
the    O
early    O
embryo    O
.    O
The    O
"    O
Nodal    O
"    O
gene    O
contains    O
two    O
enhancers    O
:    O
the    O
Proximal    O
Epiblast    O
Enhancer    O
(    O
PEE    O
)    O
and    O
the    O
Asymmetric    O
Enhancer    O
(    O
ASE    O
)    O
.    O

Much    O
of    O
the    O
spatial    O
patterning    O
that    O
occurs    O
during    O
the    O
formation    O
and    O
migration    O
of    O
the    O
primitive    O
streak    O
results    O
from    O
the    O
secretion    O
of    O
agonists    O
and    O
antagonists    O
by    O
various    O
cell    O
populations    O
,    O
including    O
the    O
growth    O
factors    O
from    O
the    O
Wnt    O
and    O
transforming    B-Cytokine114828193
growth    I-Cytokine114828193
factor    I-Cytokine114828193
β    I-Cytokine114828193
(    O
TGFβ    O
)    O
families    O
(    O
Lefty    O
1    O
,    O
Nodal    O
)    O
,    O
as    O
well    O
as    O
repressors    O
of    O
the    O
same    O
molecules    O
(    O
Dkk-1    O
,    O
Sfrp1    O
,    O
Sfrp5    O
)    O
.    O

Platelets    O
release    O
platelet    O
-    O
derived    O
growth    O
factor    O
(    O
PDGF    O
)    O
,    O
a    O
potent    O
chemotactic    O
agent    O
;    O
and    O
TGF    B-Cytokine114828193
beta    I-Cytokine114828193
,    O
which    O
stimulates    O
the    O
deposition    O
of    O
extracellular    O
matrix    O
;    O
fibroblast    O
growth    O
factor    O
,    O
insulin    O
-    O
like    O
growth    O
factor    O
1    O
,    O
platelet    O
-    O
derived    O
epidermal    O
growth    O
factor    O
,    O
and    O
vascular    O
endothelial    O
growth    O
factor    O
.    O

These    O
cells    O
produce    O
large    O
amounts    O
of    O
TGF    B-Cytokine114828193
beta    I-Cytokine114828193
and    O
other    O
suppressive    O
cytokines    O
,    O
including    O
IL-10    B-Cytokine114828193
,    O
to    O
prevent    O
damage    O
to    O
the    O
eye    O
by    O
reducing    O
inflammation    O
and    O
causing    O
T    O
cells    O
to    O
differentiate    O
to    O
inducible    O
T    O
reg    O
cells    O
.    O
Innate    O
immune    O
stimulation    O
by    O
bacteria    O
and    O
cellular    O
stress    O
is    O
normally    O
suppressed    O
by    O
myeloid    O
suppression    O
while    O
inducible    O
Treg    O
cells    O
prevent    O
activation    O
and    O
clonal    O
expansion    O
of    O
the    O
autoreactive    O
Th1    O
and    O
Th17    O
cells    O
that    O
possess    O
potential    O
to    O
cause    O
damage    O
to    O
the    O
eye    O
.    O

Epithelial    O
lingual    O
organoids    O
have    O
been    O
generated    O
using    O
BMI1    O
expressing    O
epithelial    O
stem    O
cells    O
in    O
three    O
-    O
dimensional    O
culture    O
conditions    O
through    O
the    O
manipulation    O
of    O
EGF    O
,    O
WNT    O
,    O
and    O
TGF-β    B-Cytokine114828193
This    O
organoid    O
culture    O
,    O
however    O
,    O
lacks    O
taste    O
receptors    O
,    O
as    O
these    O
cells    O
do    O
not    O
arise    O
from    O
Bmi1    O
expressing    O
epithelial    O
stem    O
cells    O
.    O

This    O
type    O
of    O
instability    O
is    O
associated    O
with    O
some    O
specific    O
mutations    O
,    O
including    O
genes    O
involved    O
with    O
DNA    O
mismatch    O
repair    O
and    O
surprisingly    O
,    O
transforming    B-Cytokine114828193
growth    I-Cytokine114828193
factor-beta    I-Cytokine114828193
.    O

Using    O
this    O
model    O
Powrie    O
further    O
identified    O
the    O
pathogenic    O
role    O
played    O
by    O
IFN-γ    O
and    O
TNF-α    B-Cytokine114828193
in    O
intestinal    O
inflammation    O
and    O
the    O
therapeutic    O
potential    O
of    O
IL-10    B-Cytokine114828193
and    O
highlighted    O
the    O
requirement    O
for    O
TGF-β    B-Cytokine114828193
in    O
the    O
prevention    O
of    O
colitis    O
by    O
the    O
CD4+CD45RBlo    O
regulatory    O
T    O
cell    O
subset    O

Other    O
genes    O
affected    O
by    O
NNK    O
include    O
sulfotransferase    O
1A1    O
(    O
SULT1A1    O
)    O
,    O
transforming    B-Cytokine114828193
growth    I-Cytokine114828193
factor    I-Cytokine114828193
beta    I-Cytokine114828193
(    O
TGF-β    O
)    O
,    O
and    O
angiotensin    O
II    O
(    O
AT2    O
)    O
.    O

EBI3    O
is    O
a    O
subunit    O
in    O
2    O
distinct    O
heterodimeric    O
cytokines    O
:    O
interleukin-27    O
(    O
IL27    B-Cytokine114828193
)    O
and    O
IL35    B-Cytokine114828193
.    O

:*    O
IL27    B-Cytokine114828193

The    O
binding    O
of    O
platelet    O
factor    O
4    O
(    O
CXCL4    B-Cytokine114828193
)    O
appears    O
to    O
be    O
critical    O
for    O
the    O
platelet    O
induced    O
killing    O
of    O
"    O
P.    O
falciparum    O
.    O

α    O
granules    O
(    O
alpha    O
granules    O
)    O
–    O
containing    O
P    O
-    O
selectin    O
,    O
platelet    B-Cytokine114828193
factor    I-Cytokine114828193
4    I-Cytokine114828193
,    O
transforming    B-Cytokine114828193
growth    I-Cytokine114828193
factor-β1    I-Cytokine114828193
,    O
platelet    O
-    O
derived    O
growth    O
factor    O
,    O
fibronectin    O
,    O
B    O
-    O
thromboglobulin    O
,    O
vWF    O
,    O
fibrinogen    O
,    O
and    O
coagulation    O
factors    O
V    O
and    O
XIII    O
.    O

CXCR3-A    O
binds    O
to    O
the    O
CXC    O
chemokines    O
CXCL9    B-Cytokine114828193
(    O
MIG    O
)    O
,    O
CXCL10    B-Cytokine114828193
(    O
IP-10    O
)    O
,    O
and    O
CXCL11    B-Cytokine114828193
(    O
I    O
-    O
TAC    O
)    O
whereas    O
CXCR3-B    O
can    O
also    O
bind    O
to    O
CXCL4    B-Cytokine114828193
in    O
addition    O
to    O
CXCL9    O
,    O
CXCL10    O
,    O
and    O
CXCL11    O
.    O

People    O
with    O
an    O
alcohol    O
use    O
disorder    O
also    O
show    O
an    O
increased    O
expression    O
of    O
proinflammatory    B-Cytokine114828193
cytokine    I-Cytokine114828193
and    O
microglia    O
protein    O
expression    O
.    O

One    O
factor    O
in    O
deployment    O
is    O
low    O
level    O
physiological    O
control    O
by    O
proinflammatory    B-Cytokine114828193
cytokine    I-Cytokine114828193
such    O
as    O
IL-1    O
triggered    O
by    O
bacterial    O
lipopolysaccharides    O
(    O
LPS    O
)    O
.    O

Activation    O
of    O
nuclear    O
factor    O
kappa    O
B    O
(    O
NFκB    O
)    O
signalling    O
leads    O
to    O
transcription    O
of    O
various    O
proinflammatory    B-Cytokine114828193
cytokines    I-Cytokine114828193
as    O
well    O
as    O
anti    O
-    O
apoptotic    O
genes    O
.    O

The    O
protein    O
encoded    O
by    O
this    O
gene    O
is    O
a    O
proinflammatory    B-Cytokine114828193
cytokine    I-Cytokine114828193
.    O

Recent    O
studies    O
show    O
pro-inflammatory    B-Cytokine114828193
cytokine    I-Cytokine114828193
processes    O
take    O
place    O
during    O
clinical    O
depression    O
,    O
mania    O
and    O
bipolar    O
disorder    O
,    O
and    O
it    O
is    O
possible    O
that    O
symptoms    O
of    O
these    O
conditions    O
are    O
attenuated    O
by    O
the    O
pharmacological    O
effect    O
of    O
antidepressants    O
on    O
the    O
immune    O
system    O
.    O

The    O
astrocytes    O
of    O
the    O
glia    O
limitans    O
are    O
believed    O
to    O
be    O
the    O
component    O
of    O
the    O
brain    O
that    O
secretes    O
the    O
pro-    B-Cytokine114828193
and    O
anti    O
-    O
inflammatory    O
factors    O
.    O

The    O
precise    O
mechanism    O
of    O
action    O
of    O
IVIG    O
in    O
patients    O
with    O
SCLS    O
is    O
unknown    O
,    O
but    O
it    O
is    O
likely    O
that    O
it    O
neutralizes    O
their    O
proinflammatory    B-Cytokine114828193
cytokines    I-Cytokine114828193
that    O
provoke    O
endothelial    O
dysfunction    O
.    O

There    O
are    O
six    O
treatment    O
options    O
approved    O
by    O
the    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
available    O
for    O
persons    O
with    O
a    O
chronic    O
hepatitis    O
B    O
infection    O
:    O
alpha-interferon    B-Cytokine114828193
,    O
pegylated    O
interferon    O
,    O
adefovir    O
,    O
entecavir    O
,    O
telbivudine    O
,    O
and    O
lamivudine    O
.    O

The    O
interferon-α/β    O
receptor    O
(    O
IFNAR    O
)    O
is    O
a    O
receptor    O
which    O
binds    O
type    B-Cytokine114828193
I    I-Cytokine114828193
interferons    I-Cytokine114828193
including    O
interferon-α    O
and    O
-β.    O
It    O
is    O
a    O
heteromeric    O
cell    O
surface    O
receptor    O
composed    O
of    O
one    O
chain    O
with    O
two    O
subunits    O
referred    O
to    O
as    O
IFNAR1    O
and    O
IFNAR2    O
.    O

Upon    O
binding    O
of    O
type    B-Cytokine114828193
I    I-Cytokine114828193
interferons    I-Cytokine114828193
,    O
IFNAR    O
activates    O
the    O
JAK    O
-    O
STAT    O
signalling    O
pathway    O
.    O

Support    O
for    O
a    O
role    O
of    O
AP-1    O
in    O
"    O
MIR155HG    O
"    O
activation    O
comes    O
from    O
studies    O
using    O
stimuli    O
relevant    O
to    O
viral    O
infection    O
such    O
as    O
TLR3    O
ligand    O
poly(I    O
:    O
C    O
)    O
or    O
interferon    B-Cytokine114828193
beta    I-Cytokine114828193
(    O
IFN-β    O
)    O
.    O

By    O
decreasing    O
the    O
levels    O
of    O
p300    O
,    O
the    O
expression    O
of    O
IFN-β    B-Cytokine114828193
,    O
ISG15    O
,    O
IL-1β    O
and    O
IL6    B-Cytokine114828193
is    O
impaired    O
,    O
resulting    O
in    O
the    O
net    O
suppression    O
of    O
antiviral    O
immunity    O
.    O

In    O
August    O
1990    O
Kenyan    O
researcher    O
Davy    O
Koech    O
,    O
director    O
of    O
the    O
Kenya    O
Medical    O
Research    O
Institute    O
,    O
announced    O
that    O
when    O
his    O
HIV    O
patients    O
chewed    O
wafers    O
laced    O
with    O
tiny    O
amounts    O
of    O
alpha    B-Cytokine114828193
interferon    I-Cytokine114828193
,    O
most    O
had    O
greatly    O
improved    O
health    O
and    O
some    O
cleared    O
HIV    O
from    O
their    O
blood    O
entirely    O
.    O

The    O
alpha    B-Cytokine114828193
interferon    I-Cytokine114828193
,    O
named    O
"    O
Kemron    O
"    O
for    O
this    O
use    O
,    O
was    O
a    O
drug    O
used    O
to    O
treat    O
cancer    O
in    O
much    O
greater    O
doses    O
.    O

Examples    O
of    O
drugs    O
commonly    O
associated    O
with    O
depressogenic    O
effects    O
include    O
some    O
anticonvulsants    O
such    O
as    O
the    O
barbiturates    O
(    O
e.g.    O
phenobarbital    O
)    O
,    O
benzodiazepines    O
(    O
e.g.    O
diazepam    O
)    O
,    O
vigabatrin    O
,    O
and    O
topiramate    O
,    O
corticosteroids    O
like    O
dexamethasone    O
and    O
prednisone    O
,    O
cytokines    O
like    O
interferon-α    B-Cytokine114828193
and    O
interleukin-2    B-Cytokine114828193
,    O
certain    O
antihypertensives    O
such    O
as    O
amiodarone    O
,    O
clonidine    O
,    O
methyldopa    O
,    O
reserpine    O
,    O
and    O
tetrabenazine    O
(    O
used    O
as    O
an    O
antipsychotic    O
/    O
antihyperkinetic    O
)    O
,    O
and    O
agents    O
with    O
antiandrogen    O
,    O
antiestrogen    O
,    O
and/or    O
anti    O
-    O
neurosteroid    O
activities    O
such    O
as    O
GnRH    O
agonists    O
(    O
e.g.    O
,    O
leuprolide    O
,    O
goserelin    O
)    O
,    O
anastrozole    O
(    O
an    O
aromatase    O
inhibitor    O
)    O
,    O
finasteride    O
(    O
a    O
5α-reductase    O
inhibitor    O
)    O
,    O
and    O
clomiphene    O
(    O
a    O
SERM    O
)    O
,    O
as    O
well    O
as    O
others    O
including    O
flunarizine    O
,    O
mefloquine    O
,    O
and    O
efavirenz    O
.    O

Examples    O
of    O
endogenous    O
compounds    O
that    O
have    O
been    O
implicated    O
in    O
stress    O
and    O
depression    O
include    O
corticotropin    O
-    O
releasing    O
hormone    O
(    O
CRH    O
)    O
,    O
cytokines    O
(    O
e.g.    O
,    O
interferon-α    B-Cytokine114828193
,    O
interleukin-2    B-Cytokine114828193
)    O
,    O
tachykinins    O
(    O
e.g.    O
,    O
substance    O
P    O
)    O
,    O
glucocorticoids    O
(    O
e.g.    O
,    O
cortisol    O
,    O
cortisone    O
)    O
,    O
and    O
dynorphin    O
.    O

EBOV    O
proteins    O
blunt    O
the    O
human    O
immune    O
system    O
's    O
response    O
to    O
viral    O
infections    O
by    O
interfering    O
with    O
the    O
cells    O
'    O
ability    O
to    O
produce    O
and    O
respond    O
to    O
interferon    O
proteins    O
such    O
as    O
interferon-alpha    B-Cytokine114828193
,    O
interferon-beta    B-Cytokine114828193
,    O
and    O
interferon    O
gamma    O
.    O

On    O
TLR    O
activation    O
,    O
proteins    O
including    O
interferon    O
regulatory    O
factor    O
3    O
and    O
interferon    O
regulatory    O
factor    O
7    O
trigger    O
a    O
signaling    O
cascade    O
that    O
leads    O
to    O
the    O
expression    O
of    O
type    B-Cytokine114828193
1    I-Cytokine114828193
interferon    I-Cytokine114828193
.    O

Interferon    B-Cytokine114828193
type    I-Cytokine114828193
I    I-Cytokine114828193
:    O
All    O
type    O
I    O
IFNs    O
bind    O
to    O
a    O
specific    O
cell    O
surface    O
receptor    O
complex    O
known    O
as    O
the    O
IFN-α/β    O
receptor    O
(    O
IFNAR    O
)    O
that    O
consists    O
of    O
IFNAR1    O
and    O
IFNAR2    O
chains    O
.    O

The    O
type    O
I    O
interferons    O
present    O
in    O
humans    O
are    O
IFN-α    B-Cytokine114828193
,    O
IFN-β    B-Cytokine114828193
,    O
IFN-ε    O
,    O
IFN-κ    O
and    O
IFN-ω.    O

According    O
to    O
recent    O
evidences    O
antidepressants    O
also    O
seem    O
to    O
exert    O
beneficial    O
effects    O
in    O
experimental    O
autoimmune    O
neuritis    O
in    O
rats    O
by    O
decreasing    O
Interferon-beta    B-Cytokine114828193
(    O
IFN    O
-    O
beta    O
)    O
release    O
or    O
augmenting    O
NK    O
activity    O
in    O
depressed    O
patients    O
.    O

Upon    O
viral    O
infection    O
,    O
FADD    O
is    O
needed    O
to    O
increase    O
the    O
levels    O
of    O
Irf7    O
a    O
molecule    O
which    O
is    O
needed    O
for    O
the    O
production    O
of    O
IFN-α    B-Cytokine114828193
IFN-α    O
is    O
a    O
key    O
molecule    O
involved    O
in    O
the    O
response    O
against    O
viruses    O
.    O

Folkman    O
's    O
team    O
later    O
tested    O
it    O
in    O
adults    O
with    O
hemangiomas    O
;    O
they    O
also    O
used    O
interferon    B-Cytokine114828193
alpha    I-Cytokine114828193
,    O
an    O
already    O
approved    O
drug    O
that    O
they    O
had    O
already    O
shown    O
to    O
be    O
an    O
angiogenesis    O
inhibitor    O
,    O
to    O
treat    O
infants    O
with    O
hemangiomas    O
in    O
some    O
of    O
the    O
first    O
clinical    O
trials    O
of    O
angiogenesis    O
inhibitors    O
which    O
were    O
published    O
in    O
1992    O
.    O

Naltrexone    O
is    O
effective    O
in    O
suppressing    O
the    O
cytokine    O
-    O
mediated    O
adverse    O
neuropsychiatric    O
effects    O
of    O
interferon    B-Cytokine114828193
alpha    I-Cytokine114828193
therapy    O
.    O

PEGylated    O
interferon    B-Cytokine114828193
alpha    I-Cytokine114828193
for    O
use    O
in    O
the    O
treatment    O
of    O
chronic    O
hepatitis    O
C    O
and    O
hepatitis    O
B    O
(    O
Hoffmann    O
-    O
La    O
Roche    O
,    O
2001    O
)    O

Chemokine    B-Cytokine114828193
(C-C    I-Cytokine114828193
motif)    I-Cytokine114828193
ligand    I-Cytokine114828193
24    I-Cytokine114828193
(    O
CCL24    O
)    O
also    O
known    O
as    O
myeloid    O
progenitor    O
inhibitory    O
factor    O
2    O
(    O
MPIF-2    O
)    O
or    O
eosinophil    O
chemotactic    O
protein    O
2    O
(    O
eotaxin-2    O
)    O
is    O
a    O
protein    O
that    O
in    O
humans    O
is    O
encoded    O
by    O
the    O
"    O
CCL24    O
"    O
gene    O
.    O

Following    O
a    O
reduction    O
in    O
pathogen    O
count    O
,    O
many    O
pathogen    O
-    O
specific    O
Tregs    O
are    O
present    O
that    O
,    O
now    O
without    O
a    O
TLR2    O
signal    O
,    O
become    O
active    O
and    O
inhibit    O
the    O
specific    O
and    O
inflammatory    O
immune    O
reactions    O
(    O
see    O
also    O
TNF-β    B-Cytokine114828193
,    O
IL-10    B-Cytokine114828193
)    O
.    O

Scientists    O
used    O
mice    O
to    O
study    O
the    O
effect    O
of    O
lymphotoxin    B-Cytokine114828193
on    O
metabolism    O
.    O

All    O
members    O
of    O
the    O
TNF    O
family    O
,    O
with    O
the    O
exception    O
of    O
the    O
secreted    O
lymphotoxin    B-Cytokine114828193
and    O
a    O
proliferation    O
-    O
inducing    O
ligand    O
(    O
APRIL    O
)    O
,    O
are    O
type    O
II    O
transmembrane    O
proteins    O
that    O
protrude    O
from    O
immune    O
cells    O
.    O

GDF-15    B-Cytokine114828193
has    O
been    O
observed    O
in    O
lamina    O
affixa    O
cells    O
.    O

Interferome    B-Cytokine114828193
is    O
an    O
online    O
bioinformatics    O
database    O
of    O
interferon    O
-    O
regulated    O
genes    O
(    O
IRGs    O
)    O
.    O

NCR3    B-Cytokine114828193

Ciliary    O
neurotrophic    O
factor    O
,    O
Leukemia    B-Cytokine114828193
inhibitory    I-Cytokine114828193
factor    I-Cytokine114828193
,    O
Insulin    O
-    O
like    O
growth    O
factor    O
,    O
and    O
Fibroblast    O
growth    O
factor    O
.    O

:*    O
LIF    B-Cytokine114828193
(    O
Leukemia    O
inhibitory    O
factor    O
)    O

Mouse    O
embryonic    O
stem    O
cells    O
(    O
mESCs    O
)    O
undergo    O
self    O
-    O
renewal    O
in    O
the    O
presence    O
of    O
the    O
cytokine    O
leukemia    B-Cytokine114828193
inhibitory    I-Cytokine114828193
factor    I-Cytokine114828193
(    O
LIF    O
)    O
.    O

Certain    O
cytokines    O
such    O
as    O
IL-3    B-Cytokine114828193
,    O
IL-6    B-Cytokine114828193
,    O
IL-11    B-Cytokine114828193
,    O
LIF    B-Cytokine114828193
,    O
erythropoietin    O
,    O
and    O
thrombopoietin    B-Cytokine114828193
all    O
stimulate    O
the    O
maturation    O
of    O
megakaryocytic    O
progenitor    O
cells    O
.    O

There    O
are    O
many    O
other    O
proteins    O
which    O
associate    O
with    O
gp130    O
,    O
such    O
as    O
cardiotrophin    O
1    O
(    O
CT-1    O
)    O
,    O
leukemia    B-Cytokine114828193
inhibitory    I-Cytokine114828193
factor    I-Cytokine114828193
(    O
LIF    O
)    O
,    O
ciliary    O
neurotrophic    O
factor    O
(    O
CNTF    O
)    O
,    O
oncostatin    B-Cytokine114828193
M    I-Cytokine114828193
(    O
OSM    O
)    O
,    O
and    O
IL-11    B-Cytokine114828193
.    O

:    O
L03AB12    O
Albinterferon    B-Cytokine114828193
alfa-2b    I-Cytokine114828193

Wong    O
and    O
Licinio    O
contributed    O
some    O
of    O
the    O
earliest    O
work    O
on    O
the    O
role    O
of    O
cytokines    O
and    O
immune    O
mediators    O
in    O
the    O
brain    O
,    O
with    O
implications    O
for    O
the    O
underlying    O
biology    O
of    O
major    O
depressive    O
disorder    O
,    O
and    O
published    O
scientific    O
articles    O
on    O
the    O
localisation    O
of    O
gene    O
expression    O
for    O
interleukin    B-Cytokine114828193
1    I-Cytokine114828193
receptor    I-Cytokine114828193
antagonist    I-Cytokine114828193
,    O
interleukin    O
1    O
receptor    O
,    O
type    O
I    O
(    O
IL1R1    O
)    O
,    O
also    O
known    O
as    O
CD121a    O
(    O
C    O
lustre    O
of    O
D    O
ifferentiation    O
121a    O
)    O
,    O
and    O
inducible    O
nitric    O
oxide    O
synthase    O
(    O
iNOS    O
)    O
in    O
mammalian    O
brain    O
.    O

They    O
also    O
showed    O
that    O
interleukin    B-Cytokine114828193
1    I-Cytokine114828193
receptor    I-Cytokine114828193
antagonist    I-Cytokine114828193
is    O
an    O
endogenous    O
neuroprotective    O
agent    O
.    O

Both    O
pro    O
-    O
inflammatory    O
cytokines    O
(    O
such    O
as    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
,    O
Interleukin-1    O
,    O
and    O
Interleukin-6    B-Cytokine114828193
)    O
and    O
anti    O
-    O
inflammatory    O
cytokines    O
(    O
such    O
as    O
interleukin    B-Cytokine114828193
10    I-Cytokine114828193
and    O
interleukin    B-Cytokine114828193
1    I-Cytokine114828193
receptor    I-Cytokine114828193
antagonist    I-Cytokine114828193
)    O
are    O
elevated    O
in    O
the    O
serum    O
of    O
patients    O
experiencing    O
a    O
cytokine    O
storm    O
.    O

Among    O
other    O
proteins    O
,    O
β    O
trefoil    O
fold    O
is    O
found    O
in    O
Kunitz    O
inhibitors    O
of    O
several    O
plants    O
such    O
as    O
soybean    O
,    O
"    O
Erythrina    O
caffra    O
"    O
and    O
wheat    O
;    O
in    O
members    O
of    O
the    O
interleukin    O
1    O
cytokine    O
family    O
(    O
interleukin-1    B-Cytokine114828193
alpha    I-Cytokine114828193
,    O
interleukin-1    O
beta    O
and    O
interleukin-1    B-Cytokine114828193
receptor    I-Cytokine114828193
antagonist    I-Cytokine114828193
)    O
;    O
and    O
in    O
fibroblast    O
growth    O
factors    O
1    O
and    O
2    O
.    O

NCR2    B-Cytokine114828193

Studies    O
suggest    O
that    O
this    O
impaired    O
fertilization    O
reflects    O
the    O
loss    O
of    O
EP2    O
functions    O
in    O
stimulating    O
cumulus    O
cells    O
clusters    O
which    O
surround    O
oocytes    O
to    O
:    O
a    O
)    O
form    O
the    O
CCL7    B-Cytokine114828193
chemokine    O
which    O
serves    O
as    O
a    O
chemoattractant    O
that    O
guides    O
sperm    O
cells    O
to    O
oocytes    O
and    O
b    O
)    O
disassemble    O
the    O
extracellular    O
matrix    O
which    O
in    O
turn    O
allows    O
sperm    O
cells    O
to    O
penetrate    O
to    O
the    O
oocyte    O
.    O

Several    O
CC    O
chemokines    O
:    O
CCL1    B-Cytokine114828193
,    O
CCL2    B-Cytokine114828193
,    O
CCL3    B-Cytokine114828193
,    O
CCL4    O
,    O
CCL5    B-Cytokine114828193
,    O
CCL7    B-Cytokine114828193
,    O
CCL8    B-Cytokine114828193
,    O
CCL11    B-Cytokine114828193
,    O
CCL13    B-Cytokine114828193
,    O
CCL14    B-Cytokine114828193
,    O
CCL15    B-Cytokine114828193
,    O
CCL16    B-Cytokine114828193
,    O
CCL18    B-Cytokine114828193
,    O
and    O
CCL23    B-Cytokine114828193

Several    O
CC    O
chemokines    O
:    O
CCL1    B-Cytokine114828193
,    O
CCL2    B-Cytokine114828193
,    O
CCL3    B-Cytokine114828193
,    O
CCL4    O
,    O
CCL5    B-Cytokine114828193
,    O
CCL7    B-Cytokine114828193
,    O
CCL8    B-Cytokine114828193
,    O
CCL11    B-Cytokine114828193
,    O
CCL13    B-Cytokine114828193
,    O
CCL14    B-Cytokine114828193
,    O
CCL15    B-Cytokine114828193
,    O
CCL16    B-Cytokine114828193
,    O
CCL18    B-Cytokine114828193
,    O
and    O
CCL23    B-Cytokine114828193

Fibronectin    B-Cytokine114828193
type    I-Cytokine114828193
III    I-Cytokine114828193
domain-containing    I-Cytokine114828193
protein    I-Cytokine114828193
5    I-Cytokine114828193
,    O
the    O
precursor    O
of    O
irisin    B-Cytokine114828193
,    O
is    O
a    O
protein    O
that    O
is    O
encoded    O
by    O
the    O
FNDC5    B-Cytokine114828193
gene    O
.    O

Signalling    O
molecules    O
released    O
by    O
adipose    O
tissue    O
are    O
referred    O
to    O
as    O
adipokine    B-Cytokine114828193
.    O

These    O
fatty    O
acids    O
can    O
be    O
released    O
by    O
adipokine    B-Cytokine114828193
signaling    O
of    O
high    O
glucagon    O
and    O
epinephrine    O
levels    O
,    O
which    O
inversely    O
corresponds    O
to    O
low    O
insulin    O
levels    O
.    O

Leptin    O
was    O
the    O
first    O
fat    O
cell    O
-    O
derived    O
hormone    O
(    O
adipokine    B-Cytokine114828193
)    O
to    O
be    O
discovered    O
.    O

CXCL17    B-Cytokine114828193

Leukocyte-promoting    B-Cytokine114828193
factor    I-Cytokine114828193

Furthermore    O
,    O
ELISA    O
assays    O
showed    O
elevated    O
levels    O
of    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
(    O
TNF    O
-    O
A    O
)    O
,    O
macrophage    B-Cytokine114828193
inflammatory    I-Cytokine114828193
protein-2    I-Cytokine114828193
(    O
MIP-2    O
)    O
,    O
and    O
interleukin    B-Cytokine114828193
6    I-Cytokine114828193
(    O
IL-6    O
)    O
.    O

NLRC4    O
is    O
best    O
associated    O
with    O
triggering    O
formation    O
of    O
the    O
inflammasome    B-Cytokine114828193
.    O

NALPs    O
are    O
implicated    O
in    O
the    O
activation    O
of    O
proinflammatory    O
caspases    O
(    O
e.g.    O
,    O
CASP1    O
)    O
via    O
their    O
involvement    O
in    O
multiprotein    O
complexes    O
called    O
inflammasome    B-Cytokine114828193
.    O

:    O
:*    O
Inflammasome    B-Cytokine114828193

Sulfonylureas    O
are    O
also    O
used    O
experimentally    O
to    O
inhibit    O
interleukin    O
1    O
beta    O
release    O
from    O
the    O
NALP3    O
(    O
or    O
NLRP3    O
)    O
inflammasome    B-Cytokine114828193
.    O

He    O
has    O
uncovered    O
new    O
molecules    O
and    O
biochemical    O
processes    O
that    O
are    O
triggered    O
by    O
sensors    O
of    O
infection    O
and    O
tissue    O
injury    O
,    O
including    O
the    O
toll    O
-    O
like    O
receptors    O
and    O
inflammasome    B-Cytokine114828193
,    O
and    O
the    O
signals    O
they    O
drive    O
that    O
stimulate    O
inflammation    O
,    O
notably    O
cytokines    O
in    O
the    O
interleukin-1    O
family    O
.    O

Calico    O
has    O
licensed    O
experimental    O
drug    O
compounds    O
P7C3    O
analogues    O
involved    O
in    O
enhancing    O
the    O
activity    O
of    O
the    O
enzyme    O
nicotinamide    B-Cytokine114828193
phosphoribosyltransferase    I-Cytokine114828193
,    O
which    O
plays    O
a    O
role    O
in    O
nicotinamide    O
adenine    O
dinucleotide    O
biosynthesis    O
.    O

ENA-78    O
-    O
CXCL5    B-Cytokine114828193

These    O
polarities    O
arise    O
within    O
the    O
developing    O
embryo    O
through    O
a    O
combination    O
of    O
several    O
processes    O
:    O
1    O
)    O
asymmetric    O
cell    O
division    O
,    O
in    O
which    O
two    O
daughter    O
cells    O
receive    O
different    O
amounts    O
of    O
cellular    O
material    O
(    O
e.g.    O
mRNA    O
,    O
proteins    O
)    O
,    O
2    O
)    O
asymmetric    O
localization    O
of    O
specific    O
proteins    O
or    O
RNAs    O
within    O
cells    O
(    O
which    O
is    O
often    O
mediated    O
by    O
the    O
cytoskeleton    O
)    O
,    O
3    O
)    O
concentration    O
gradients    O
of    O
secreted    O
proteins    O
across    O
the    O
embryo    O
such    O
as    O
Wnt    O
,    O
Nodal    O
,    O
and    O
Bone    B-Cytokine114828193
Morphogenic    I-Cytokine114828193
Proteins    I-Cytokine114828193
(    O
BMPs    O
)    O
,    O
and    O
4    O
)    O
differential    O
expression    O
of    O
membrane    O
receptors    O
and    O
ligands    O
that    O
cause    O
lateral    O
inhibition    O
,    O
in    O
which    O
the    O
receptor    O
-    O
expressing    O
cell    O
adopts    O
one    O
fate    O
and    O
its    O
neighbors    O
another    O
.    O

It    O
is    O
formed    O
by    O
the    O
secretion    O
of    O
BMP-4    B-Cytokine114828193
by    O
the    O
ectoderm    O
.    O

The    O
paraxial    O
and    O
other    O
regions    O
of    O
the    O
mesoderm    O
are    O
thought    O
to    O
be    O
specified    O
by    O
bone    B-Cytokine114828193
morphogenetic    I-Cytokine114828193
protein    I-Cytokine114828193
,    O
or    O
BMPs    O
,    O
along    O
an    O
axis    O
spanning    O
from    O
the    O
center    O
to    O
the    O
sides    O
of    O
the    O
body    O
.    O

It    O
binds    O
Bone    B-Cytokine114828193
morphogenetic    I-Cytokine114828193
proteins    I-Cytokine114828193
,    O
members    O
of    O
the    O
TGF    O
beta    O
superfamily    O
of    O
ligands    O
,    O
which    O
are    O
involved    O
in    O
paracrine    O
signalling    O
.    O

They    O
belong    O
to    O
a    O
class    O
of    O
receptor    O
serine    O
/    O
threonine    O
kinases    O
that    O
bind    O
members    O
of    O
the    O
TGF    O
beta    O
superfamily    O
of    O
ligands    O
-    O
the    O
Bone    B-Cytokine114828193
morphogenetic    I-Cytokine114828193
protein    I-Cytokine114828193
.    O

These    O
receptors    O
bind    O
members    O
of    O
the    O
TGFβ    O
superfamily    O
of    O
growth    O
factor    O
and    O
cytokine    O
signaling    O
proteins    O
such    O
as    O
TGFβ    B-Cytokine114828193
(    O
TGFβ1    B-Cytokine114828193
,    O
TGFβ2    O
,    O
TGFβ3    O
)    O
,    O
bone    B-Cytokine114828193
morphogenetic    I-Cytokine114828193
protein    I-Cytokine114828193
(    O
BMPs    O
)    O
,    O
growth    O
differentiation    O
factors    O
(    O
GDFs    O
)    O
,    O
activin    O
and    O
inhibin    O
,    O
myostatin    O
,    O
anti    O
-    O
Müllerian    O
hormone    O
(    O
AMH    O
)    O
,    O
and    O
nodal    O
.    O

A    O
toolkit    O
gene    O
can    O
be    O
expressed    O
in    O
a    O
different    O
pattern    O
,    O
as    O
when    O
the    O
beak    O
of    O
Darwin    O
's    O
large    O
ground    O
-    O
finch    O
was    O
enlarged    O
by    O
the    O
"    O
BMP    B-Cytokine114828193
"    O
gene    O
,    O
or    O
when    O
snakes    O
lost    O
their    O
legs    O
as    O
"    O
distal    O
-    O
less    O
"    O
became    O
under    O
-    O
expressed    O
or    O
not    O
expressed    O
at    O
all    O
in    O
the    O
places    O
where    O
other    O
reptiles    O
continued    O
to    O
form    O
their    O
limbs    O
.    O

Some    O
manufacturers    O
have    O
recently    O
begun    O
supplying    O
these    O
products    O
with    O
soluble    O
bone    O
-    O
forming    O
factors    O
such    O
as    O
bone    B-Cytokine114828193
morphogenetic    I-Cytokine114828193
protein    I-Cytokine114828193
to    O
attempt    O
to    O
create    O
a    O
synthetic    O
product    O
with    O
osteoinductive    O
properties    O
.    O

These    O
include    O
:    O
Activin    O
(    O
or    O
Inhibin    O
)    O
,    O
Bone    B-Cytokine114828193
morphogenetic    I-Cytokine114828193
proteins    I-Cytokine114828193
and    O
Nodal    O
.    O

Bone    B-Cytokine114828193
morphogenetic    I-Cytokine114828193
protein    I-Cytokine114828193

LEMD3    O
also    O
has    O
several    O
implications    O
in    O
regulating    O
the    O
cytokine    O
family    O
such    O
as    O
the    O
transforming    B-Cytokine114828193
growth    I-Cytokine114828193
factor    I-Cytokine114828193
beta    I-Cytokine114828193
(    O
TGF-β    O
)    O
and    O
bone    B-Cytokine114828193
morphogenic    I-Cytokine114828193
protein    I-Cytokine114828193
(    O
BMPs    O
)    O
.    O

Depending    O
on    O
the    O
tissue    O
type    O
,    O
cells    O
that    O
bind    O
to    O
this    O
bioscaffold    O
will    O
have    O
significant    O
,    O
measurable    O
increases    O
in    O
select    O
tissue    O
repair    O
factors    O
,    O
including    O
aggrecan    O
,    O
connective    O
tissue    O
growth    O
factor    O
(    O
CTGF    O
)    O
,    O
transforming    O
growth    O
factors    O
(    O
TGF-β1    O
and    O
TBF-β3    O
)    O
,    O
bone    B-Cytokine114828193
morphogenic    I-Cytokine114828193
protein    I-Cytokine114828193
(    O
BMP-2    O
)    O
and    O
other    O
repair    O
factors    O
.    O

Extrinsic    O
signals    O
involved    O
are    O
BMP    B-Cytokine114828193
,    O
Wnt    O
,    O
and    O
FGF    O
and    O
intrinsic    O
transcription    O
factors    O
like    O
SoxB1    O
related    O
genes    O
.    O

These    O
cells    O
migrate    O
from    O
their    O
initial    O
position    O
and    O
aggregate    O
in    O
the    O
vicinity    O
of    O
the    O
dorsal    O
aorta    O
,    O
a    O
primitive    O
blood    O
vessel    O
,    O
which    O
activates    O
the    O
differentiation    O
of    O
these    O
cells    O
through    O
the    O
release    O
of    O
proteins    O
known    O
as    O
BMP    B-Cytokine114828193
.    O

Gastric    O
organoids    O
have    O
been    O
generated    O
directly    O
from    O
pluripotent    O
stem    O
cells    O
through    O
the    O
temporal    O
manipulation    O
of    O
the    O
FGF    O
,    O
WNT    O
,    O
BMP    B-Cytokine114828193
,    O
retinoic    O
acid    O
and    O
EGF    O
signalling    O
pathways    O
in    O
three    O
-    O
dimensional    O
culture    O
conditions    O
.    O

However    O
,    O
nanodiamonds    O
bind    O
to    O
both    O
bone    B-Cytokine114828193
morphogenetic    I-Cytokine114828193
protein    I-Cytokine114828193
and    O
fibroblast    O
growth    O
factor    O
,    O
both    O
of    O
which    O
encourage    O
bone    O
and    O
cartilage    O
to    O
rebuild    O
and    O
can    O
be    O
delivered    O
orally    O
.    O

The    O
most    O
widely    O
studied    O
type    O
of    O
osteoinductive    O
cell    O
mediators    O
are    O
bone    B-Cytokine114828193
morphogenetic    I-Cytokine114828193
protein    I-Cytokine114828193
(    O
BMPs    O
)    O
.    O

They    O
consist    O
of    O
either    O
Human    O
Growth    O
Factors    O
or    O
Morphogens    O
(    O
Bone    B-Cytokine114828193
Morphogenic    I-Cytokine114828193
Proteins    I-Cytokine114828193
in    O
conjunction    O
with    O
a    O
carrier    O
medium    O
,    O
such    O
as    O
collagen    O
)    O
.    O

mifamurtide    B-Cytokine114828193
(    O
USAN    O
)    O

CCL4    O
,    O
also    O
known    O
as    O
Macrophage    B-Cytokine114828193
inflammatory    I-Cytokine114828193
protein    I-Cytokine114828193
(    O
MIP-1β    O
)    O
is    O
a    O
CC    O
chemokine    O
with    O
specificity    O
for    O
CCR5    O
receptors    O
.    O

Macrophage    B-Cytokine114828193
inflammatory    I-Cytokine114828193
protein    I-Cytokine114828193

Together    O
with    O
Interleukin-2    B-Cytokine114828193
(    O
IL-2    B-Cytokine114828193
)    O
,    O
Interleukin-4    B-Cytokine114828193
(    O
IL-4    B-Cytokine114828193
)    O
,    O
Interleukin-7    B-Cytokine114828193
(    O
IL-7    B-Cytokine114828193
)    O
,    O
Interleukin-9    B-Cytokine114828193
(    O
IL-9    B-Cytokine114828193
)    O
,    O
granulocyte    B-Cytokine114828193
colony-stimulating    I-Cytokine114828193
factor    I-Cytokine114828193
(    O
G-CSF    B-Cytokine114828193
)    O
,    O
and    O
granulocyte    O
-    O
macrophage    O
colony    O
-    O
stimulating    O
factor    O
(    O
GM    O
-    O
CSF    O
)    O
,    O
IL-15    O
belongs    O
to    O
the    O
four    O
α-helix    O
bundle    O
family    O
of    O
cytokine    O
.    O

The    O
gene    O
IL2RG    O
codes    O
for    O
the    O
common    O
gamma    O
chain    O
protein    O
,    O
which    O
is    O
a    O
common    O
subunit    O
of    O
the    O
individual    O
receptors    O
for    O
Interleukin    B-Cytokine114828193
2    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
7    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
9    I-Cytokine114828193
,    O
Interleukin    O
15    O
and    O
Interleukin    B-Cytokine114828193
21    I-Cytokine114828193
.    O

The    O
most    O
important    O
receptors    O
for    O
X    O
-    O
SCID    O
are    O
those    O
for    O
Interleukin    B-Cytokine114828193
2    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
7    I-Cytokine114828193
,    O
and    O
Interleukin    O
15    O
.    O

Specifically    O
,    O
Interleukin    B-Cytokine114828193
2    I-Cytokine114828193
and    O
Interleukin    B-Cytokine114828193
7    I-Cytokine114828193
are    O
responsible    O
for    O
T    O
-    O
cell    O
proliferation    O
and    O
survival    O
.    O

Several    O
CC    O
chemokines    O
:    O
CCL1    B-Cytokine114828193
,    O
CCL2    B-Cytokine114828193
,    O
CCL3    B-Cytokine114828193
,    O
CCL4    O
,    O
CCL5    B-Cytokine114828193
,    O
CCL7    B-Cytokine114828193
,    O
CCL8    B-Cytokine114828193
,    O
CCL11    B-Cytokine114828193
,    O
CCL13    B-Cytokine114828193
,    O
CCL14    B-Cytokine114828193
,    O
CCL15    B-Cytokine114828193
,    O
CCL16    B-Cytokine114828193
,    O
CCL18    B-Cytokine114828193
,    O
and    O
CCL23    B-Cytokine114828193

Finally    O
,    O
it    O
was    O
established    O
that    O
regulatory    O
T    O
-    O
cell    O
(    O
Tregs    O
)    O
development    O
required    O
miR-155    O
-    O
5p    O
and    O
this    O
miRNA    O
was    O
shown    O
to    O
play    O
a    O
role    O
in    O
Treg    O
homeostasis    O
and    O
overall    O
survival    O
by    O
directly    O
targeting    O
SOCS1    O
,    O
a    O
negative    O
regulator    O
for    O
IL-2    B-Cytokine114828193
signaling    O
.    O

Through    O
randomized    O
trials    O
,    O
it    O
has    O
been    O
found    O
that    O
treatment    O
with    O
ch14.18    O
is    O
most    O
effective    O
when    O
combined    O
with    O
cytokines    O
,    O
such    O
as    O
granulocyte    O
macrophage    O
colony    O
-    O
stimulating    O
factor    O
(    O
GM    O
-    O
CSF    O
)    O
and    O
interleukin-2    B-Cytokine114828193
(    O
IL-2    O
)    O
.    O

According    O
to    O
a    O
2012    O
article    O
in    O
Cancer    O
Management    O
and    O
Research    O
,    O
a    O
well    O
timed    O
treatment    O
and    O
the    O
use    O
of    O
agent    O
Interleukin    B-Cytokine114828193
2    I-Cytokine114828193
could    O
force    O
the    O
immune    O
system    O
into    O
overdrive    O
,    O
expanding    O
and    O
maximising    O
the    O
period    O
of    O
T    O
-    O
effector    O
cell    O
activity    O
.    O

Examples    O
of    O
drugs    O
commonly    O
associated    O
with    O
depressogenic    O
effects    O
include    O
some    O
anticonvulsants    O
such    O
as    O
the    O
barbiturates    O
(    O
e.g.    O
phenobarbital    O
)    O
,    O
benzodiazepines    O
(    O
e.g.    O
diazepam    O
)    O
,    O
vigabatrin    O
,    O
and    O
topiramate    O
,    O
corticosteroids    O
like    O
dexamethasone    O
and    O
prednisone    O
,    O
cytokines    O
like    O
interferon-α    B-Cytokine114828193
and    O
interleukin-2    B-Cytokine114828193
,    O
certain    O
antihypertensives    O
such    O
as    O
amiodarone    O
,    O
clonidine    O
,    O
methyldopa    O
,    O
reserpine    O
,    O
and    O
tetrabenazine    O
(    O
used    O
as    O
an    O
antipsychotic    O
/    O
antihyperkinetic    O
)    O
,    O
and    O
agents    O
with    O
antiandrogen    O
,    O
antiestrogen    O
,    O
and/or    O
anti    O
-    O
neurosteroid    O
activities    O
such    O
as    O
GnRH    O
agonists    O
(    O
e.g.    O
,    O
leuprolide    O
,    O
goserelin    O
)    O
,    O
anastrozole    O
(    O
an    O
aromatase    O
inhibitor    O
)    O
,    O
finasteride    O
(    O
a    O
5α-reductase    O
inhibitor    O
)    O
,    O
and    O
clomiphene    O
(    O
a    O
SERM    O
)    O
,    O
as    O
well    O
as    O
others    O
including    O
flunarizine    O
,    O
mefloquine    O
,    O
and    O
efavirenz    O
.    O

Examples    O
of    O
endogenous    O
compounds    O
that    O
have    O
been    O
implicated    O
in    O
stress    O
and    O
depression    O
include    O
corticotropin    O
-    O
releasing    O
hormone    O
(    O
CRH    O
)    O
,    O
cytokines    O
(    O
e.g.    O
,    O
interferon-α    B-Cytokine114828193
,    O
interleukin-2    B-Cytokine114828193
)    O
,    O
tachykinins    O
(    O
e.g.    O
,    O
substance    O
P    O
)    O
,    O
glucocorticoids    O
(    O
e.g.    O
,    O
cortisol    O
,    O
cortisone    O
)    O
,    O
and    O
dynorphin    O
.    O

Other    O
cytokines    O
,    O
such    O
as    O
interleukin    O
1    O
,    O
interleukin    B-Cytokine114828193
2    I-Cytokine114828193
,    O
interleukin-12    B-Cytokine114828193
,    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor    I-Cytokine114828193
and    O
colony-stimulating    B-Cytokine114828193
factor    I-Cytokine114828193
,    O
can    O
also    O
enhance    O
interferon    O
production    O
.    O

Molecules    O
called    O
pro    O
-    O
inflammatory    O
cytokines    O
,    O
which    O
include    O
interleukin-1    O
(    O
IL-1    O
)    O
,    O
Interleukin-2    B-Cytokine114828193
(    O
IL-2    O
)    O
,    O
interleukin-6    B-Cytokine114828193
(    O
IL-6    O
)    O
,    O
Interleukin-12    B-Cytokine114828193
(    O
IL-12    O
)    O
,    O
Interferon    O
-    O
gamma    O
(    O
IFN    O
-    O
Gamma    O
)    O
and    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor    I-Cytokine114828193
alpha    I-Cytokine114828193
(    O
TNF    O
-    O
alpha    O
)    O
can    O
affect    O
brain    O
growth    O
as    O
well    O
as    O
neuronal    O
function    O
.    O
Circulating    O
immune    O
cells    O
such    O
as    O
macrophages    O
,    O
as    O
well    O
as    O
glial    O
cells    O
(    O
microglia    O
and    O
astrocytes    O
)    O
secrete    O
these    O
molecules    O
.    O

It    O
has    O
also    O
been    O
found    O
to    O
activate    O
T    O
cell    O
proliferation    O
and    O
release    O
of    O
IL-2    B-Cytokine114828193
.    O

Together    O
with    O
Interleukin-2    B-Cytokine114828193
(    O
IL-2    B-Cytokine114828193
)    O
,    O
Interleukin-4    B-Cytokine114828193
(    O
IL-4    B-Cytokine114828193
)    O
,    O
Interleukin-7    B-Cytokine114828193
(    O
IL-7    B-Cytokine114828193
)    O
,    O
Interleukin-9    B-Cytokine114828193
(    O
IL-9    B-Cytokine114828193
)    O
,    O
granulocyte    B-Cytokine114828193
colony-stimulating    I-Cytokine114828193
factor    I-Cytokine114828193
(    O
G-CSF    B-Cytokine114828193
)    O
,    O
and    O
granulocyte    O
-    O
macrophage    O
colony    O
-    O
stimulating    O
factor    O
(    O
GM    O
-    O
CSF    O
)    O
,    O
IL-15    O
belongs    O
to    O
the    O
four    O
α-helix    O
bundle    O
family    O
of    O
cytokine    O
.    O

Due    O
to    O
sharing    O
of    O
receptor    O
subunits    O
between    O
IL-2    B-Cytokine114828193
and    O
IL-15    O
,    O
both    O
of    O
these    O
cytokines    O
have    O
similar    O
downstream    O
effects    O
including    O
the    O
induction    O
of    O
B    O
-    O
cell    O
lymphoma    O
(    O
Bcl-2    O
)    O
,    O
MAP    O
(    O
mitogen    O
-    O
activated    O
protein    O
kinase    O
)    O
kinase    O
pathway    O
and    O
the    O
phosphorylation    O
of    O
Lck    O
(    O
lymphocyte    O
-    O
activated    O
protein    O
tyrosine    O
kinase    O
)    O
and    O
Syk    O
(    O
spleen    O
tyrosine    O
kinase    O
)    O
kinases    O
,    O
which    O
leads    O
to    O
cell    O
proliferation    O
and    O
maturation    O
(    O
Figure    O
5    O
)    O
.    O

Some    O
subunits    O
of    O
the    O
IL-15    O
receptor    O
are    O
shared    O
in    O
common    O
with    O
the    O
receptor    O
for    O
a    O
structurally    O
related    O
cytokine    O
called    O
Interleukin    B-Cytokine114828193
2    I-Cytokine114828193
(    O
IL-2    O
)    O
allowing    O
both    O
cytokines    O
to    O
compete    O
for    O
and    O
negatively    O
regulate    O
each    O
other    O
's    O
activity    O
.    O

Expression    O
of    O
this    O
protein    O
is    O
increased    O
after    O
the    O
activation    O
of    O
T    O
-    O
cells    O
by    O
mitogens    O
or    O
the    O
activation    O
of    O
NK    O
cells    O
by    O
IL-2    B-Cytokine114828193
.    O

Signal    O
3    O
is    O
the    O
APC    O
secretion    O
of    O
stimulatory    O
cytokines    O
such    O
as    O
IL-2    B-Cytokine114828193
which    O
enhances    O
T    O
cell    O
stimulation    O
,    O
though    O
this    O
is    O
not    O
required    O
for    O
T    O
cell    O
activation    O
.    O

It    O
inhibits    O
activation    O
of    O
T    O
cells    O
and    O
B    O
cells    O
by    O
reducing    O
the    O
production    O
of    O
interleukin-2    B-Cytokine114828193
(    O
IL-2    O
)    O
.    O

Basiliximab    O
(    O
trade    O
name    O
Simulect    O
)    O
is    O
a    O
chimeric    O
mouse    O
-    O
human    O
monoclonal    O
antibody    O
to    O
the    O
α    O
chain    O
(    O
CD25    O
)    O
of    O
the    O
IL-2    B-Cytokine114828193
receptor    O
of    O
T    O
cells    O
.    O

Daclizumab    O
was    O
created    O
by    O
scientists    O
at    O
PDL    O
BioPharma    O
(    O
called    O
"    O
Protein    O
Design    O
Labs    O
"    O
at    O
that    O
time    O
)    O
by    O
humanizing    O
the    O
mouse    O
mAb    O
called    O
anti    O
-    O
Tac    O
,    O
which    O
targets    O
CD25    O
,    O
the    O
IL-2    O
receptor    O
α    O
chain    O
;    O
it    O
blocks    O
the    O
interaction    O
of    O
IL-2    B-Cytokine114828193
with    O
the    O
IL-2    O
receptor    O
and    O
prevents    O
activation    O
of    O
T    O
cells    O
.    O

Glucocorticoids    O
suppress    O
cell    O
-    O
mediated    O
immunity    O
by    O
inhibiting    O
genes    O
that    O
code    O
for    O
the    O
cytokines    O
IL-1    O
,    O
IL-2    B-Cytokine114828193
,    O
IL-3    B-Cytokine114828193
,    O
IL-4    B-Cytokine114828193
,    O
IL-5    O
,    O
IL-6    B-Cytokine114828193
,    O
IL-8    B-Cytokine114828193
and    O
IFN-γ    O
,    O
the    O
most    O
important    O
of    O
which    O
is    O
IL-2    O
.    O

Whereas    O
in    O
the    O
show    O
she    O
was    O
offered    O
the    O
drug    O
interleukin-2    B-Cytokine114828193
,    O
in    O
reality    O
the    O
drug    O
is    O
never    O
recommended    O
to    O
patients    O
when    O
melanoma    O
has    O
spread    O
to    O
the    O
brain    O
,    O
as    O
it    O
can    O
cause    O
bleeding    O
and    O
strokes    O
.    O

The    O
cyclosporin    O
-    O
cyclophilin    O
A    O
complex    O
inhibits    O
a    O
calcium    O
/    O
calmodulin    O
-    O
dependent    O
phosphatase    O
,    O
calcineurin    O
,    O
the    O
inhibition    O
of    O
which    O
is    O
thought    O
to    O
suppress    O
organ    O
rejection    O
by    O
halting    O
the    O
production    O
of    O
the    O
pro    O
-    O
inflammatory    O
molecules    O
TNF    B-Cytokine114828193
alpha    I-Cytokine114828193
and    O
interleukin    B-Cytokine114828193
2    I-Cytokine114828193
.    O

He    O
succeeded    O
in    O
cDNA    O
clonings    O
of    O
IL-4    B-Cytokine114828193
and    O
IL-5    O
cytokines    O
involved    O
in    O
class    O
switching    O
and    O
IL-2    B-Cytokine114828193
receptor    O
alpha    O
chain    O
in    O
1986    O
,    O
and    O
went    O
on    O
further    O
to    O
discover    O
AID    O
in    O
2000    O
,    O
demonstrating    O
its    O
importance    O
in    O
class    O
switch    O
recombination    O
and    O
somatic    O
hypermutation    O
.    O

The    O
levels    O
of    O
inflammatory    O
cytokines    O
(    O
e.g.    O
,    O
IL-1β    O
,    O
IL-2    B-Cytokine114828193
,    O
IL-6    B-Cytokine114828193
,    O
and    O
TNF-α    B-Cytokine114828193
)    O
in    O
blood    O
plasma    O
are    O
affected    O
by    O
zinc    O
deficiency    O
and    O
zinc    O
supplementation    O
produces    O
a    O
dose    O
-    O
dependent    O
response    O
in    O
the    O
level    O
of    O
these    O
cytokines    O
.    O

The    O
gene    O
IL2RG    O
codes    O
for    O
the    O
common    O
gamma    O
chain    O
protein    O
,    O
which    O
is    O
a    O
common    O
subunit    O
of    O
the    O
individual    O
receptors    O
for    O
Interleukin    B-Cytokine114828193
2    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
7    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
9    I-Cytokine114828193
,    O
Interleukin    O
15    O
and    O
Interleukin    B-Cytokine114828193
21    I-Cytokine114828193
.    O

The    O
most    O
important    O
receptors    O
for    O
X    O
-    O
SCID    O
are    O
those    O
for    O
Interleukin    B-Cytokine114828193
2    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
Interleukin    B-Cytokine114828193
7    I-Cytokine114828193
,    O
and    O
Interleukin    O
15    O
.    O

Specifically    O
,    O
Interleukin    B-Cytokine114828193
2    I-Cytokine114828193
and    O
Interleukin    B-Cytokine114828193
7    I-Cytokine114828193
are    O
responsible    O
for    O
T    O
-    O
cell    O
proliferation    O
and    O
survival    O
.    O

He    O
is    O
acredited    O
with    O
developing    O
the    O
use    O
of    O
IL-2    B-Cytokine114828193
and    O
immune    O
cells    O
for    O
the    O
treatment    O
of    O
patients    O
with    O
melanoma    O
in    O
a    O
procedure    O
termed    O
adoptive    O
cell    O
transfer    O
.    O

The    O
IL-5    O
gene    O
is    O
located    O
on    O
chromosome    O
11    O
in    O
the    O
mouse    O
,    O
and    O
chromosome    O
5    O
in    O
humans    O
,    O
in    O
close    O
proximity    O
to    O
the    O
genes    O
encoding    O
IL-3    B-Cytokine114828193
,    O
IL-4    B-Cytokine114828193
,    O
and    O
granulocyte    O
-    O
macrophage    O
colony    O
-    O
stimulating    O
factor    O
(    O
GM    O
-    O
CSF    O
)    O
,    O
which    O
are    O
often    O
co    O
-    O
expressed    O
in    O
TH2    O
cells    O
.    O

The    O
α    O
subunit    O
is    O
specific    O
for    O
the    O
IL-5    O
molecule    O
,    O
whereas    O
the    O
βc    O
subunit    O
also    O
recognised    O
by    O
interleukin    B-Cytokine114828193
3    I-Cytokine114828193
(    O
IL3    O
)    O
and    O
granulocyte    O
-    O
macrophage    O
colony    O
-    O
stimulating    O
factor    O
(    O
GM    O
-    O
CSF    O
)    O
.    O

Activated    O
mast    O
cells    O
also    O
synthesize    O
and    O
secrete    O
lipid    O
-    O
derived    O
mediators    O
(    O
such    O
as    O
prostaglandins    O
,    O
leukotrienes    O
,    O
and    O
platelet    O
-    O
activating    O
factor    O
)    O
and    O
cytokines    O
(    O
such    O
as    O
interleukin    O
1    O
,    O
interleukin    B-Cytokine114828193
3    I-Cytokine114828193
,    O
interleukin    B-Cytokine114828193
4    I-Cytokine114828193
,    O
interleukin    O
5    O
,    O
interleukin    B-Cytokine114828193
6    I-Cytokine114828193
,    O
interleukin    B-Cytokine114828193
13    I-Cytokine114828193
,    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
,    O
GM    O
-    O
CSF    O
,    O
and    O
several    O
chemokine    B-Cytokine114828193
.    O

Erythropoietin    O
is    O
the    O
primary    O
erythropoietic    O
factor    O
that    O
cooperates    O
with    O
various    O
other    O
growth    O
factors    O
(    O
e.g.    O
,    O
IL-3    B-Cytokine114828193
,    O
IL-6    B-Cytokine114828193
,    O
glucocorticoids    O
,    O
and    O
SCF    O
)    O
involved    O
in    O
the    O
development    O
of    O
erythroid    O
lineage    O
from    O
multipotent    O
progenitors    O
.    O

Interleukin    B-Cytokine114828193
3    I-Cytokine114828193
(    O
IL-3    B-Cytokine114828193
)    O
is    O
a    O
protein    O
that    O
in    O
humans    O
is    O
encoded    O
by    O
the    O
"    O
IL3    O
"    O
gene    O
.    O

Glucocorticoids    O
suppress    O
cell    O
-    O
mediated    O
immunity    O
by    O
inhibiting    O
genes    O
that    O
code    O
for    O
the    O
cytokines    O
IL-1    O
,    O
IL-2    B-Cytokine114828193
,    O
IL-3    B-Cytokine114828193
,    O
IL-4    B-Cytokine114828193
,    O
IL-5    O
,    O
IL-6    B-Cytokine114828193
,    O
IL-8    B-Cytokine114828193
and    O
IFN-γ    O
,    O
the    O
most    O
important    O
of    O
which    O
is    O
IL-2    O
.    O

Several    O
CC    O
chemokines    O
:    O
CCL1    B-Cytokine114828193
,    O
CCL2    B-Cytokine114828193
,    O
CCL3    B-Cytokine114828193
,    O
CCL4    O
,    O
CCL5    B-Cytokine114828193
,    O
CCL7    B-Cytokine114828193
,    O
CCL8    B-Cytokine114828193
,    O
CCL11    B-Cytokine114828193
,    O
CCL13    B-Cytokine114828193
,    O
CCL14    B-Cytokine114828193
,    O
CCL15    B-Cytokine114828193
,    O
CCL16    B-Cytokine114828193
,    O
CCL18    B-Cytokine114828193
,    O
and    O
CCL23    B-Cytokine114828193

As    O
secretory    O
cells    O
,    O
monocytes    O
and    O
macrophages    O
are    O
vital    O
to    O
the    O
regulation    O
of    O
immune    O
responses    O
and    O
the    O
development    O
of    O
inflammation    O
;    O
they    O
produce    O
a    O
wide    O
array    O
of    O
powerful    O
chemical    O
substances    O
(    O
monokine    B-Cytokine114828193
)    O
including    O
enzymes    O
,    O
complement    O
proteins    O
,    O
and    O
regulatory    O
factors    O
such    O
as    O
interleukin-1    O
.    O

IL-10    B-Cytokine114828193

BCRF1    O
(    O
IL-10    B-Cytokine114828193
)    O

CFS    O
patients    O
have    O
an    O
abnormal    O
response    O
to    O
exercise    O
,    O
including    O
increased    O
production    O
of    O
complement    O
products    O
,    O
increased    O
oxidative    O
stress    O
combined    O
with    O
decreased    O
antioxidant    O
response    O
,    O
and    O
increased    O
Interleukin    B-Cytokine114828193
10    I-Cytokine114828193
,    O
and    O
TLR4    O
,    O
some    O
of    O
which    O
correlates    O
with    O
symptom    O
severity    O
.    O

Keratinocytes    O
also    O
modulate    O
the    O
immune    O
system    O
:    O
apart    O
from    O
the    O
above    O
-    O
mentioned    O
antimicrobial    O
peptides    O
and    O
chemokines    B-Cytokine114828193
they    O
are    O
also    O
potent    O
producers    O
of    O
anti    O
-    O
inflammatory    O
mediators    O
such    O
as    O
IL-10    B-Cytokine114828193
and    O
TGF-β    B-Cytokine114828193
When    O
activated    O
,    O
they    O
can    O
stimulate    O
cutaneous    O
inflammation    O
and    O
Langerhans    O
cell    O
activation    O
via    O
TNFα    B-Cytokine114828193
and    O
IL-1β    O
secretion    O
.    O

There    O
are    O
two    O
major    O
mechanisms    O
of    O
immune    O
evasion    O
such    O
as    O
induction    O
of    O
immune    O
suppressive    O
IL-10    B-Cytokine114828193
responses    O
and    O
the    O
generation    O
of    O
poor    O
and    O
functionally    O
impaired    O
CD8(+    O
)    O
T    O
-    O
cell    O
responses    O
.    O

Meta    O
analysis    O
on    O
cytokine    O
levels    O
in    O
depressed    O
patients    O
have    O
demonstrated    O
increased    O
levels    O
of    O
IL-1    O
,    O
IL-6    B-Cytokine114828193
,    O
C    O
-    O
reactive    O
protein    O
,    O
but    O
not    O
IL-10    B-Cytokine114828193
in    O
depressed    O
patients    O
.    O

Lymphotoxin-alpha    B-Cytokine114828193
,    O
formerly    O
known    O
as    O
Tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-beta    I-Cytokine114828193
(    O
TNF-β    O
)    O
,    O
is    O
a    O
cytokine    O
that    O
is    O
inhibited    O
by    O
interleukin    B-Cytokine114828193
10    I-Cytokine114828193
.    O

Unsuccessful    O
protein    O
folding    O
can    O
be    O
caused    O
by    O
HLA    O
-    O
B27    O
,    O
disturbing    O
balance    O
of    O
important    O
(    O
IL-10    B-Cytokine114828193
and    O
TNF    O
)    O
signaling    O
proteins    O
.    O

One    O
hypothesis    O
is    O
that    O
psoriasis    O
involves    O
a    O
defect    O
in    O
regulatory    O
T    O
cells    O
,    O
and    O
in    O
the    O
regulatory    O
cytokine    O
interleukin-10    B-Cytokine114828193
.    O

Both    O
pro    O
-    O
inflammatory    O
cytokines    O
(    O
such    O
as    O
tumor    B-Cytokine114828193
necrosis    I-Cytokine114828193
factor-alpha    I-Cytokine114828193
,    O
Interleukin-1    O
,    O
and    O
Interleukin-6    B-Cytokine114828193
)    O
and    O
anti    O
-    O
inflammatory    O
cytokines    O
(    O
such    O
as    O
interleukin    B-Cytokine114828193
10    I-Cytokine114828193
and    O
interleukin    B-Cytokine114828193
1    I-Cytokine114828193
receptor    I-Cytokine114828193
antagonist    I-Cytokine114828193
)    O
are    O
elevated    O
in    O
the    O
serum    O
of    O
patients    O
experiencing    O
a    O
cytokine    O
storm    O
.    O

SSRIs    O
,    O
SNRIs    O
and    O
tricyclic    O
antidepressants    O
acting    O
on    O
serotonin    O
,    O
norepinephrine    O
and    O
dopamine    O
receptors    O
have    O
been    O
shown    O
to    O
be    O
immunomodulatory    O
and    O
anti    O
-    O
inflammatory    O
against    O
pro    O
-    O
inflammatory    O
cytokine    O
processes    O
,    O
specifically    O
on    O
the    O
regulation    O
of    O
Interferon    O
-    O
gamma    O
(    O
IFN    O
-    O
gamma    O
)    O
and    O
Interleukin-10    B-Cytokine114828193
(    O
IL-10    O
)    O
,    O
as    O
well    O
as    O
TNF-alpha    B-Cytokine114828193
and    O
Interleukin-6    B-Cytokine114828193
(    O
IL-6    O
)    O
.    O

Production    O
of    O
an    O
interleukin-10    B-Cytokine114828193
,    O
an    O
endogenous    O
,    O
pro    O
-    O
regulatory    O
cytokine    O
,    O
has    O
also    O
been    O
implicated    O
.    O

These    O
cells    O
produce    O
large    O
amounts    O
of    O
TGF    B-Cytokine114828193
beta    I-Cytokine114828193
and    O
other    O
suppressive    O
cytokines    O
,    O
including    O
IL-10    B-Cytokine114828193
,    O
to    O
prevent    O
damage    O
to    O
the    O
eye    O
by    O
reducing    O
inflammation    O
and    O
causing    O
T    O
cells    O
to    O
differentiate    O
to    O
inducible    O
T    O
reg    O
cells    O
.    O
Innate    O
immune    O
stimulation    O
by    O
bacteria    O
and    O
cellular    O
stress    O
is    O
normally    O
suppressed    O
by    O
myeloid    O
suppression    O
while    O
inducible    O
Treg    O
cells    O
prevent    O
activation    O
and    O
clonal    O
expansion    O
of    O
the    O
autoreactive    O
Th1    O
and    O
Th17    O
cells    O
that    O
possess    O
potential    O
to    O
cause    O
damage    O
to    O
the    O
eye    O
.    O

Type    O
II    O
cytokine    O
receptors    O
include    O
those    O
that    O
bind    O
type    O
I    O
and    O
type    O
II    O
interferons    O
,    O
and    O
those    O
that    O
bind    O
members    O
of    O
the    O
interleukin-10    B-Cytokine114828193
family    O
(    O
interleukin-10    O
,    O
interleukin-20    O
and    O
interleukin-22    O
)    O
.    O

Using    O
this    O
model    O
Powrie    O
further    O
identified    O
the    O
pathogenic    O
role    O
played    O
by    O
IFN-γ    O
and    O
TNF-α    B-Cytokine114828193
in    O
intestinal    O
inflammation    O
and    O
the    O
therapeutic    O
potential    O
of    O
IL-10    B-Cytokine114828193
and    O
highlighted    O
the    O
requirement    O
for    O
TGF-β    B-Cytokine114828193
in    O
the    O
prevention    O
of    O
colitis    O
by    O
the    O
CD4+CD45RBlo    O
regulatory    O
T    O
cell    O
subset    O

These    O
include    O
interleukin    B-Cytokine114828193
12    I-Cytokine114828193
(    O
IL-12    O
)    O
,    O
interferon    O
gamma    O
(    O
IFNγ    O
)    O
and    O
interleukin    B-Cytokine114828193
10    I-Cytokine114828193
(    O
IL-10    O
)    O
.    O

Many    O
novel    O
medications    O
being    O
researched    O
target    O
the    O
IL-23    B-Cytokine114828193
axis    O
,    O
particularly    O
IL-23p19    B-Cytokine114828193
inhibitors    O
,    O
as    O
IL-23p19    O
is    O
present    O
in    O
increased    O
concentrations    O
in    O
psoriasis    O
skin    O
lesions    O
while    O
contributing    O
less    O
to    O
protection    O
against    O
opportunistic    O
infections    O
.    O

Treatments    O
directed    O
at    O
tumor    O
necrosis    O
factor    O
(    O
TNF    O
)    O
(    O
infliximab    O
,    O
etanercept    O
)    O
and    O
interleukin-1    O
(    O
anakinra    B-Cytokine114828193
)    O
have    O
shown    O
a    O
good    O
response    O
in    O
resistant    O
arthritis    O
and    O
pyoderma    O
gangrenosum    O
.    O

Kineret    B-Cytokine114828193
(Anakinra)    I-Cytokine114828193
(    O
for    O
rheumatoid    O
arthritis    O
)    O
(    O
exclusively    O
licensed    O
to    O
Biovitrium    O
,    O
now    O
Swedish    O
Orphan    O
Biovitrum    O
,    O
in    O
December    O
2008    O
)    O

Treatment    O
using    O
anakinra    B-Cytokine114828193
(    O
Kineret    O
)    O
has    O
been    O
shown    O
effective    O
for    O
FCAS    O
,    O
although    O
this    O
does    O
mean    O
daily    O
injections    O
of    O
the    O
immunosuppressant    O
into    O
an    O
area    O
such    O
as    O
the    O
lower    O
abdomen    O
.    O

(    O
Shendi    O
et    O
al    O
.    O
treated    O
a    O
young    O
woman    O
in    O
whom    O
anakinra    B-Cytokine114828193
was    O
ineffective    O
with    O
tocilizumab    O
)    O
.    O

This    O
gene    O
is    O
a    O
member    O
of    O
ADAMTS    O
(    O
a    O
disintegrin    O
and    O
metalloproteinase    O
with    O
thrombospondin    B-Cytokine114828193
motifs)-like    O
gene    O
family    O
and    O
encodes    O
a    O
protein    O
with    O
seven    O
thrombospondin    O
type    O
1    O
repeats    O
.    O

Thrombospondin    B-Cytokine114828193

DBL    O
domains    O
can    O
bind    O
to    O
a    O
variety    O
of    O
cell    O
receptors    O
including    O
thrombospondin    B-Cytokine114828193
(    O
TSP    O
)    O
,    O
complement    O
receptor    O
1    O
(    O
CR1    O
)    O
,    O
chondroitin    O
sulfate    O
A    O
(    O
CSA    O
)    O
,    O
P    O
-    O
selectin    O
,    O
endothelial    O
protein    O
C    O
receptor    O
(    O
EPCR    O
)    O
,    O
and    O
heparan    O
sulfate    O
.    O

Aggrecanases    O
are    O
extracellular    O
proteolytic    O
enzymes    O
that    O
are    O
members    O
of    O
the    O
ADAMTS    O
(    O
A    O
Disintegrin    O
And    O
Metalloprotease    O
with    O
Thrombospondin    B-Cytokine114828193
Motifs    O
)    O
family    O
.    O

Both    O
proteins    O
contain    O
thrombospondin    B-Cytokine114828193
(    O
TS    O
)    O
motifs    O
required    O
for    O
proper    O
recognition    O
of    O
substrates    O
.    O

=    O
=    O
=    O
Thrombospondin    B-Cytokine114828193
superfamily===    O

Chemokine    B-Cytokine114828193
(C-C    I-Cytokine114828193
motif)    I-Cytokine114828193
ligand    I-Cytokine114828193
26    I-Cytokine114828193
(    O
CCL26    O
)    O
is    O
a    O
small    O
cytokine    O
belonging    O
to    O
the    O
CC    O
chemokine    B-Cytokine114828193
family    O
that    O
is    O
also    O
called    O
Eotaxin-3    O
,    O
Macrophage    O
inflammatory    O
protein    O
4-alpha    O

Early    O
trials    O
of    O
this    O
technique    O
have    O
been    O
shown    O
to    O
be    O
very    O
effective    O
in    O
eliminating    O
tumours    O
,    O
most    O
notably    O
so    O
far    O
OncoVEX    B-Cytokine114828193
GM-CSF    I-Cytokine114828193
(    O
BioVex    O
Inc    O
,    O
Woburn    O
,    O
MA    O
)    O
which    O
is    O
in    O
Phase    O
3    O
clinical    O
trials    O
for    O
melanoma    O
.    O

In    O
2011    O
,    O
five    O
of    O
Harris    O
&    O
Harris    O
Group    O
’s    O
portfolio    O
companies    O
completed    O
liquidity    O
events    O
including    O
two    O
IPOs    O
(    O
Solazyme    O
and    O
NeoPhotonics    O
)    O
and    O
three    O
sale    O
transactions    O
(    O
BioVex    B-Cytokine114828193
Group    I-Cytokine114828193
to    O
Amgen    O
,    O
Innovalight    O
to    O
DuPont    O
and    O
Crystal    O
IS    O
to    O
Asahi    O
Kasei    O
)    O
.    O

CD40LG    O
(    O
TNFSF5    O
)    O
;    O
CD70    O
(    O
TNFSF7    O
)    O
;    O
EDA    O
;    O
FASLG    O
(    O
TNFSF6    O
)    O
;    O
LTA    B-Cytokine114828193
(TNFSF1)    I-Cytokine114828193
;    O
LTB    B-Cytokine114828193
(TNFSF3)    I-Cytokine114828193
;    O


